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Summary 
 
Percutaneous coronary intervention (PCI) improves the blood supply to the heart 
by unblocking narrowed coronary arteries. Implantation of a coronary stent is 
usually required to scaffold the artery and improve long-term vessel patency. 
Drug-eluting stents (DES) have been developed to decrease the incidence of stent 
renarrowing,  known  as  in-stent  restenosis  (ISR),  the  main  limitation  of  bare 
metal stents (BMS). DES release potent drugs into the artery wall to inhibit cell 
division  and  attenuate  ISR.  However,  this  strategy  can  also  impair  vascular 
healing and increase the risk of stent thrombosis, which is a serious concern. 
Novel approaches to this problem are urgently required. Oxidative stress reflects 
a state in which reactive oxygen species (ROS) prevail over antioxidant defences. 
PCI  causes  a  major  release  of  ROS  from  the  injured  artery  wall  and  these 
molecules  appear  to  play  an  important  role  in  critical  signalling  pathways 
involved  in  vascular  repair.  Numerous  animal  studies  have  found  that  oral 
antioxidants may reduce ISR and improve healing, yet these strategies have not 
been effective in humans. Stent-based delivery of antioxidants may offer more 
efficacious, targeted protection against oxidative stress than oral administration. 
The  role  of  oxidative  stress  in  endothelial  repair  mediated  by  bone  marrow-
derived  endothelial  progenitor  cells  (EPCs)  in  patients  with  coronary  heart 
disease is also poorly defined. The main aims of this thesis were: to determine 
the in vitro effects of oxidative stress on key aspects of thrombosis and vascular 
healing; to evaluate a novel antioxidant-eluting stent in an in vivo porcine model; 
and  to  examine  the  relationship  between  oxidised  low-density  lipoprotein 
(oxLDL), EPCs and coronary endothelial function in patients with stable angina.   21 
Oxidative stress, generated by the xanthine/xanthine oxidase reaction, inhibited 
whole  blood  aggregation  in  a  concentration-dependent  fashion.  This  was 
probably  due  to  an  excess  of  ROS  which  impaired,  rather  than  stimulated, 
thrombosis.  Healthy  endothelial  cells  (ECs)  also  inhibited  whole  blood 
aggregation, but this was not mitigated by oxidative stress. EC migration was 
assessed using an in vitro endothelial wound scratch assay. Oxidative stress was 
highly toxic to ECs and inhibited migratory activity. Nitrone D, a novel spin 
trapping antioxidant, was evaluated for its suitability as a novel DES coating. 
Nitrone  D  displayed  weak  antithrombotic  effects,  but  markedly  inhibited  EC 
migration. Nitrone D was therefore unsuitable for a DES that was intended to 
improve re-endothelialisation.  
 
Oral probucol has established efficacy in animal models of restenosis, but not in 
humans. Probucol has been successfully incorporated as a dual DES coating with 
rapamycin in clinical trials. Succinobucol is a novel derivative of probucol with 
more potent antioxidant, anti-inflammatory and antiproliferative effects. A novel 
polymer-free  succinobucol-eluting  stent  (SES)  and  succinobucol/rapamycin-
eluting stent (SRES) were developed and compared to a commercially available 
polymer-free rapamycin-eluting stent (RES) and BMS. Pharmacokinetic studies 
demonstrated optimal drug elution from the SES. However, in a porcine coronary 
model, the SES significantly increased neointimal thickness and aggravated ISR. 
The  RES  reduced  neointimal  thickness  non-significantly,  whereas  the  SRES 
caused no difference in neointimal thickness, compared with the BMS. The SES 
was associated with greater inflammation and persistent fibrin deposition around 
the stent struts, which are signs of defective healing. There were no significant   22 
differences  in  endothelial  regeneration  between  the  groups.  Subsequent  cell 
culture studies found that succinobucol was toxic to ECs and smooth muscle 
cells. In the clinical study, circulating levels of EPCs were strongly correlated 
with  coronary  endothelial  function,  which  is  a  novel  finding.  Plasma  oxLDL 
levels were not correlated with EPCs or coronary endothelial function.  
 
In conclusion, ROS reflect a large array of molecules released after PCI that are 
multi-faceted regulators of platelets and vascular cells. As such, they represent a 
complex  target  for  novel  DES  technologies.  Excessive  ROS  may  inhibit 
thrombus  formation  and  delay  re-endothelialisation.  However,  potent 
antioxidants  delivered  to  injured  arterial  tissue  after  PCI  may  not  necessarily 
encourage the physiological processes required to accelerate vascular repair. At 
high dose, local delivery of antioxidants may actually promote inflammation and 
aggravate ISR. Although oxLDL is known to induce endothelial dysfunction, it is 
not correlated with the number of circulating EPCs. These findings underline the 
complicated role of oxidative stress in vascular repair after PCI. Further studies 
are required to clarify whether antioxidants will ever provide advantages over 
existing options in the rapidly evolving field of interventional cardiology. 
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1.1  Preamble 
 
Coronary heart disease (CHD) is the leading cause of death and disability in the 
developed  world.  In  2007,  the  age-standardised  mortality  rates  from  CHD  in 
Scotland were 89 per 100 000 men and 30 per 100 000 women, which are the 
highest in the United Kingdom (UK) (1). Although the incidence of CHD has 
decreased over the past decade, the economic burden is huge, costing the UK 
around  £9.0  billion  a  year  in  2006  (1).  As  a  result,  much  effort  is  directed 
towards the development of effective, safe and lasting treatments for CHD.  
 
Initial  management  of  CHD  includes  lifestyle  modification  and  drug  therapy 
which aim to reduce myocardial ischaemia and prevent myocardial infarction. 
Despite  these  measures,  many  patients  remain  symptomatic  and  therefore 
mechanical  methods  of  improving  coronary  artery  blood  flow  have  been 
developed (coronary revascularisation). The earliest attempts to achieve coronary 
revascularisation led to the introduction of coronary artery bypass graft surgery 
(CABG),  in  which  autologous  venous  and  arterial  grafts  are  used  to  bypass 
coronary artery stenoses or occlusions. CABG requires a general anaesthetic and 
is  a  major  open  heart  operation,  with  a  modest  but  appreciable  early  post-
operative  risk  of  death  (1-2%),  a  typical  hospital  stay  of  several  days  and  a 
rehabilitation period of several months.  
 
Percutaneous  coronary  intervention  (PCI)  offers  an  alternative  and  much  less 
invasive  method  of  coronary  revascularisation.  It  is  performed  under  a  local 
anaesthetic  and  involves  percutaneous  access  to  the  coronary  arteries  via  a   25 
catheter  which  usually  enters  the  circulation  via  the  radial  or  femoral  artery. 
Placement of a thin guide wire into a diseased coronary artery allows the passage 
of  specialised  equipment  which  is  used  to  dilate  a  stenosis  by  inflation  of  a 
balloon catheter and ideally, deployment of an endovascular stent. PCI is capable 
of reopening a narrowed or blocked coronary artery (or coronary artery bypass 
graft),  restoring  normal  epicardial  blood  flow  and  more  importantly,  re-
establishing  normal  myocardial  perfusion.  Patients  undergoing  PCI  typically 
require minimal preparation, recover within hours and can often be discharged on 
the day of the procedure. Although procedural mortality associated with PCI is 
very low (0.1%), many patients suffer from progressive renarrowing or sudden 
blockage  of  the  stent,  therefore,  the  probability  of  requiring  repeat 
revascularisation after PCI is  currently  higher than that after CABG (2). The 
natural history of PCI since inception has proven that refinement of technology 
can help to improve this situation, but current devices have brought with them 
their  own  limitations.  Consequently,  the  discovery  of  novel  approaches  to 
improve the performance of stents remains crucial to the future development and 
success of PCI.  
 
1.2  PCI 
 
1.2.1  Historical aspects 
In 1964, Dotter and Judkins were first to report a new percutaneous technique to 
treat lower limb arteriosclerotic disease (3). However, it wasn’t until 1979 that 
Gruntzig  et  al.  (4)  published  the  first  case  series  of  50  patients  in  whom 
percutaneously  introduced  inflatable  balloon  catheters  were  used  to  treat   26 
coronary artery stenoses. The success of early balloon coronary angioplasty was 
tempered by the relatively high incidence of acute vessel closure and chronic 
renarrowing  (restenosis),  which  often  led  to  recurrent  symptoms  and  a 
requirement  for  repeat  procedures.  In  1985,  Palmaz  et  al.  published  the 
successful use of an endovascular metallic stent to prevent acute vessel recoil and 
limit late negative remodelling after balloon dilatation in dogs (5). The following 
year, Sigwart and Puel reported the first case series of patients who received self-
expandable stainless steel stents to treat ilio-femoral and coronary artery disease 
after failed balloon angioplasty or CABG (6). Due to the major reduction in the 
rate  of  restenosis  and  requirement  for  repeat  revascularisation,  there  was  a 
massive expansion in the use of coronary stents worldwide. By the end of the 
1990s, stents had become integrated into almost all PCI procedures. Like other 
modern medical treatments, PCI was subject to critical assessment of efficacy 
and cost-effectiveness and in 2000 the National Institute of Clinical Evidence 
published a report supporting the routine use of stents during PCI (7). The British 
Cardiovascular Intervention Society have reported national audit data showing 
that uptake of PCI to treat CHD has increased exponentially over the past twenty 
years, with 83 130 PCI procedures (1 345 PCI per million) performed in 105 
centres in the UK in 2009, producing a ratio of PCI to CABG in excess of 3:1. 
(Figure 1.1) (8). 
 
1.2.2  Clinical evidence 
In patients with stable angina, PCI is effective mainly to reduce symptoms. A 
systematic review of 6 prospective randomised controlled trials of PCI versus  
   27 
 
Figure 1.1  PCI versus CABG frequency in the UK. 
An exponential rise in PCI procedures has occurred since the early 1990s, whereas the 
number of CABG operations has remained fairly constant. 
 
medical therapy in stable angina confirmed an improvement in symptoms and 
quality of life, but no significant differences in the subsequent risk of death or 
myocardial infarction (9). The majority of trials included in this review were 
performed in the 1990s, when most patients received balloon angioplasty only. 
The routine use of stents has considerably reduced the requirement for repeat 
revascularisation compared to balloon angioplasty, however a major randomised 
controlled trial in 2 287 stable angina patients failed to demonstrate a reduction 
in death or myocardial  infarction, compared to  optimal medical therapy (10). 
This trial was limited by the exclusion of high risk patients and crossover to 
revascularisation in around 30% of the medical therapy group during the course 
of the study. A large meta-analysis comparing PCI versus CABG in stable angina 
has yielded no difference in mortality or myocardial infarction, especially when 
stents are utilised (11).    28 
 
PCI can also be used to treat acute coronary syndromes, such as unstable angina 
or  acute  myocardial  infarction.  After  non-ST  elevation  myocardial  infarction 
(NSTEMI), an early invasive revascularisation strategy incorporating PCI or, to a 
lesser  extent  CABG,  has  been  shown  to  prevent  subsequent  myocardial 
infarction and recurrent angina (12). Five year follow up data from a large UK 
randomised clinical trial has shown that high risk patients with non-ST elevation 
myocardial infarction achieve an overall mortality benefit with the routine use of 
invasive management (13). PCI for the treatment of ST elevation myocardial 
infarction (STEMI) has clear benefits compared with drug therapy and is now the 
preferred reperfusion strategy in the UK. A systematic review of the evidence for 
PCI to treat STEMI has demonstrated reductions in death, myocardial infarction 
and stroke, compared with thrombolytic drugs (14).  
 
1.2.3  Coronary stents 
The  introduction  of  coronary  stents  to  improve  the  performance  of  balloon 
dilation alone has been a major advance. The basic form of an uncoated coronary 
stent is known as a bare metal stent (BMS). The stent must be biologically inert 
and ideally provide a non-thrombogenic surface for blood flow. It must possess 
good  radial  strength  to  scaffold  the  artery  reliably;  however  it  must  also  be 
conformable to tortuous coronary anatomy and vessel irregularities. The field of 
stent design is continually evolving, although most BMS consist of a stainless 
steel  or  cobalt  chromium  tube  into  which  laser  guided  cuts  are  made.  The 
unexpanded  stent  is  pre-mounted  onto  an  angioplasty  balloon  catheter  and  is 
visible fluoroscopically during transit through the coronary circulation. When the   29 
stent is optimally positioned over a coronary stenosis, the stent is deployed by 
inflating the balloon to high pressure (e.g. 14 atmospheres). The balloon is then 
fully  deflated  by  applying  negative  pressure,  which  leaves  the  stent  fully 
expanded against the artery wall before the balloon catheter can be withdrawn.  
 
Stents compress the fissured intima against the underlying media, reducing the 
propagation of arterial dissection after balloon dilation. Moreover, by scaffolding 
the artery, the lumen is protected from acute elastic recoil and chronic negative 
remodelling  of  the  artery,  which  are  the  main  causes  of  restenosis  following 
balloon angioplasty (15). Due to their superior efficacy compared with balloon 
angioplasty alone, stents are now utilised in over 90% of PCI procedures (8). 
However late luminal loss is not abolished by stenting. Renarrowing still occurs 
and is caused primarily by excessive growth of neointimal tissue as a response to 
the  deep  vessel  wall  injury  resulting  from  stent  struts  and  the  presence  of  a 
foreign  body.  This  phenomenon  is  known  as  in-stent  restenosis  (ISR),  which 
occurs to a greater extent than after balloon angioplasty and an example is shown 
in Figure 1.2. 
 
1.2.4  In-stent restenosis 
ISR  occurs  in  10-50%  cases,  depending  on  various  stent,  lesion  and  patient 
characteristics  (16).  The  main  predictors  of  ISR  are  the  presence  of  diabetes 
mellitus, the treatment of long coronary lesions and small vessel diameter. ISR 
usually presents as a recurrence of stable angina symptoms but in around 10% of 
cases it can present as an acute coronary syndrome (17).  
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Figure 1.2  Angiographic illustration of ISR. 
An angiogram of the right coronary artery (RCA) shows a coronary catheter (C) placed 
at the ostium of the RCA, following injection of radio-opaque contrast. The magnified 
insert on the right demonstrates a previously implanted stent in the proximal segment of 
the artery (position of struts indicated by broken parallel lines) which has developed 
partial  obstruction.  This  is  due  to  encroachment  of  the  lumen  by  neointimal  tissue, 
causing ISR (visualised as a loss of contrast density within stent). 
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The  process  of  ISR  resembles  the  natural  wound  healing  process  following 
vessel injury, typically occurring over several weeks to months. An integrated  
view of the molecular and cellular events leading to ISR has been proposed by 
Welt and Rogers (18). Stent deployment causes severe endothelial denudation, 
which leads to platelet and fibrin deposition on the injured artery wall. Activated 
platelets expressing adhesion molecules, such as P-selectin, attach to circulating 
leucocytes  via  platelet  receptors,  such  as  P-selectin  glycoprotein  ligand. 
Leucocytes  roll  along  the  injured  wall  and  then  bind  tightly  to  the  surface 
through  the  leucocyte  integrin  Mac-1  (CD11b/CD18)  class  of  adhesion 
molecules  via  direct  attachment  to  the  platelet  receptor  glycoprotein  1bα 
(GP1bα)  and  through  cross-linking  with  fibrinogen  to  the  GPIIbIIIa  receptor. 
Under the influence of chemokines, such as monocyte chemoattractant protein-1 
(MCP-1), interleukin-6 (IL-6) and IL-8, released from vascular smooth muscle 
cells  (SMCs)  and  resident  macrophages,  leucocytes  infiltrate  the  artery  wall. 
Growth factors such as fibroblast growth factor (FGF), platelet-derived growth 
factor (PDGF), insulin-like growth factor (IGF), transforming growth factor-β 
(TGF-β)  and  vascular  endothelial  growth  factor  (VEGF)  are  released  from 
platelets, leucocytes and SMCs, which stimulate SMCs to proliferate and migrate 
from  the  media  into  the  neointima.  Ongoing  SMC  proliferation,  macrophage 
infiltration  and  extracellular  matrix  production  cause  neointimal  hyperplasia 
(NIH); the pathognomic feature of ISR. Although the luminal renarrowing due to 
elastic  recoil  and  negative  remodelling  common  after  balloon  angioplasty  is 
prevented  by  the  stent  struts,  the  neointimal  response  is  exaggerated  and 
proportional  to  the  degree  of  stent  injury  (19).  Endothelial  repair  involves 
endothelial  cell  (EC)  migration,  which  may  be  the  critical  and  rate-limiting   32 
initiating step, followed by EC proliferation (20). As the denuded endothelium 
regenerates, it completely recovers the neointimal surface, allowing the vessel to 
resume normal function.  
 
1.2.5  Endothelial regeneration 
The vascular endothelium lines the circulatory system throughout the body and 
provides a highly selective permeability barrier to contain the blood within the 
vascular space. The endothelium is integral to the control of several key vascular 
functions  and  provides  extensive  signalling  capabilities  to  other  cells  via  the 
release of cytokines and growth factors. Delayed or incomplete healing of the 
endothelium after PCI is undesirable for a number of reasons.  
 
First,  the  early  regrowth  of  a  functional  endothelial  layer  is  capable  of 
attenuating NIH, the principle cause of  ISR. After injury, ECs regulate SMC 
proliferation by the release of well-characterised growth promoters and inhibitors 
(21). Damage to the endothelium results in the activation of SMC proliferation, 
whereas  repair  of  the  endothelium  leads  to  the  reversal  of  this  process  and 
restoration of SMC quiescence (22). Endothelial progenitor cells (EPCs), derived 
from the bone marrow, also appear to contribute to endothelial regrowth, and 
intravenous  transfusion  of  EPCs  has  been  shown  to  reduce  NIH  in  a  mouse 
model of arterial injury (23). An early pilot study in patients using stents coated 
with  anti-CD34  antibodies  to  target  EPC  surface  antigens  (Genous™  Bio-
engineered R stent, OrbusNeich, Hong Kong) demonstrated clinical efficacy with 
a low incidence of ISR (24). However, more recently the Genous™ stent was 
associated  with  a  poor  performance  in  lesions  at  higher  risk  of  ISR,  with   33 
antirestenotic efficacy approaching that of a BMS, albeit with no cases of stent 
thrombosis (25). Gene transfer of VEGF in a rabbit model of balloon injury has 
inhibited NIH in some cases (26), but not in others (27), and the role of catheter-
based local VEGF gene delivery after human PCI is under investigation (28). A 
strategy utilising VEGF gene-eluting stents may be effective if the results of a 
promising rabbit study can be reproduced (29), although one clinical study had 
disappointing results (30). 
 
Second, the regeneration of the endothelium is crucial to restore normal vascular 
tone through the action of a number of vasoactive substances, including nitric 
oxide (NO) and prostacyclin. Coronary endothelial dysfunction is characterised 
by  a  reduction  in  NO  bioavailability  and  is  a  recognised  precursor  to  the 
development  of  coronary  artery  disease  and  subsequent  vascular  events  (31). 
Therefore,  it  is  conceivable  that  persistent  endothelial  dysfunction  after  PCI 
would increase the risk of late procedural complications.  
 
Finally,  and  particularly  after  stent  deployment,  regrowth  of  a  functional 
endothelium is fundamental to luminal patency. An intact endothelial monolayer 
provides  a  non-thrombogenic  surface  for  blood  flow  and  acts  as  the  primary 
regulator of haemostasis and thrombosis. The endothelium also serves as a non-
permeable barrier between circulating platelets and agonists, such as collagen, 
widely present in coronary plaque and artery wall, which profoundly stimulate 
platelet  aggregation.  The  endothelium  restricts  exposure  of  blood  coagulation 
factors to the subendothelial layer, which is rich in tissue factor, the primary 
trigger of the coagulation system. ECs themselves directly inhibit thrombosis via   34 
the antiplatelet effects of released NO (32), prostacyclin (33) and CD39, an ecto-
ADPase (34). Endothelial-derived heparan sulfate, thrombomodulin and tissue 
factor pathway inhibitor are inhibitors of coagulation (35). The endothelium also 
regulates the endogenous fibrinolytic system by the release of endothelial tissue 
plasminogen  activator  (tPA),  which  plays  a  significant  role  in  thrombus 
dissolution  during  acute  coronary  syndromes  (36).  Thus,  in  the  milieu  of  an 
intrinsically  thrombogenic  metal  stent,  an  absent  or  functionally  deficient 
endothelium  significantly  impairs  the  natural  defence  of  the  stented  coronary 
artery against acute occlusion, an event known as stent thrombosis. 
 
1.2.6  Stent thrombosis 
Implantation of a coronary stent immediately creates an intensely prothrombotic 
environment, which can lead rapidly to stent thrombosis (figure 1.3). As well as 
denuding the endothelium and exposing the intimal contents, the stent itself is 
highly  thrombogenic.  Platelet  activation  and  aggregation  are  unavoidable 
consequences of arterial injury and preventative measures must be employed to 
prevent  stent  thrombosis.  Improved  operator  technique  and  newer  equipment 
have reduced the incidence of acute stent thrombosis, but the greatest impact has 
been made by the adoption of intensive adjunctive antithrombotic regimens. This 
usually includes at least two different antiplatelet drugs (aspirin, clopidogrel and, 
in high risk cases, a glycoprotein 2B/3A inhibitor) and intravenous anticoagulant 
therapy (heparin or bivalirudin). Despite this, stent thrombosis remains one of the 
most serious and life-threatening complications of PCI. Stent thrombosis is often 
a catastrophic clinical event, resulting in a large myocardial infarction with a 
high risk of death (37).    35 
 
 
 
Figure 1.3  Angiographic illustration of stent thrombosis. 
A, Coronary angiogram with a coronary catheter (C) placed at the ostium of the right 
coronary  artery  (RCA)  with  a  stenotic  lesion  (L)  in  the  proximal  segment.  
B, Angiographic result following dilation of the lesion and coronary stent implantation. 
C,  Repeat  angiogram  several  days  later  shows  an  early  stent  thrombosis  (ST)  with 
occlusive  thrombus  blocking  the  stent,  which  caused  a  large  inferior  myocardial 
infarction. D, Final angiographic result after the stent thrombosis has been treated using 
thrombus aspiration and further stenting. 
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Overall,  the  risk  of  stent  thrombosis  is  related  to  a  large  number  of  patient, 
procedural  and  stent  factors  (Figure  1.4).  Premature  discontinuation  of 
antiplatelet  drug  therapy  is  the  strongest  predictor  of  stent  thrombosis  and 
patients with renal failure, diabetes or acute coronary syndrome are also at higher 
risk (38;39). Patients undergoing non-cardiac surgery after coronary stenting are 
at  greatly  increased  risk  of  stent  thrombosis  and  associated  cardiovascular 
complications  during  the  first  two  months  after  PCI  (40)  and  therefore  non-
cardiac  surgery  should  be  deferred  for  several  months  unless  absolutely 
necessary. A recent study showed no difference in the rates of stent thrombosis 
between BMS and drug-eluting stents (DES) in the early post-operative period, 
although  important  data  on  antiplatelet  prescribing  in  either  group  were  not 
reported (41). It is now recommended that dual antiplatelet therapy is continued 
where possible during the perioperative period  to mitigate against the risk of 
stent thrombosis, unless there is an unacceptable risk of serious bleeding (42), 
such as neurosurgery. 
 
Figure 1.4  Risk factors for stent thrombosis. 
LV, left ventricular; RVD, reference vessel diameter.   37 
In  randomised  clinical  trials,  stent  thrombosis  typically  occurred  after 
approximately 1-2% of PCIs (43;44). However, observational data from patient 
registries suggests the incidence of stent thrombosis in real world populations 
may be higher. Combined data from two large European centres (including 8 146 
patients) reported a 3 year incidence of angiographically proven stent thrombosis 
of 3%, occurring at a constant rate of 0.6% per year after the first year. (39). A 
registry of 5 842 ST-elevation myocardial infarction patients reported a 3.5% 
incidence  of  angiographically  confirmed  stent  thrombosis  within  a  month  of 
primary  PCI,  of  which  half  occurred  during  the  first  24  hours  (45).  This 
discrepancy  underlines  the  differences  in  patient  populations  selected  for 
randomised clinical trials compared with contemporary clinical practice, with the 
latter  group  having  more  severe  underlying  disease,  greater  comorbidity  and 
more complex PCI, increasing the risk of stent thrombosis (39). 
 
In order to more accurately quantify the incidence of stent thrombosis across 
different  populations  and  make  comparison  between  studies,  the  Academic 
Research Consortium (ARC) have introduced a classification system which has 
standardised the reporting of such events (46), the true incidence of which may 
be underestimated if based solely on angiographic confirmation (43). Definite 
stent  thrombosis  requires  the  presence  of  an  acute  coronary  syndrome  with 
angiographic or post-mortem evidence of thrombus or occlusion. Probable stent 
thrombosis includes unexplained death within 30 days of the procedure or acute 
myocardial infarction involving the vessel territory of the implanted stent without 
angiographic  confirmation.  Possible  stent  thrombosis  includes  all  unexplained 
deaths occurring at least 30 days after the procedure. Using this classification   38 
system, the cumulative rate of definite and probable stent thrombosis probably 
more accurately reflects and is now commonly used to approximate the incidence 
of stent thrombosis in research studies.  
 
Stent thrombosis is also categorised as early, occurring between 0-30 days (this 
can be sub-classified further into acute within 24 hours and subacute after 24 
hours); late, occurring between 31 days and 1 year; or very late, occurring more 
than 1 year after stent implantation (46). This distinction is important because 
stent thrombosis may occur at different time periods after PCI due to different 
pathophysiological processes.  
 
The first month after PCI represents the period when patients are at greatest risk 
of  stent  thrombosis  (39).  Early  stent  thrombosis  is  often  associated  with  a 
procedural or technical problem with the stent. In an intravascular ultrasound 
(IVUS) registry of 53 patients with definite early stent thrombosis, 94% of cases 
demonstrated at least one abnormality on the original IVUS at the time of index 
PCI,  such  as  undersizing  of  the  stent,  strut  malapposition  to  the  surrounding 
artery  wall,  edge  dissection,  thrombus  formation  or  untreated  disease  at  the 
inflow or outflow of stent (47). A registry of 201 early stent thromboses after ST-
elevation  myocardial  infarction  discovered  that  unrecognised  dissection,  stent 
undersizing and small stent diameter were the strongest predictors for acute stent 
thrombosis  (45).  Lack  of  dual  antiplatelet  therapy  or  non-cardiac  surgery  are 
major  risk  factors  for  subacute  stent  thrombosis  (38;41;45).  The  distinction 
between BMS and DES does not appear to play an important role in early stent 
thrombosis, as even BMS require  at least one month to re-endothelialise and   39 
therefore are both at increased risk of stent thrombosis during this time period, 
particularly if other risk factors are present. Late stent thrombosis occurs less 
frequently  than  early  stent  thrombosis  although  early  discontinuation  of 
antiplatelet  therapy  remains  an  important  trigger  (38;48).  More  complex  PCI 
such as bifurcation stenting is also associated with higher risk during this period 
(38). Very late stent thrombosis, occurring at least one year after stenting, usually 
reflects impaired endothelial healing or persistent drug/polymer toxicity. The risk 
of stent thrombosis for BMS during this period is relatively low, because the 
stent struts are generally covered with new endothelial and neointimal tissue. The 
limitations of DES with regard to suboptimal healing and their increased risk of 
very late stent thrombosis will be discussed in more detail in section 1.2.7. A 
Japanese  registry  of  294  212  PCI  procedures  (exclusively  sirolimus-eluting 
stents) yielding 611 ARC-definite stent thromboses confirmed previous studies 
that  the  majority  of  events  occur  within  the  first  month  after  stenting  (49). 
Characteristic factors predicting stent thrombosis after one month (late or very 
late stent thromboses) versus early stent thrombosis included haemodialysis, end-
stage  renal  disease,  chronic  total  occlusions  and  age  <65  years.  Exploratory 
analyses demonstrated some differences in patient characteristics between late 
and very late stent thrombosis groups, with older age, lower body mass index and 
greater burden of vascular disease or diabetes more prevalent in patients with late 
as opposed to very late events, suggesting that comorbidity is a more prominent 
factor during the late period whilst usually receiving dual antiplatelet therapy. 
The one year mortality rate after late stent thrombosis appears to be higher than 
after acute or very late events (45;49), probably due to differences in presentation 
and important clinical factors as described above.   40 
1.2.7  Drug-eluting stents 
Implantation of a metal stent into a diseased coronary artery has provided the 
cardiologist  with  a  unique  opportunity  to  deliver  drugs  directly  into  the 
surrounding artery wall in an attempt to modify the maladaptive thrombotic and 
hyperplastic responses to vessel injury and improve clinical performance. Local 
drug delivery  from a DES aims to reduce the toxicity and compliance  issues 
related to systemic administration. In order to control the drug release from the 
stent platform, the drug is eluted in a pre-specified pattern. To achieve this, the 
active drug is commonly carried by a polymer. The ideal polymer is biologically 
inert and should not promote inflammation or hypersensitivity because this may, 
in itself, lead to ISR or stent thrombosis (50).  
 
Clinical efficacy of first generation DES 
The  first  DES  introduced  to  clinical  practice  was  the  sirolimus-eluting  stent. 
Sirolimus (also known as rapamycin) is a natural macrocyclic lactone, which is a 
product  of  the  bacterium  Streptomyces  hygroscopicus.  Sirolimus  acts  by 
inhibiting the mammalian target of rapamycin (mTOR). It has significant anti-
inflammatory and immunosuppressive effects and is used to prevent rejection 
after organ transplantation. Recognition of its potent antiproliferative properties 
led  to  clinical  studies, which  confirmed  its  efficacy  as  an  antirestenotic  stent 
coating. The Cypher® stent (Cordis, Johnson and Johnson) is a commercially 
available sirolimus-eluting stent and utilises a stainless steel stent and permanent 
polymer to control drug release. Early human experience with both slow and fast 
release  profiles  for  the  sirolimus-eluting  stent  was  favourable,  demonstrating 
long term efficacy in the prevention of NIH, particularly with the slow release   41 
version which is currently used in clinical practice (51). There have been many 
large randomised controlled trials comparing sirolimus-eluting stents with BMS 
in stable CHD. Early trials such as RAVEL (52) and SIRIUS (53) were first to 
report. In a subsequent meta-analysis, it was found that sirolimus-eluting stents 
led to an impressive reduction in ISR in the first year compared with BMS, from 
37% to 6% respectively (54). In addition, large improvements in target lesion 
revascularisation were found comparing sirolimus-eluting stents with BMS, from 
19% to 4% respectively. Up to a year, there was no difference in the incidence of 
myocardial infarction or death in patients with the sirolimus-eluting stent. It was 
worth noting that these trials involved relatively low risk patients and lesions, 
often in the absence of multiple medical comorbidities or presence of multivessel 
disease, which is misrepresentative of contemporary interventional practice. The 
real  world  effectiveness  of  sirolimus-eluting  stents  has  been  examined  in 
prospective registries, and these have shown repeat revascularisation rates of up 
to 10% within a year in more complex cases (55). 
 
Paclitaxel-eluting stents were next to show encouraging results. Paclitaxel is an 
anticancer drug which also has potent antiproliferative effects. Paclitaxel-eluting 
stents are currently marketed as the Taxus® stent (Boston Scientific). The main 
source of evidence came from the TAXUS trial program (56). Paclitaxel is also 
carried in a permanent polymer, and both slow and moderate release profiles 
have been studied. Although both DES provided excellent suppression of NIH, 
the slow release Taxus® is currently the only commercially available version. A 
meta-analysis of the TAXUS program demonstrated a reduction in ISR using the   42 
Taxus® from 24% to 7%, and reductions in target lesion revascularisation from 
12% to 3%, compared with BMS (54).  
 
A comprehensive meta-analysis of all randomised trials and observational studies 
of first generation DES (sirolimus- or paclitaxel-eluting stents) in which greater 
than 100 patients were enrolled with at least one year follow-up was performed 
by Kirtane et al. (57). This demonstrated that in randomised trials (9 470 patients 
in 22 studies), first generation DES led to a significant reduction in target vessel 
revascularisation compared with BMS (hazard ratio, 0.45; 95% CI, 0.37 to 0.54), 
with no significant differences in mortality or myocardial infarction. When all 
observational studies were analysed (182 901 patients in 34 studies), DES were 
associated  with  a  similar  reduction  in  target  vessel  revascularisation  (hazard 
ratio, 0.54; 95% CI, 0.48 to 0.61), but also a significant reduction in mortality 
(HR, 0.78; 95% CI 0.71 to 0.86) and myocardial infarction (HR, 0.87; 95% CI, 
0.78 to 0.97), compared with BMS. Whilst accepting the potential for selection 
bias and residual confounding of observational data, this suggests that real-world 
use  of  DES  retains  efficacy  outside  of  the  carefully  selected  populations  of 
randomised controlled trials and may be responsible for a lower rate of adverse 
cardiac events in higher risk patients with more complex CHD, compared with 
BMS.  In  the  UK,  DES  are  used  in  greater  than  60%  of  PCI  procedures, 
especially in diabetic patients and those patients with long or narrow coronary 
lesions, where the risk of ISR is higher and efficacy of DES greater in absolute 
terms (8).  
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Limitations of the first generation DES 
First generation DES limit ISR by inhibiting the cell cycle of proliferating cells. 
Sirolimus-eluting  stents  also  reduce  MCP-1  and  IL-6  expression  (58),  and 
paclitaxel  is  known  to  influence  inflammatory  cell  adhesion  (59).  However, 
whilst they are designed to arrest vascular SMC growth, it is not surprising that 
these potent antiproliferative compounds also have long-term effects on other 
nearby  cells.  Importantly,  paclitaxel  inhibits  EC  migration,  whereas  both 
paclitaxel  and  sirolimus  inhibit  EC  proliferation  (60).  Sirolimus  also  inhibits 
proliferation  of  EPCs  (61).  These  toxic  effects  are  evident  in  pathological 
examinations of sirolimus- and paclitaxel-eluting stents, which frequently show 
evidence  of  poor  healing,  characterised  by  persistent  fibrin  deposition  and 
incomplete  re-endothelialisation  (62).  In  addition,  chronic  eosinophilic 
infiltration  (hypersensitivity),  probably  due  to  the  polymer,  may  be  seen  and 
these findings have been closely linked to stent thrombosis. As well as impairing 
the endothelium regrowth, both sirolimus- and paclitaxel-eluting stents induce 
endothelial tissue factor expression which promotes a thrombogenic environment 
(63).  Angioscopic  examination  of  the  sirolimus-eluting  stent  in  situ  has 
visualised incomplete healing and exposed stent struts persisting at a time when a 
BMS has fully re-endothelialized, and this may be associated with subclinical 
thrombus formation (64-66). Sirolimus- and paclitaxel-eluting stents may also 
lead to an increased risk of late acquired malapposition (67); a finding which 
may predict stent thrombosis (47). The sirolimus-eluting stent has been shown to 
cause endothelial vasomotor dysfunction in the adjacent vessel segments (68), 
indicating functional impairment resulting from DES implantation. 
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Owing  to  suboptimal  endothelial  regeneration  after  DES  treatment,  combined 
antiplatelet therapy with aspirin and clopidogrel is extended by at least several 
months  during  the  perceived  re-endothelialisation  period.  If  prolonged  dual 
antiplatelet regimes are used, DES do not appear to increase the risk of stent 
thrombosis  at  12  months  compared  with  BMS  (69).  However,  as  follow-up 
continues beyond a year, there is concern that first generation DES may present 
an increased risk of late myocardial infarction and death, a clinical surrogate of 
stent thrombosis (70;71). Although complete patient level meta-analyses of the 
randomised trials with first generation DES demonstrated no overall difference in 
cardiovascular events compared with BMS, there is an increased risk of late stent 
thrombosis (72). Therefore, there is now a considerable need to ensure the next 
generation  of  DES  are  effective  and  safe,  and  that  means  ensuring  the 
endothelium is able to regenerate in a timely fashion. 
 
Recent developments in DES and polymers 
Following  the  introduction  of  the  sirolimus-  and  paclitaxel-eluting  stents  and 
especially since the reporting of late stent thrombosis, there has been interest in 
testing  novel  DES  with  alternative  biological  profiles.  By  modifying  the 
chemical  structure  of  sirolimus  (rapamycin)  slightly,  it  is  possible  to  create 
derivatives  with  improved  tissue  absorption  and  differential  effects  on  cell 
proliferation.  Zotarolimus  is  a  highly  lipophilic  sirolimus  analogue  with 
antiproliferative  and  anti-inflammatory  properties.  A  zotarolimus-eluting  stent 
has been tested as part of the Endeavor® stent program (Medtronic Vascular), 
utilising  a  cobalt  alloy  stent  platform  and  biocompatible  phosphorylcholine 
polymer. The zotarolimus-eluting stent effectively reduced ISR compared with   45 
BMS (73), but led to higher rates of ISR and repeat revascularisation compared 
with  first  generation  sirolimus-eluting  stents  (74).  The  thin-strut  permanent 
fluoropolymer-based  everolimus-eluting  cobalt  chromium  stent  (Xience  V®; 
Abbott  Advanced  Cardiovascular  Systems)  has  excellent  efficacy  in  terms  of 
reducing the incidence of ISR compared with BMS (75) and paclitaxel-eluting 
stents (76). 3 year randomised clinical trial data involving 1 302 patients in the 
SPIRIT II and SPIRIT III randomised trials reported a significant reduction in 
myocardial  infarction  and  target  lesion  revascularisation  in  the  everolimus-
eluting  Xience  V®  stent  group  compared  with  the  paclitaxel-eluting  Taxus® 
stent  group.  The  cumulate  rates  of  ARC-defined  definite  or  probable  stent 
thromboses were 1.2% in the everolimus-eluting stent patients versus 1.9% in 
paclitaxel-eluting stent patients, which was not significant  (77). 
 
Polymers  used  to  coat  the  stent  and  act  as  a  drug  delivery  mechanism  for 
biologically active agents vary in suitability, with some causing a considerable 
increase  in  neointima  formation  in  animal  models  (78).  Although 
phosphorylcholine  (which  occurs  naturally  in  red  blood  cell  membranes)  is 
thought  to  be  a  highly  biocompatible  polymer,  its  clinical  use  in  DES 
(specifically  zotarolimus-eluting  Endeavor®  stents)  has  been  associated  with 
increased rates of ISR compared with other durable polymeric DES platforms 
(73;74), most likely due to excessively rapid drug release. Furthermore, similar 
neointimal  responses  to  BMS  have  been  reported  in  some  cases  (79).  A 
preclinical comparison of a phosphorylcholine versus a fluorinated copolymer 
(as found on everolimus-eluting Xience V® stents) in rabbit iliac arteries has   46 
reported that the extent of re-endothelialisation and inflammatory response was 
similar (80).  
 
Localized hypersensitivity reactions in the artery wall associated with long-term 
exposure  to  first  generation  DES  polymers  (62)  have  prompted  attempts  to 
provide effective drug elution without the use of a permanent polymer. One such 
development is the introduction of the bioabsorbable polymer, which degrades 
over  6-9  months,  removing  the  chronic  stimulus  for  polymer-induced 
inflammatory  reactions  after  drug  elution  is  complete.  An  everolimus-eluting 
stent with a bioabsorbable polymer (polylactic acid, which degrades into carbon 
dioxide and water) has undergone investigation, and early trials demonstrate a 
reduction  in  the  incidence  of  ISR  compared  with  BMS  (81;82).  Excellent 
efficacy and safety data have also been reported in the LEADERS randomised 
trial of a biolimus-eluting stent (Biomatrix™; Biosensors International) which 
also  utilises  a  biodegradable  polylactic  acid  polymer  (83)  and  showed  non-
inferior efficacy to the polymeric sirolimus-eluting Cypher® stent. Although an 
optical  coherence  tomography  substudy  of  the  LEADERS  trial  demonstrated 
improved strut coverage in the Biomatrix™ compared with the Cypher® stent 
(84), a clear reduction in the risk of stent thrombosis using biodegradable stent 
polymers has not yet been shown.  
 
Polymer-free DES technology 
The ideal DES situation may be the carriage and controlled release of a drug 
from a stent without the necessity of a polymer, thereby obviating all potential 
toxicity. It has been shown in rabbit iliac artery stenting that whilst omission of a   47 
polymer altogether may attenuate the neointimal suppression achieved by a DES 
(likely  due  to  accelerated  drug  release),  it  may  allow  improved  re-
endothelialisation  and  reduced  local  arterial  inflammation  (85).  Reasonable 
results were demonstrated by a non-polymer paclitaxel-eluting stent (86;87). If 
non-polymer DES can achieve improved control of drug elution, equivalent to 
polymeric  DES,  then  improved  efficacy  would  be  expected.  The  Yukon® 
(Translumina®, Germany) stent platform incorporates a microporous surface to 
improve drug release characteristics and has been tested extensively as part of the 
ISAR-TEST clinical trial program. An early randomised clinical study by Dibra 
et al. initially showed that the surface modification of the Yukon® stent alone 
caused a trend to reduced ISR compared with smooth surface uncoated stents, 
suggesting  that  the  microporous  stent  surface  was  highly  biocompatible  and 
suitable for DES investigation (88). A polymer-free rapamycin-eluting Yukon® 
stent was subsequently tested in the randomised controlled ISAR-TEST study in 
450 patients and found to have equivalent efficacy to the permanent polymer 
paclitaxel-eluting Taxus® stent (89). Later studies compared the polymer-free 
Yukon® rapamycin-eluting stent with more effective DES platforms. Two year 
follow-up data from the ISAR-TEST-3 clinical study has shown that whilst that 
the polymer-free Yukon® rapamycin-eluting stent was associated with greater 
late loss in the first year, its efficacy was equivalent to both permanent polymer 
(Cypher®) or biodegradable polymer rapamycin-eluting stents after two years, 
due to late “catch-up” luminal loss in the polymer-based platforms (90). Further 
modification  of  the  polymer-free  Yukon®  rapamycin-eluting  stent  has  been 
investigated, leading to the incorporation of the antioxidant probucol as a dual 
stent  coating.  The  addition  of  probucol  has  been  shown  to  retard  rapamycin   48 
release analogous to that of a permanent polymer (91). A polymer-free Yukon® 
dual  rapamycin/probucol-eluting  stent  (dual-DES)  has  delivered  excellent 
clinical results as part of the ISAR-TEST-2 randomised clinical trial. This study 
in 1 007 patients found that the dual-DES led to significantly lower rates of ISR 
and target lesion revascularisation than the Endeavor® zotarolimus-eluting stent 
and a trend to lower rates compared with the Cypher® sirolimus-eluting stents 
after two years follow-up (92). Exploratory analysis of this study showed that the 
extent of late clinical restenosis (target lesion revascularisation between 1 and 2 
years)  was  significantly  greater  in  the  Cypher®  group,  compared  with  the 
polymer-free  dual-DES.  Similar  to  previous  trials,  there  was  no  significant 
difference  in  death,  myocardial  infarction  or  stent  thrombosis,  although  these 
studies are not individually powered to detect differences in these outcomes. 
 
Perhaps the final frontier for stent-based drug delivery is the fully bioabsorbable 
DES, so long as the mechanical properties of metal stents can be successfully 
reproduced (93). A landmark clinical study of a fully bioabsorbable everolimus-
eluting  stent  utilising  a  polylactic  acid  polymer  reported  promising  results, 
although the mean in-stent late loss of 0.48 mm and diameter stenosis of 27% 
after two years is inferior to contemporary DES (94). Future refinement of the 
bioresorbable scaffold is likely to allow these devices to compete with the next 
generation of metal stent based devices. 
 
To summarise the DES story so far, the uptake of evolving technology has led to 
major  improvements  allowing  the  provision  of  lasting  percutaneous  coronary 
revascularisation  for  patients  with  CHD.  Improvements  in  stent  design  and   49 
incorporation  of  novel  drugs  and  polymers  with  improved  efficacy  and 
biocompatibility have resulted in rates of ISR much lower to that first witnessed 
using BMS. In terms of antiproliferative drugs, limited preclinical data suggests 
that everolimus (95;96), tacrolimus (97;98) or biolimus (99) may have superior 
effects  on  EC  biology  compared  with  sirolimus.  Increasing  experience  with 
biodegradable and polymer-free DES has hinted that the risk of late “catch up” 
restenosis and very late stent thrombosis (both occurring after one year) may be 
lower with these platforms. However, there is currently no consistent data yet to 
prove that either second or third generation DES result in lower rates of hard 
clinical  events  such  as  stent  thrombosis,  myocardial  infarction  and  death. 
Evaluation  of  aggregate  long-term  efficacy  and  safety  data  from  large-scale 
randomised trials of these newer DES is awaited with interest. 
 
1.3  Oxidative stress 
 
1.3.1  Oxidative stress and cardiovascular disease 
Reactive oxygen species (ROS) are highly reactive molecules released from the 
artery wall and circulating cells that have a profound impact on many biological 
processes.  Increased  production  of  ROS  is  a  characteristic  feature  of  several 
cardiovascular  diseases  such  as  atherosclerosis,  hypertension  and  diabetes 
mellitus. ROS are capable of oxidising other substances by becoming reduced 
themselves. Oxidative stress is a phenomenon which describes the net influence 
of  oxidants  such  as  ROS  over  antioxidant  defences.  Oxygen  is  an  abundant 
molecule  found  in  humans  and  the  relatively  stable  oxygen  molecule  can 
undergo univalent reduction to form the superoxide anion (O2
-), a powerful ROS   50 
and a major component of oxidative stress. The formation of O2
- occurs through 
the  action  of  a  number  of  enzymes,  the  foremost  of  which  is  believed  to  be 
nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate 
(NADH/NADPH)  oxidase.  This  enzyme  is  active  in  ECs,  vascular  SMCs, 
leucocytes and platelets, often as a response to vascular injury. 
 
Other enzymes contributing to oxidative stress include xanthine oxidase (XO), 
which generates O2
- by catalyzing hypoxanthine and xanthine to uric acid, nitric 
oxide synthase (NOS), which generates the free radical NO from L-arginine and 
the  lipoxygenases,  which  oxidise  polyunsaturated  fatty  acids  to  hydroperoxy 
fatty-acid derivatives. Oxygen can also be converted into O2
- nonenzymatically 
as a result of electron transfers in the mitochondrial electron transfer chain (100). 
O2
-  can  be  dismutated  to  form  another  biologically  active  ROS,  hydrogen 
peroxide (H2O2) through the action of superoxide dismutase (SOD). H2O2 can be 
decomposed  into  water  and  oxygen  by  the  enzyme  catalase.  Other  highly 
influential ROS include peroxynitrite (ONOO
-), which is formed by the reaction 
between O2
- and NO, and the hydroxyl anion (OH
-), which is generated by the 
reaction between O2
- and H2O2. Both ONOO
- and OH
- anions are very strong 
oxidants.  
 
Oxidative stress is critically involved in the pathophysiology of atherosclerosis 
(Figure  1.5)  (101).  Circulating  low  density  lipoprotein  (LDL)  in  the  blood  is 
oxidised by ROS to form oxidised low-density lipoprotein (oxLDL). OxLDL is 
capable of causing damage to the vascular endothelium and this promotes the 
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Figure 1.5  Oxidative modification hypothesis of atherogenesis. 
Circulating monocytes in the bloodstream are drawn into the subendothelial space and 
become macrophages. Native LDL is taken up and oxidised by ROS such as O2
- released 
from  local  vascular  SMCs,  ECs  and  macrophages.  Macrophages  take  up  oxLDL  to 
become foam cells, which are precursors to atherosclerotic development. OxLDL causes 
endothelial dysfunction and injury which encourages monocyte recruitment and inhibits 
macrophage regress back into lumen. 
 
transport  of  lipoproteins  into  the  artery  wall  to  form  the  fatty  streak  (102). 
Oxidative stress, and in particular the activity of the ROS producing enzyme, 
NADPH  oxidase,  is  an  important  contributor  to  coronary  plaque  instability, 
which can trigger acute coronary syndromes by leading to plaque rupture and 
resulting in thrombotic occlusion of the artery (103).  
 
1.3.2  Antioxidants and cardiovascular disease 
In response to numerous different ROS found in biological systems, cells have 
evolved  to  develop  potent  defensive  antioxidant  strategies.  Endogenous 
antioxidant enzymes include SOD, catalase, glutathione peroxidase and glucose-  52 
6-phosphate  dehydrogenase.  Non-enzymatic  antioxidants  include  glutathione, 
ascorbate  (vitamin  C),  α-tocopherol  (vitamin  E)  and  high-density  lipoprotein 
(HDL). 
 
Given  that  oxidative  stress  is  a  hallmark  of  many  cardiovascular  disease 
processes, much work has been done to determine if oral supplementation of 
antioxidants  can  prevent  clinical  events  such  as  myocardial  infarction  and 
cardiovascular death. Some early trials showed promising results. In addition to 
its antiplatelet and anti-inflammatory actions, Vitamin E reduces the oxidation of 
LDL and is perhaps the most widely tested antioxidant therapy in clinical studies 
(104).  The  Cambridge  Heart  Antioxidant  Study  (CHAOS)  randomised  2  002 
patients  with  proven  CHD  to  oral  vitamin  E  or  placebo  and  demonstrated  a 
reduction  in  the  primary  endpoint  of  cardiovascular  death  or  non-fatal 
myocardial infarction (105). However, the encouraging results of CHAOS have 
not  been  confirmed  in  larger  randomised  studies.  In  the  9  541  patient  Heart 
Outcomes  Prevention  Evaluation  (HOPE)  trial,  vitamin  E  failed  to  reduce 
cardiovascular events in patients with high cardiovascular risk (106). Similarly, 
negative results were reported using Vitamin E in the post-myocardial infarction 
GISSI-Prevenzione  trial  (107)  and  the  Heart  Protection  Study  (HPS),  which 
investigated the use of a combination of antioxidant vitamins for primary and 
secondary prevention (108). 
 
The failure of systemic antioxidants to reduce cardiovascular events in clinical 
trials has been discussed widely and some authors speculate on an inability to 
target therapies to population subtypes with enhanced oxidative stress such as   53 
diabetics  or  end-stage  renal  disease  (109).  Others  suggest  that  more  potent 
antioxidants are required to demonstrate clinical benefit (110). Crucially, very 
few studies have evaluated oxidative status at a cellular level in treated patients, 
instead  opting  to  supplement  antioxidants  without  confirming  antioxidant 
efficacy.  Nevertheless,  on  the  basis  of  current  evidence,  oral  antioxidant 
supplementation is not recommended for the prevention of cardiovascular events. 
The  local  delivery  of  antioxidants  directly  to  the  vascular  wall  represents  an 
opportunity  to  achieve  high  concentration  at  the  intended  site  of  action  with 
relatively few side-effects, although this technique is currently poorly studied.  
 
1.3.3  Oxidative stress and PCI 
Evidence for increased oxidative stress following PCI 
Inflation  of  an  angioplasty  balloon  to  high  atmospheric  pressure  to  dilate  a 
stenotic  coronary  artery  with  deployment  of  a  metal  stent  causes  extensive 
mechanical trauma to the artery wall, resulting in marked vessel injury. As a 
result, the artery releases a large amount of ROS. 
 
Ex-vivo rabbit artery rings subjected to balloon injury demonstrated immediate 
release of ROS as a result of vessel wall NADPH oxidoreductase activity (111). 
The  release  was  proportional  to  degree  of  injury  and  not  prevented  by  prior 
removal of the endothelium or antagonism of other ROS generating sources such 
as XO, NOS or mitochondrial electron transport. Another study demonstrated 
that ex-vivo porcine coronary artery segments continue to release large amounts 
of O2
- for at least several days after in vivo balloon injury (112). O2
- production 
was essentially abolished after pretreatment of the artery ring with the NADPH   54 
oxidase  inhibitor,  diphenyleneiodonium  (DPI),  again  underlining  the 
predominance of this enzyme in ROS generation after balloon injury.  
 
A method for in vivo estimation of oxidative stress as a result of PCI in humans 
involves  simultaneous  assay  of  coronary  sinus  blood,  which  provides  venous 
drainage for the heart. Compared to upstream left main coronary artery blood, 
isoprostanes  (end-products  of  ROS  mediated-lipid  peroxidation)  are  increased 
(113). Coronary angioplasty in humans also causes an acute increase in plasma 
levels of oxidised lipoproteins (114;115). The acute increase in oxidative stress 
following PCI may be partly responsible for impaired microcirculatory function 
after stent deployment. In a study of stable angina patients, the administration of 
intravenous  ascorbic  acid  was  shown  to  decrease  the  release  of  oxidative 
biomarkers  (8-hydroxy-2-deoxyguanosine  and  8-iso-prostaglandin
  F2alpha)  and 
improve angiographic evidence of myocardial perfusion following elective PCI 
(116), although no differences in clinical outcome were detected. 
 
The influence of oxidative stress on cellular processes after PCI 
It is clear that oxidative stress is enhanced after arterial injury and, by influencing 
multiple signalling pathways of vascular repair, it appears to play an important 
role  in  the  regulation  of  NIH  (117).  Early  transient  exposure  to  oxidised 
glutathione,  a  recognised  consequence  of  oxidative  stress,  is  capable  of 
amplifying cell proliferation and NIH, which is sustained for weeks after arterial 
balloon  injury  and  mediated  through  a  redox-active  metal-dependent  pathway 
(118). The activation of the transcription factor nuclear factor κB (NF-κB) is 
enhanced by redox processes after injury (111) and this may have a lasting effect   55 
on the gene programme involved in NIH, including expression of vascular cell 
adhesion  molecule-1  (VCAM-1),  MCP-1  and  other  pro-inflammatory  factors 
(119;120). ROS also serve as second messengers to activate many intracellular 
proteins and enzymes, including the epidermal growth factor receptor (EGFR), c-
Src, p38 mitogen-activated protein kinase (MAPK), Ras and Akt/PKB, which 
suggests  a  significant  role  in  the  regulation  of  vascular  SMC  growth  and 
migration, modification of extracellular matrix and modulation of EC function 
(121).  The  response  of  vascular  SMCs  to  PDGF,  which  includes  tyrosine 
phosphorylation, MAPK stimulation, DNA synthesis and chemotaxis, is at least 
partly dependent on elevated intracellular levels of the ROS, H2O2 (122). The 
prominent influence of oxidative stress on NIH after vascular injury is matched 
by a major involvement in the regulation of endothelial recovery. OxLDL formed 
by the oxidative modification of native LDL in the bloodstream is widely present 
in coronary artery lesions. Atherosclerotic plaques enriched with high levels of 
oxLDL are more likely to become unstable (123), and plasma oxLDL is acutely 
elevated  after  PCI  (115).  oxLDL  is  toxic  to  EPCs  (124),  which  are  likely  to 
suffer  from  impaired  antioxidant  defences  in  the  presence  of  atherosclerosis 
(125). oxLDL is also a potent inhibitor of EC migration and this occurs via an 
O2
- dependent mechanism (126). As a result, oxLDL may influence healing of a 
stent deeply embedded in coronary lesions so that the rate of endothelialization is 
suboptimal, even after BMS. The inhibitory effect of oxLDL on EC migration in 
culture is blocked by the antioxidant vitamin E (127). Uptake of the lipophilic 
antioxidants probucol and vitamin E, both stimulate EC proliferation in culture 
(128) and are protective against the harmful effects of other ROS (129). NO 
released by the endothelium encourages migration and growth of ECs (130), and   56 
endothelial  NOS  (eNOS)  expression  is  increased  in  regenerating  endothelium 
following injury (131). However, in situations where there is major oxidative 
stress, such as PCI, there may be widespread scavenging of NO by released ROS, 
such as the reaction of NO with O2
- to form ONOO
-, one of the most potent 
endocellular  oxidants  (132).  The  protective  effect  of  NO  on  endothelial 
regeneration may be lost and, instead, ONOO
- produced, which is harmful to 
ECs (133). These findings support a role for antioxidant therapy delivered to the 
site  of  arterial  injury  to  defend  the  regenerating  endothelium  against  the 
deleterious effects of oxLDL, O2
-, ONOO
- and other toxic ROS, whilst allowing 
NO to establish a protective effect on the endothelial healing process. 
 
Inhibition of thrombus formation and promotion of endothelial regeneration after 
PCI is highly preferable to reduce the risk of stent thrombosis. The underlying 
pathophysiology of arterial thrombosis is intrinsically linked to oxidative stress 
(134). Primarily, ROS inactivate NO, which has important antiplatelet actions 
(32). Vitamin E supplementation in healthy individuals has been shown to inhibit 
platelet aggregation (135). It has also been shown to decrease oxidative stress, 
increase platelet NO release, delay intra-arterial thrombus formation (136) and 
improve fibrinolysis via a reduction in plasminogen activator inhibitor activity 
(137).  The  antioxidant,  N-acetyl-cysteine  has  been  shown  to  reduce  the 
procoagulant  response  following  aortic  balloon  injury  by  decreasing  bound 
thrombin activity and platelet adhesion (138). Other antioxidant compounds have 
been  shown  to  inhibit  platelet  aggregation.  A  series  of  caffeic  acid  anilides 
exhibited potent anti-oxidative activities and inhibited arachidonic acid-induced 
platelet aggregation (139). Pomegranate juice, a natural source of antioxidants,   57 
inhibited human platelet aggregation in response to collagen (140). Antioxidant 
flavonoids from black tea were found to decrease platelet aggregation in healthy 
human subjects (141). DPI, an inhibitor of NADPH-oxidase, also inhibits platelet 
aggregation (142). 
 
Despite the relative wealth of in vitro and animal data implying the importance 
of  oxidative  stress  and  the  ability  of  some  antioxidants  to  influence  critical 
molecular  and  cellular  vascular  pathophysiological  processes,  less  impressive 
results have been witnessed in human studies with no consistent evidence that 
these compounds have the capacity to influence hard clinical outcomes such as 
myocardial infarction or cardiovascular death.  
 
1.3.4  Antioxidants and PCI 
Much of the experimental data supporting the role of antioxidants to inhibit NIH 
and improve endothelial repair has been reinforced by several in vivo studies 
suggesting that strategies to decrease oxidative stress can reduce restenosis and 
encourage re-endothelialization after PCI (Table 1.1). As the major source of 
ROS after balloon injury is via NADPH oxidase, inhibitors of this enzyme have 
been tested and found to reduce NIH in animal models (143;144). Delivery of 
extracellular SOD gene therapy to the artery wall after balloon denudation of the 
rabbit  aorta  reduced  NIH  and  improved  endothelial  recovery  (145).  Another 
study in atherosclerotic rabbit iliac arteries showed that gene transfer of SOD and 
catalase  dramatically  reduced  ROS  release  from  the  artery  wall  after  balloon 
angioplasty (146). This was accompanied by less neointimal inflammation and  
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Table 1.1  Main antioxidant studies for restenosis and re-endothelialisation. 
Study 
(ref) 
Anti-
oxidant 
Species and dose  Main findings 
Jacobson et al. 
(143) 
NOX 
inhibitor 
Rat carotid balloon injury  
IP minipump 
Reduced NIH (p<0.05) 
Dourron et al. 
(144) 
NOX 
inhibitor 
Rat  carotid  balloon  injury 
Gene transfer 
Reduced NIH (p<0.05) 
Laukkanen et al. 
(145) 
SOD  Rabbit  aortic  balloon  injury 
Gene transfer 
Reduced NIH, improved  
re-endothelialisation (both p<0.001) 
Durand et al. 
(146) 
SOD/CAT  Rabbit  iliac  balloon  injury 
Gene transfer 
Reduced restenosis, improved  
re-endothelialisation (both p<0.05) 
Schneider et al.  
(147) 
Probucol  Pig  coronary  balloon  injury 
Oral 2 g/day 
Reduced NIH (p=0.007) 
Miyauchi et al. 
(148) 
Probucol  Rabbit carotid balloon injury 
Oral 1.3 g/day 
Reduced NIH (p<0.05) 
Lau et al.  
(149) 
Probucol  Rabbit  aortic  balloon  injury 
Oral 0.75% wt/wt 
Reduced NIH, improved  
re-endothelialisation (both p<0.05) 
Tanous et al. 
(150) 
Probucol  Rabbit aortic stent  
Oral 1% wt/wt 
Reduced NIH and restenosis (both p<0.05), 
improved re-endothelialisation (p=0.008) 
Tardif et al.  
(151) 
Probucol  Human PTCA  
Oral 1 g/day 
Reduced restenosis (improved remodelling) 
(p=0.003) and repeat PTCA (p=0.009) 
Yokoi et al.  
(152) 
Probucol  Human PTCA  
Oral 1 g/day 
Reduced restenosis (p<0.01) 
Sekiya et al. 
 (153) 
Probucol  Human coronary stent  
Oral 500 mg/day 
Reduced restenosis rate (17% vs 32%, 
p=NS), with cilostazol (p<0.05) 
Kim et al.  
(154) 
Probucol  Human coronary stent  
Oral 500 mg/day 
Reduced restenosis rate (21% vs 24%, 
p=NS) 
Wakeyama et al. 
(155) 
Probucol  Human coronary stent  
Oral 500 mg/day 
Reduced NIH (<0.001) and reduced 
restenosis (p=0.1)  
Tardif et al.  
(156) 
Probucol  Human coronary stent  
Oral 1 g/day 
Increased follow up LA (p<0.05) due to 
greater acute gain 
Nunes et al.  
(157)  
Probucol  Human coronary stent  
Oral 1 g/day 
No effect on NIH or restenosis 
Kim et al.  
(158) 
Probucol  Pig coronary DES  
Stent delivery 
No effect on NIH or restenosis 
Tardif et al.  
(156) 
AGI-1067 
(succinobucol) 
Human coronary stent  
Oral 280 mg/day 
Increased follow up LA (p<0.05) due to 
greater acute gain 
Kim et al.  
(158) 
Carvedilol  Pig coronary DES  
Stent delivery 
Reduced NIH (p=0.004) and reduced 
restenosis (p=0.002) 
NOX,  NADPH  oxidase;  IP,  intraperitoneal;  CAT,  catalase;  PTCA,  percutaneous 
transluminal coronary angioplasty; LA, lumen area. 
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reduced restenosis, with improved re-endothelialization and endothelial function. 
However, there is no data yet to suggest that incorporation of gene transfer to 
reduce restenosis in humans is a viable option and therefore these studies have 
poor  applicability.  Most  techniques  to  deliver  gene-based  therapy  during 
angioplasty rely on infusion of active treatments directly into the artery wall and 
therefore  have  significant  practical  limitations,  compared  with  DES.  Despite 
some  evidence  that  NO  encourages  EC  growth  in  vitro,  L-arginine  (a  NO 
precursor) had no effect on re-endothelialization in denuded rabbit iliac arteries, 
although it effectively inhibited neointimal growth (159).  
 
Early trials of probucol administration in animal models of balloon angioplasty 
demonstrated a reduction in NIH and restenosis (147;148). Probucol restricts the 
severity of NIH by inhibiting vascular SMC proliferation via enhanced G1/S-
phase  growth  arrest  and  improving  endothelial  healing  (149).  A  major 
mechanism by which probucol mediates these beneficial effects is believed to be 
via  up-regulation  of  heme  oxygenase-1,  which  induces  SMC  apoptosis  (by 
producing heme breakdown products carbon monoxide, biliverdin and bilirubin) 
and promotes EC function (160). In keeping with these findings, supplementation 
of probucol inhibited NIH and improved re-endothelialisation in a rabbit model 
of aortic balloon injury (149). Owing to the positive animal studies, probucol has 
now  been  extensively  tested  in  clinical  trials,  perhaps  more  than  any  other 
antioxidant  compound.  The  Multivitamins  and  Probucol  (MVP)  trial  and 
Probucol Angioplasty Restenosis trial (PART) both reported a clear reduction in 
restenosis after coronary angioplasty (151;152). However, a subsequent IVUS 
substudy  of  the  MVP  trial  showed  that  the  beneficial  effect  of  probucol  was   60 
related to improved post-angioplasty remodelling, rather than suppression of NIH 
(161).  
 
Investigation  in  the  stent  era  has  continued  with  a  variety  of  clinical  trials 
examining  the  effects  of  oral  probucol  on  ISR.  Oral  probucol  approximately 
halved ISR rates in one clinical trial, although the effect was only significant 
when  the  drug  was  combined  with  the  phosphodiesterase  inhibitor,  cilostazol 
(153).  A  trend  to  inhibit  ISR  was  reported  in  another  clinical  study  (162); 
however,  the  trial  design  was  criticised  due  to  inadequate  preloading  of  oral 
probucol, which accumulates slowly in tissues and is usually commenced four 
weeks before the procedure. A clinical trial designed to determine the effect of 
candesartan and probucol on ISR found no benefits from angiotensin receptor 
blockade;  however,  using  probucol,  there  were  significant  reductions  in 
angiographic late loss and NIH by IVUS analysis (155).  
 
The large Canadian Antioxidant Restenosis Trial (CART-1) was a multi-centre, 
double-blind, placebo-controlled randomised trial in 305 patients comparing oral 
administration of probucol, succinobucol (AGI-1067) or placebo after PCI (156), 
involving stents in 85% of patients. Succinobucol is a novel probucol derivative 
with  superior  pharmacokinetic,  antioxidant  and  anti-inflammatory  properties 
compared with probucol (163-165). It has been shown to prevent atherosclerosis 
in animal models (164;166) and is discussed in more detail in Chapter 5. Two 
weeks  prior  to  PCI,  patients  were  assigned  to  one  of  the  5  treatment  groups 
(probucol 500 mg twice daily, succinobucol 70 mg, 140 mg, 280 mg once daily 
or placebo)  and treated for 2 weeks before and 4 weeks after PCI. Angiographic   61 
follow-up  with  baseline  and  6-month  IVUS  examinations  was  performed  to 
evaluate the efficacy of each group. Positive results were reported, with greater 
stent  luminal  area  present  in  the  highest  dose  of  succinobucol  and  probucol 
groups, compared with placebo after 6 months. There was a significant dose-
response  relationship  for  succinobucol,  suggesting  a  true  biological  effect. 
Although  CART-1  is  often  cited  to  provide  evidence  that  succinobucol  and 
probucol are both capable of reducing ISR, no statistically significant difference 
was  demonstrated  for  this  end-point  unless  compliant  patients  were  analysed 
separately.  Furthermore,  detailed  IVUS  analysis  showed  clearly  that 
supplementation of neither oral succinobucol nor probucol caused inhibition of 
neointimal growth and the advantages in final luminal area were due to greater 
acute luminal gain at the time of the index PCI. The underlying mechanism for 
this effect was not clear but speculatively may have been related to improved 
endothelial function of the diseased segment or favourable alterations in plaque 
composition due to antioxidant pre-treatment, allowing greater luminal gain at 
the time of balloon dilation and stent deployment. CART-2 was a subsequent 
IVUS study originally designed to investigate the effect of oral succinobucol 280 
mg once daily on ISR following PCI, however due to considerable difficulties 
with the technical quality of serial IVUS examinations, the trial was altered to 
examine the effect of succinobucol on coronary plaques in adjacent segments. 
Although atherosclerosis regression was evident in the succinobucol group, this 
effect was not significantly different from placebo (167). Taking the data from 
the CART-1 and CART-2 clinical studies and that of the ISAR-TEST clinical 
research  program  into  consideration,  succinobucol  is  unlikely  to  be  an 
efficacious  oral  antirestenotic  agent  in  clinical  practice  but  may  provide   62 
advantageous  if  successfully  incorporated  in  a  fully  biocompatible  DES  or 
potentially as a dual coating with a recognised inhibitor of restenosis (such as 
rapamycin) to improve its performance, similar to the probucol/rapamycin dual 
DES, and this strategy appears to merit further exploration. 
 
In more recent clinical study, oral probucol failed to reduce ISR following PCI, 
as determined by IVUS (157). This result should be viewed with some caution 
because confounding factors known to increase the risk of ISR were present in 
the probucol group, such as the treatment of significantly smaller vessels and a 
higher  incidence  of  diabetes  and  acute  lesions.  A  rabbit  study  which  looked 
specifically at the effects of probucol on healing after stent injury reported a 
considerable  improvement  in  stent  endothelialization,  accompanied  by  a 
reduction in NIH and less evidence of stent thrombosis (150). In this trial, oral 
probucol therapy also reduced leucocyte accumulation around the stent struts, 
suggesting  its  anti-inflammatory  effects  may  exert  a  significant  role  in 
suppression of NIH, at least in animals.  
 
These studies testing the ability of antioxidants to reduce restenosis after balloon 
angioplasty  or  stenting  have  generally  relied  on  oral  administration.  Studies 
which  consistently  demonstrated  the  most  impressive  reductions  in  ISR  were 
performed in animals, where oral regimens are possible at a dose not possible in 
clinical  practice.  The  application  of  stent-based  delivery  of  antioxidants  may 
provide an ideal opportunity to achieve optimal local tissue concentration, whilst 
minimizing  toxic  systemic  side-effects.  Such  work  has  been  performed  with 
carvedilol, a β-blocker with potent antioxidant activity. It has been shown that   63 
implantation  of  a  carvedilol-coated  stent  in  a  porcine  model  was  capable  of 
inhibiting  ISR  and  providing  complete  re-endothelialization  (158).  The  same 
study  failed  to  demonstrate  a  beneficial  effect  from  a  probucol-coated  stent, 
although there were concerns about adequate drug delivery in this study.  
 
Given  the  broadly  favourable  preclinical  data  for  high-dose  oral  antioxidant 
supplementation  after  coronary  angioplasty  and  the  modest  effect  of  oral 
antioxidants evident in humans, the challenge of future trials is likely to focus on 
the  incorporation  of  novel  potent  antioxidants  into  contemporary  DES 
technology,  which  will  provide  targeted  delivery  and  increased  local  tissue 
concentration  without  the  potential  drawbacks  of  systemic  toxicity  and 
administration,  mirroring  the  successful  development  of  other  potent 
antiproliferative agents delivered via DES. 
 
1.4   Preclinical models of restenosis 
 
Several  animal  models  have  played  a  pivotal  role  in  preclinical  studies  to 
examine the biological events resulting from PCI and to test the efficacy and 
safety of stents prior to investigation in human studies.  
 
1.4.1  Murine models 
Murine  models  of  arterial  injury  and  restenosis  are  favoured  by  cost-
effectiveness and ease of handling and housing, as well as providing a relatively 
accessible  way  to  examine  the  influence  of  a  wide  variety  of  molecular 
biomarkers.  The  rat  carotid  model  for  restenosis  was  developed  following   64 
extensive use as a model for human atherosclerosis. Whilst these models have 
provided  extensive  data  on  the  effects  of  endothelial  denudation  on  SMC 
proliferation and inflammatory responses (168), the cumulative shortcomings of 
the murine models are significant. The effects of arterial injury cause a modest 
neointimal response in rodents and critically, results in these models have failed 
to consistently replicate the effect of test  compounds in human studies, most 
notably the effect of angiotensin-converting enzyme inhibitors (169).  
 
1.4.2  Hypercholesterolaemic rabbit iliac model 
The rabbit iliac model has been used extensively to study atherosclerosis and 
restenosis.  Rabbits  are  readily  susceptible  to  dietary  increases  in  cholesterol 
which  leads  to  rapid  atherosclerotic  development,  which  is  similar  but  not 
identical to that found in humans. Important differences exist in the histological 
composition and behaviour of atheromatous lesions in the rabbit model compared 
with humans, leading to limitations in the translation of data into clinical studies. 
An important criticism of this model for assessment of restenosis therapies is that 
the  abundant  foam  cells  and  extracellular  matrix  generated  by  the 
hypercholesterolaemic  state  are  not  heavily  involved  in  human  neointimal 
formation.  Nevertheless,  despite  these  caveats,  the  rabbit  iliac  stenting  model 
remains a relatively cost-effective way to assess the efficacy of antiproliferative 
drugs and has provided valuable data on the relative safety and toxicity of DES 
in the past decade (85;170). 
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1.4.3  Porcine coronary artery model 
Early  pig  models  were  able  to  demonstrate  that  the  acute  trauma  related  to 
coronary angioplasty was responsible for severe injury and provocation of the 
restenotic  cascade  in  humans  (171;172).  The  response  of  healthy  porcine 
coronary  arteries  to  overstretch  injury  closely  replicates  that  found  in  human 
restenosis. Stent injury in the porcine coronary artery leads to thick neointimal 
development  within  28  days,  identical  to  human  restenotic  tissue.  Coronary 
artery  anatomy  is  similar  to  humans  and  therefore  allows  the  use  of  human 
catheterisation  equipment  to  accurately  reflect  clinical  practice.  The  flow 
dynamics of the porcine coronary vasculature closely parallels that of humans, 
enabling a more reliable estimate of drug pharmacokinetics to take place. The 
disadvantages of the pig model are higher costs compared to smaller animals 
with related housing practicalities and expenses. Other considerations in the pig 
are potential differences in the inflammatory reactions to stent injury, which may 
display excessive granulomatous or eosinophilic infiltrates (173). Crucially, the 
effects of DES in the porcine model have been most predictive of their effects in 
humans, providing the strongest rationale for testing novel devices in this species 
(174). The pig coronary artery model has therefore become the standard model 
for the preclinical evaluation of DES (175). 
 
1.5  Hypothesis and aims 
 
The current literature indicates that oxidative stress may play a substantial role in 
modifying platelet and cellular responses following PCI. The events leading to 
ISR  and  stent  healing  are  complicated  and  not  completely  understood,  but   66 
oxidative stress appears be involved in a number of important aspects. This thesis 
will investigate the effect of oxidative stress on several key processes closely 
involved  in  the  response  to  arterial  injury  and  the  ability  of  antioxidants  to 
favourably modify vascular healing. Specific approaches to decrease the impact 
of ROS will be tested, although it is appreciated that focussing on one particular 
antioxidant  strategy  may  be  insufficient  to  totally  eliminate  the  effects  of 
oxidative stress during vascular repair, as other oxidative pathways may remain 
active.  As  this  may  limit  efficacy  after  PCI,  complementary  antiproliferative 
strategies in addition to a purely antioxidant approach may be considered. 
 
The first part of the thesis will focus on in vitro aspects occurring immediately 
after  stent  deployment.  The  effect  of  abundant  ROS  released  after  PCI  may 
directly promote blood aggregation which could contribute to a higher risk of 
early stent thrombosis, the period at greatest risk because the stent has not yet 
endothelialised. Enhancement of platelet aggregation in human whole blood by 
locally released oxidants may increase the risk of myocardial infarction, carrying 
a substantial risk of death. This thesis will therefore examine the direct effect of 
ROS on blood aggregation and also whether ROS influence the antithrombotic 
properties of the endothelium, which is responsible for rapidly recovering the 
stent surface and providing protection against stent thrombosis. The direct effect 
of ROS on the migration of healthy ECs will also be investigated, as this may 
indicate  that  locally  increased  oxidative  stress  has  the  capacity  to  impair 
endothelialisation of stents, thereby exacerbating the risk of stent thrombosis and 
also  promoting  the  rapid  growth  of  neointimal  tissue,  which  is  known  to  be 
inhibited by regenerated endothelium.   67 
In vivo testing will provide the basis for the second part of this thesis. I will 
evaluate  the  ability  of  a  novel  potent  antioxidant  loaded  on  a  DES  to  offer 
improved healing and reduced neointimal thickening in a preclinical model of 
restenosis, using the pig coronary artery overstretch injury method. This is likely 
to  provide  valuable  information  on  the  potential  for  antioxidant  DES  to 
outperform  other  novel  DES  in  clinical  studies.  The  highly  biocompatible 
polymer-free  microporous  Yukon®  stent  platform  will  be  used  to  avoid  the 
negative  impact  of  persistent  polymers  on  arterial  healing  and  minimise  the 
likelihood of late “catch-up” restenosis or aggravated inflammation. This stent 
platform will also enable “in-house” individualised DES coating and is already 
supported by large-scale clinical research studies (ISAR program, Munich Heart 
Centre). Scarce data exists reporting the effectiveness of an antioxidant-eluting 
stent  approach  in  a  preclinical  or  clinical  research  setting.  I  hypothesise  that 
delivery of a suitable, potent antioxidant from a polymer-free DES may be able 
to  achieve  local  suppression  of  oxidative  stress,  thus  inhibiting  platelet 
aggregation and neointimal growth, and accelerating re-endothelialisation, with 
minimal systemic toxicity (figure 1.6). These attributes may reduce the risk of 
ISR and stent thrombosis. 
 
The  final  part  of  the  thesis  will  investigate  more  broadly  the  influence  of 
circulating  ROS  on  another  important  aspect  of  stent  healing  and  the  risk  of 
thrombosis.  As  described  already,  it  is  now  recognised  that  regrowth  of 
functional endothelium is supported by the mobilisation and homing of EPCs to  
sites of endothelial damage. This systemic mechanism of vascular  restoration  
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Figure 1.6  The potential role of antioxidants after PCI. The endothelium prevents 
thrombosis  via  the  actions  of  prostacyclin  (PGI2),  ADPase,  tPA  and  NO,  prevents 
contact between blood and the subendothelial layer (rich in procoagulant materials), and 
inhibits NIH. First-generation DES inhibit NIH, but impair re-endothelialisation. PCI 
injury causes major O2
- release (primarily via NOX), which impairs re-endothelialisation 
and promotes NIH. Antioxidants may limit NIH and reduce thrombosis by accelerating 
re-endothelialisation and scavenging O2
-. 
 
may  constitute  an  important  component  of  re-endothelialisation  after  arterial 
injury  secondary  to  PCI  (176).  The  relationship  between  systemic  levels  of 
oxidative  stress  in  the  bloodstream,  which  is  elevated  due  to  PCI,  on  this 
endothelial repair system is not well known. The potential for circulating EPCs 
to maintain coronary endothelial function in patients with CHD is also poorly 
recognised. This thesis will therefore investigate the correlation between plasma 
levels of oxLDL (a major component of oxidative stress in humans), the number 
of circulating EPCs and endothelial function in patients with CHD. Patients with   69 
stable angina already scheduled for PCI will be recruited to facilitate invasive 
testing  of  their  coronary  endothelial  function  at  the  time  of  their  planned 
coronary  intervention  and  also  to  provide  access  to  patient  blood  from  a 
population with significant CHD undergoing PCI.  
 
To summarise, the overall aims of this thesis are: 
 
1  Using human whole blood and cultured porcine ECs, to investigate 
the influence of oxidative stress and antioxidants on WBA, the EC-
platelet interaction and EC migration.  
 
2  Using  an  in  vivo  model  of  porcine  coronary  stent  implantation,  to 
determine whether a novel antioxidant-eluting stent leads to reduced 
NIH and improved healing. 
 
3  In patients with angina, to determine whether plasma levels of oxLDL 
are associated with impaired endothelial repair (reduced circulating 
EPCs),  impaired  coronary  endothelial  function  or  increased  whole 
blood aggregation. 
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Chapter 2 
 
The effect of oxidative stress on whole blood aggregation 
and the endothelial cell-platelet interaction 
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2.1  Introduction 
 
Oxidative  stress  is  recognised  as  an  important  mediator  of  atherothrombotic 
events in cardiovascular disease (134). The classic paradigm is the formation of 
platelet-rich  thrombus  overlying  a  region  of  injured  or  dysfunctional 
endothelium. In addition to many other factors, oxidative stress participates in 
the regulation of platelet activation and thrombus formation. The effects of ROS 
on thrombus formation are of direct clinical relevance to PCI, which is known to 
stimulate  the  release  of  ROS  from  the  surrounding  vascular  wall.  The  direct 
effects of ROS on platelet function are reportedly varied. Previous platelet assays 
in healthy individuals have reported both pro- and anti-aggregatory effects when 
platelets are exposed to exogenous ROS (177). Platelets themselves also generate 
ROS and this appears to be of significant relevance during recruitment, adhesion 
and aggregation (178). 
 
Although there is good evidence that oxidative stress damages the endothelium 
in  vivo,  which  predisposes  individuals  to  thrombosis,  the  close  interactions 
between  ROS  and  ECs  are  not  completely  understood.  Healthy  ECs  inhibit 
thrombosis  (179),  but  the  direct  actions  of  ROS  on  ECs  may  influence  their 
antithrombotic properties, which may elevate the risk of stent thrombosis. 
 
WBA  offers  the  most  physiological  setting  in  which  to  examine  platelet-
mediated  thrombus  formation.  Furthermore,  it  closely  replicates  the  milieu  in 
which  clinical  thrombosis  occurs,  where  other  blood  constituents  including 
erythrocytes (180), leucocytes (181) and plasma-derived substances (182;183)   72 
are involved. ECs are thought to inhibit platelet aggregation by release of NO 
(32), prostacyclin (33), and the activity of endothelial ectonucleotidases (184), 
although in the presence of heightened oxidative stress, some of these effects 
may be deficient. My aims were to quantify the effects of ROS on WBA and to 
assess the influence of ROS on the EC-platelet interaction in patients with CHD. 
 
2.2  Methods 
 
2.2.1  Chemiluminescence 
Lucigenin  chemiluminescence  (CL)  was  used  in  non-biological  samples  to 
confirm generation of ROS (specifically superoxide anion, O2
-) as a consequence 
of the X/XO reaction (185). 900 µl phosphate buffered saline (PBS) was added to 
a clear plastic sample cuvette. This was prewarmed at 37 ºC for 5 minutes in an 
incubation chamber. 100 µl lucigenin solution (Sigma-Aldrich, Dorset, UK) was 
prepared in distilled water and added to the cuvette with the test substance(s). As 
lugenin  may  itself  interfere  with  O2
-  generation  (186),  a  range  of  lucigenin 
concentrations were tested and the concentration producing the least additional 
chemiluminescence signal was used for subsequent experiments. The cuvette was 
transferred immediately to a chemiluminometer (Berthold, Germany). The delay 
was set to 10 seconds and the chemiluminescence signal was recorded after 120 
seconds in relative light units per seconde (RLU/s). Xanthine (Sigma-Aldrich, 
Dorset, UK) was dissolved in 10 mM NaOH and XO (Sigma-Aldrich, Dorset, 
UK) was dissolved in PBS. 
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2.2.2  Study population for WBA 
This study was approved by the West Glasgow and University of Strathclyde 
ethics committees. All participants were provided with a Participant Information 
Sheet  (PIS)  and  gave  their  informed  written  consent.  Preliminary  WBA 
experiments  were  performed  on  venous  blood  donated  by  healthy  human 
volunteers,  recruited  from  the  University  of  Strathclyde  cardiovascular 
laboratory.  In  order  to  examine  the  effect  of  oxidative  stress  in  a  population 
closely matched to those undergoing PCI, adult patients with symptomatic stable 
CHD  who  were  referred  to  the  Western  Infirmary  Glasgow  for  out-patient 
cardiology  appointments  were  recruited.  All  patients  were  over  age  18  and 
receiving  chronic  oral  aspirin  therapy.  Patients  were  excluded  if  there  was  a 
history of myocardial infarction within 3 months, if they were unable to give 
informed consent or if they were taking any other antithrombotic therapy.  
 
2.2.3  Whole blood aggregometry 
After recruitment, venous blood was withdrawn into vacuum filled plastic 3.5 ml 
Vacuette®  tubes  (Greiner  Bio-One,  Austria)  containing  3.2%  sodium  citrate 
(0.109 mol/L). Four Vacuette® tubes (approximately 14 ml) of whole blood were 
collected from each donor or patient. Unless used to assess WBA over time, 
blood was tested within 3.5 hours of venepuncture. WBA was measured using an 
impedance aggregometer (Chrono-log, Model 590) and impedance was recorded 
using a dual channel chart recorder  (Kipp &  Zonen, BD 41). 500 µl citrated 
whole blood was diluted 1:1 with 500 µl normal saline to a total volume of 1 ml 
in a plastic sample cuvette. A stir bar was added to the cuvette, placed in the 
device reaction well and prewarmed for 5 minutes at 37 ºC, with a stirring speed   74 
of 900 rpm. An electrode containing two fine palladium wires was inserted. The 
platelets in the whole blood adhered to the wires, forming a uniform platelet 
monolayer.  A  small  voltage  difference  was  applied  across  the  wires,  and  the 
electrical impedance was measured. In the absence of aggregating agonist, the 
impedance between the two wires became constant after 2 minutes, producing a 
stable baseline which constituted zero. The aggregometer was then calibrated to 
20 ohms (Ω) equivalent to 40 mm deflection using the chart recorder controls. 
When an agonist was added to the cuvette, platelets in the blood were activated 
and  started  to  aggregate,  coating  the  palladium  wires  on  the  electrode  and 
causing  a  corresponding  increase  in  electrical  impedance.  This  change  in 
impedance  was  directly  proportional  to  the  extent  of  aggregation  and  was 
measured in Ω on the chart recorder set at 2 cm/min and followed for 5 minutes 
after addition of agonist. Collagen and adenosine diphosphate (ADP) (Labmedics 
Limited, Manchester, UK) were used as platelet agonists in all experiments. For 
X/XO  experiments,  individual  aggregation  values  were  calculated  as  a 
percentage of aggregation compared to control conditions, for both agonists and 
blood was incubated with the test substance(s) for 1 minute prior to addition of 
each agonist. 
 
2.2.4  EC culture  
Freshly removed pig hearts were obtained from a local abattoir within 2 hours of 
slaughter. The pulmonary artery was removed and pinned to a Sylgard coated 
block. Using a sterile scalpel blade, porcine pulmonary artery ECs were scraped 
gently from the luminal surface of the main pulmonary artery, under a sterile 
hood. ECs were transferred to a 15 ml tube of large vessel EC growth medium   75 
package  (basal  medium,  growth  supplement  and  antibiotic  [TCS  Cellworks, 
Buckinghamshire, UK]). The cell suspension was centrifuged at 10,000 rpm for 5 
minutes. The supernatant was removed and the ECs were resuspended in 1 ml 
fresh  growth  medium.  This  was  added  to  T-25  cell  culture  flasks  (Nunc, 
Kamstrupvej,  Denmark)  with  additional  growth  medium  and  cultured  in  an 
incubator at 37 ºC in a humidified atmosphere of 5% CO2. Growth medium was 
replaced every two days and ECs were transferred to T-75 flasks when 90% 
confluence was reached. Fresh growth medium was prepared once weekly. All 
ECs were used from passages 2 to 4. 
 
2.2.5  EC-platelet interaction 
ECs were collected from the flasks by removal of growth medium and addition 
of 2 ml TrypLE Express (Invitrogen Corporation, Paisley, UK) to detach the 
cells. Following 15 minutes, the cell suspension was transferred to centrifuge 
flasks and spun in a centrifuge (Mistral 1000, MSE centrifuge) at 10,000 rpm for 
5 minutes. The supernatant was removed and the pellet of cells resuspended in 1 
ml  blank  EC  growth  medium.  The  number  of  ECs  in  1  ml  suspension  was 
counted using a haemocytometer. 1 x 10
5 ECs were added to the sample cuvette 
using  an  appropriate  volume  of  cell  suspension  and  made  up  to  500  µl  with 
normal saline, to which 500 µl whole blood was added. In control experiments, 
an equivalent volume of blank growth medium was added to the cuvette in place 
of cell suspension. WBA was tested as previously described and the effect of 
ECs  was  determined  in  the  absence  and  presence  of  X/XO  and  following  5 
minutes pre-treatment of ECs with 100 µM Nω-nitro-L-arginine methyl ester (L-
NAME) (Sigma-Aldrich, Dorset, UK), an inhibitor of NOS.   76 
2.2.6  Statistical analysis 
The SD of pilot WBA data under control conditions was found to be 25%. A 
sample  size  of  14  patients  was  calculated  to  provide  80%  power  to  detect  a 
treatment difference at a two-sided 0.05 significance level, if the true difference 
between  groups  was  40%.  All  data  are  expressed  as  mean  ±  SEM  unless 
otherwise  stated.  Groups  were  compared  by  independent  samples  t  test  or 
repeated measures analysis of variance and post-hoc Dunnett’s test. Statistical 
analysis  was  performed  using  the  SPSS  statistical  software  package  14.0  for 
Windows (SPSS Inc., Chicago, IL, USA).  
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2.3  Results 
 
2.3.1  Lucigenin concentration-response  
The effect of 5 µM, 50 µM and 250 µM lucigenin on chemiluminescence was 
examined. This represents a range of concentrations which have the potential 
influence  baseline  ROS  production  and  redox-recycling,  however  minimal 
effects are previously reported for 5 µM (185). 5 µM lucigenin in the absence of 
X/XO caused very low chemiluminescence (62 ± 2 RLU/s). In the presence of 
100 µM X and 10 mU/ml XO, both higher doses of lucigenin (50 µM and 250 
µM)  caused  significantly  increased  chemiluminescence,  compared  to  5  µM 
lucigenin (p < 0.001) (Figure 2.1). 5 µM lucigenin was therefore used for all 
subsequent  chemiluminescence  experiments,  as  this  gave  the  least  assay 
interference, as previously confirmed (185). 
 
Figure 2.1  The  effect  of  lucigenin  on  chemiluminescence.  Chemiluminescence 
(CL)  using  different  concentrations  of  lucigenin,  in  the  presence  of  a  constant 
concentration of 100 µM X and 10 mU/ml XO (n = 4), * p < 0.001 vs. other groups.   78 
2.3.2  Confirmation of O2
- production by X/XO 
There was a highly significant positive correlation (r = 0.94, p = 0.006) between 
chemiluminescence  and  XO  concentration  in  the  presence  of  a  constant 
concentration of 100 µM X (Figure 2.2). 50 U/ml SOD completely abolished 
chemiluminescence in the presence of 100 µM X and 10 mU/ml XO (p < 0.001), 
indicating  that  O2
-  was  the  principal  active  molecule  generated  under  the 
conditions of these experiments (Figure 2.3). 
 
 
Figure 2.2  The effect of X/XO on chemiluminescence. CL due to increasing XO 
concentration (log 10 scale) in the presence of a constant concentration of 100 µM X (n 
= 2), r = 0.94, p = 0.006. 
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Figure 2.3  The effect of SOD on X/XO-induced chemiluminescence. CL due to 
100 µM X and 10 mU/ml XO with the effect of 50 U/ml SOD (n = 4-8), * p < 0.001 vs. 
control. 
 
2.3.3  Baseline characteristics of WBA participants 
Venous blood was withdrawn from 12 healthy donors and used for preliminary 
experiments. 8 (67%) donors were male and the mean age was 30.5 years (SD 
9.2).  No  donor  had  a  significant  past  medical  history  or  was  taking  regular 
medication. The baseline characteristics of 23 recruited patients are shown in 
Table 2.1. There was a high prevalence of additional cardiovascular risk factors 
and  regular  medications  prescribed.  As  patients  were  tested  on  the  day  of 
recruitment,  all  patients  were  taking  regular  aspirin.  No  patient  was  taking 
clopidogrel or any other antithrombotic medication. 
 
 
   80 
Table 2.1  Baseline characteristics of WBA patients 
  Prevalence, 
(n = 23) 
Patients’ characteristics   
Age, mean (SD), y  62.7 (8.9) 
Male, n (%)  17 (73.9) 
Current smoker, n (%)  6 (26.1) 
Hypertension, n (%)  11 (47.8) 
Hypercholesterolaemia, n (%)  15 (65.2) 
Diabetes mellitus, n (%)  10 (43.4) 
Family history of premature CHD, n (%)  8 (34.8) 
Previous myocardial infarction, n (%)  9 (39.1) 
Previous stroke, n (%)  1 (4.3) 
Previous PCI or CABG, n (%)  7 (30.4) 
Multivessel disease, n (%)  13 (56.5) 
Preserved LV function, n (%)  18 (78.3) 
Heart failure, n (%)  3 (13.0) 
Drug treatment   
Aspirin, n (%)  23 (100.0) 
Clopidogrel, n (%)  0 (0.0) 
Statin, n (%)  22 (95.7) 
ACE inhibitor or ARB, n (%)  17 (73.9) 
Beta-blocker, n (%)  17 (73.9) 
Calcium channel blocker, n (%)  9 (39.1) 
Diuretic, n (%)  5 (21.7) 
Nitrate, n (%)  17 (73.9) 
Nicorandil, n (%)  11 (47.8)   81 
2.3.4  WBA intra-individual variability 
Preliminary evaluation was performed on a single donor blood sample to assess 
the intra-individual variability of WBA. 6 experiments were performed within 
one hour of venepuncture using 3 µg/ml collagen as agonist. Agreement between 
replicates was excellent, as shown in Figure 2.4 (mean 13.67 Ω, SD 0.5164). 
 
 
Figure 2.4  Intra-individual variability of WBA (n = 6). 
 
2.3.5  WBA agonist concentration-response 
A  range  of  collagen  and  ADP  concentrations  were  tested  to  assess  the 
concentration-response  for  each  agonist,  using  donor  blood.  The  EC50  for 
collagen was found to be 3 µg/ml (Figure 2.5) and for ADP was 5 µM (Figure 
2.6). The EC50 agonist concentrations were used for all subsequent experiments 
to study the potential of ROS to modify aggregation in either direction without 
the limitation of testing near minimal or maximal conditions. Therefore, although 
maximal impedance values for each agonist were different due to their different   82 
activation  mechanisms,  agonist  concentrations  were  matched  for  the  level  of 
activation of their respective receptors. 
 
 
Figure 2.5  WBA concentration-response curve for collagen (n = 7). 
 
 
 
Figure 2.6  WBA concentration-response curve for ADP (n = 5). 
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2.3.6  WBA time-response 
Due  to  the  serial  nature  of  experiments  performed  on  each  blood  sample,  I 
assessed the variation in WBA over time, for each agonist. WBA was tested 
under  identical  conditions  using  donor  blood  at  intervals  of  up  to  6  hours 
following venepuncture. There was a slight trend for collagen-induced WBA to 
decrease after 6 hours although this was not statistically significant (Figure 2.7). 
ADP-induced WBA showed minor variation over time, although there was no 
significant change in aggregation between 1 and 4 hours (Figure 2.8). 
 
Figure 2.7  WBA time-response curve for collagen (3 µg/ml, n = 5), p = NS. 
 
 
Figure 2.8  WBA time-response curve for ADP (5 µM, n = 4), p = NS.   84 
2.3.7  Comparison of WBA between donors and patients 
There was no significant difference in WBA between donor blood and patient 
blood, for each agonist. Under identical control conditions, WBA was 15.9 ± 1.5 
Ω for donor blood (n = 12) compared with 15.4 ± 0.8 Ω for patient blood (n = 23) 
in response to 3 µg/ml collagen (p = NS). WBA was 7.8 ± 1.5 Ω for donor blood 
(n = 10) compared with 9.3 ± 0.9 Ω for patient blood (n = 23) in response to 5 
µM ADP (p = NS). 
 
2.3.8  Effect of X/XO on WBA  
The effect of oxidative stress on WBA in 14 CHD patients was determined using 
the  X/XO  reaction.  The  concentration  of  X  was  kept  constant  at  100  µM, 
whereas  the  concentration  of  XO  was  tested  at  10,  50  and  100  mU/ml  to 
engender  incremental  levels  of  oxidative  stress,  previously  confirmed  using 
chemiluminescence. ROS produced by X/XO caused a concentration-dependent 
inhibition  of  WBA  in  CHD  patients  compared  to  control,  for  both  collagen 
(Figure 2.9) and ADP (Figure 2.10). 100 µM X and 100 mU/ml XO inhibited 
WBA in response to collagen by 28.9% (95% CI 15.9% - 41.8%, p < 0.001) and 
in response to ADP by 36.0% (95% CI 9.6% - 62.4%, p = 0.005). The effect in 
patients  with  diabetes  mellitus  did  not  differ  significantly  from  the  effect  in 
patients without diabetes mellitus (n = 7, data not shown). A smaller number of 
identical  experiments  were  performed  using  healthy  donor  blood,  which  also 
demonstrated concentration-dependent inhibition of WBA, which was significant 
at the highest dose of XO (n = 4, data not shown). 
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Figure 2.9  The effect of X/XO on WBA in response to collagen. X (µM) + XO 
(mU/ml) caused a concentration-dependent inhibition of WBA in response to 3 µg/ml 
collagen in CHD patients (n = 14), * p < 0.05 vs. control. 
 
 
Figure 2.10  The  effect  of  X/XO  on  WBA  in  response  to  ADP.  X  (µM)  +  XO 
(mU/ml) caused a concentration-dependent inhibition of WBA in response to 5 µM ADP 
in CHD patients (n = 14), * p < 0.05 vs. control.   86 
2.3.9  EC-platelet interaction  
The effects of ECs on WBA in 9 CHD patients are shown in Figures 2.11 and 
2.12. The addition of 1 x 10
5 cultured ECs caused a significant decrease in WBA 
in response to collagen by 31.2% (95% CI 12.2% - 50.2%, p < 0.01) and ADP by 
31.6% (95% CI 2.5 - 60.7%, p < 0.05). The inhibitory effect of ECs on WBA 
remained significant after pre-treatment of ECs with the combination of 100 µM 
X and 10 mU/ml XO, in response to collagen (29.1% [95% CI 10.1% - 48.1%, p 
<  0.01])  and  ADP  (32.6%  [95%  CI  3.4  -  61.7%,  p<0.05]).  However,  pre-
treatment with 100 µM L-NAME attenuated the inhibitory effect of ECs, which 
was no longer statistically significant in response to either collagen (21.6% [95% 
CI -7.2% - 50.5%, p = NS]) or ADP (9.2% [95% CI -44.7% - 63.1%, p = NS]).  
 
Figure 2.11  The effect of ECs alone and after pretreatment with X/XO or L-NAME 
on WBA in response to collagen. Cultured ECs inhibited WBA in response to 3 µg/ml 
collagen. This effect was not affected by 100 µM X and 10 mU/ml XO but was no 
longer significant after pre-treatment of ECs with 100 µM L-NAME (n = 9), * p < 0.05 
vs. control.   87 
 
Figure 2.12  The effect of ECs alone and after pretreatment with X/XO or L-NAME 
on WBA in response to ADP. Cultured ECs inhibited WBA in response to 5 µM ADP. 
This  effect  was  not  affected  by  100  µM  X  and  10  mU/ml  XO  but  was  no  longer 
significant after pre-treatment of ECs with 100 µM L-NAME (n = 9), * p < 0.05 vs. 
control. 
 
2.4  Discussion 
 
After arterial injury or atherosclerotic plaque rupture, circulating platelets adhere 
to the damaged vessel wall and become activated by agonists in the extracellular 
matrix such as collagen, von Willebrand factor and fibrinogen. Other agonists 
such as ADP, thrombin, adrenaline and platelet activating factor potentiate the 
platelet response. Once activated, platelets release granules containing cytokines 
and  growth  factors  which  lead  to  a  cascade  of  events  resulting  in  platelet 
aggregation, formation  of a platelet plug and in some cases vessel occlusion, 
causing a myocardial infarction or stroke. Recently, evidence has accumulated   88 
that ROS are heavily involved in the regulation of platelet function, although 
their precise role is complex (177).  
 
Clarifying  the  actions  of  ROS  on  WBA  in  patients  with  symptomatic  CHD 
extends our understanding of the pathophysiology of acute thrombosis, which in 
patients who have undergone PCI is associated with a very high mortality (38). 
This chapter investigated the direct effects of oxidative stress on human whole 
blood, which has direct relevance to PCI as large amounts of ROS are released 
from  the  artery  wall  during  this  period  and  may  be  implicated  in  stent 
thrombosis. The greatest influence of ROS on the stent-vessel wall interaction is 
likely to be derived from locally generated ROS as a result of arterial injury 
(principally via NOX) but also from elevated systemic levels of circulating ROS, 
which are increased in patients with CHD. 
 
2.4.1  Preliminary results 
My initial experiments confirmed that the X/XO reaction was generating ROS 
within the time frame of WBA. The potential interference of lucigenin used in 
these experiments was minimal, due to the very low concentration used, which 
has  been  shown  to  exert  only  minor  effects  on  O2
-  production  (185).  5  µM 
lucigenin was associated with very low chemiluminescence in my experiments. I 
demonstrated that the WBA assay was reliable and consistent, with a low intra-
individual variability. All samples were tested within a time frame that I have 
shown to have no impact on WBA. Notably, WBA was not significantly different 
between healthy donors and patients. I propose that the administration of chronic 
aspirin therapy negated the increased platelet aggregation likely to be present in   89 
CHD patients compared with healthy individuals on no antithrombotic therapy. 
The lack of difference supported the translation of preliminary methodological 
data to the patient population.  
 
2.4.2  Effect of ROS on platelet aggregation 
One of the primary purposes of the current study was to examine, for the first 
time, the effects of exogenous ROS on WBA in patients with clinically proven 
CHD. My results have shown that ROS,
 generated by the X/XO reaction, cause a 
concentration-dependent inhibition of WBA in these patients. This reduction in 
aggregation  is  demonstrated  in  response  to  the  biologically  relevant  agonists, 
collagen and ADP. Whilst I have confirmed using chemiluminescence that O2
- is 
generated by X/XO, this reaction also leads to the downstream production of the 
highly  reactive  molecule,  H2O2  (187),  which  plays  a  significant  role  in  the 
modulation of platelet function. Additionally, although resting platelets do not 
produce  NO,  intracellular  NO  is  formed  following  stimulation  with  platelet 
agonists (188), and this can react with O2
- to produce ONOO
- (132), a potent 
oxidant and additional contributor to platelet aggregation (189). I propose that 
these secondary molecules may have played a major role in the inhibition of 
WBA in these experiments. 
 
The reported effects of ROS on platelet function are variable and depend on a 
variety of factors, especially the type and concentration of ROS and the milieu in 
which it acts. Using washed platelets in buffer, exposure to ROS generated by 
X/XO led to irreversible aggregation to subthreshold levels of ADP, although 
there was no effect on collagen-induced platelet aggregation (190). In another   90 
study, collagen (but not ADP or thrombin) induced O2
- release from platelets, 
which stimulated ADP-dependent platelet recruitment to preformed thrombus, 
but did not in itself cause platelet aggregation (190). Others have shown that 
addition  of  X/XO  to  washed  platelets  led  to  release  of  the  surrogate  marker 
serotonin, thought to occur as a result of platelet aggregation, whereas exposure 
of  platelets  to  X/XO  also  lowered  the  threshold  for  thrombin-induced 
aggregation (191). This effect was blocked by SOD suggesting that O2
- was the 
relevant molecule involved. The  O2
-  generator  pyrogallol increased thrombin-
induced platelet aggregation, an effect which was also blocked by SOD (192), 
and increased arachidonic acid-induced platelet aggregation, an effect which was 
inhibited by dipyridamole (193). Put together, these data suggest the more likely 
effect of O2
- on isolated platelets is pro-aggregatory, albeit mild in some cases. 
 
Importantly, the addition of X/XO to platelets in platelet rich plasma (PRP) has 
led to different results compared to those found in isolated platelets. In healthy 
volunteers, X/XO led to potent inhibition of platelet aggregation in response to 
ADP,  collagen  and  U-46619  (a  thromboxane  mimetic)  (194).  These  findings 
were  attributed  to  the  abolition  of  the  second  wave  release  reaction  with  an 
overproduction  of  H2O2,  stimulation  of  guanylate  cyclase  and  an  increase  in 
cGMP. This inhibitory effect on platelet aggregation was blocked by catalase, 
but not by SOD, which suggested that H2O2 was the crucial inhibitory ROS. The 
inhibitory effect of H2O2 on ADP-induced aggregation has been confirmed in 
other studies (195;196). There have been reports that lower concentrations of 
H2O2 have the capacity to enhance subthreshold collagen and arachidonic acid-
induced aggregation, but not ADP-induced aggregation (197;198). The influence   91 
of ONOO
- on isolated platelets has been varied, causing either pro-aggregatory 
(199) or anti-aggregatory effects (200;201), but studies in PRP show that ONOO
- 
consistently  inhibits  collagen,  ADP,  and  thrombin-induced  aggregation 
(199;202).  Subsequent  reports  suggested  that  the  NO-dependent  inhibitory 
effects  of  ONOO
-  occurred  at  lower  concentrations  than  the  pro-aggregatory 
effects (203). 
 
Taking  all  of  these  data  into  consideration,  the  actions  of  ROS  on  platelet 
function are diverse, depending on the molecule involved, and concentration-
dependent. Furthermore, assessment of platelet function must take into account 
the environment in which aggregation is stimulated. Although washed platelets 
suspended in buffer can provide information on the specific effects of substances 
on  isolated  platelets,  a  more  physiological  environment  can  be  simulated  in 
plasma or whole blood, which allow other blood constituents and endogenous 
antioxidants to be represented which may antagonise the stimulation of platelets 
induced by ROS (204).  
 
The key finding from my results is that oxidative stress (generated by X/XO) 
caused  a  concentration-dependant  inhibition  of  platelet  aggregation  in  whole 
blood derived from patients with CHD. I propose that this was caused by the 
generation  of  secondary  inhibitory  ROS  such  as  H2O2  and  ONOO
-,  possibly 
related  to  endogenous  substances  present  in  whole  blood.  The  main  goal  of 
future studies would be to confirm the precise species involved, the mechanism 
and the importance of this effect with reference to the levels of oxidative stress 
present  in  clinical  situations  such  as  PCI.  A  closer  estimate  of  the  potential   92 
mechanism of this effect could be assessed by studying the effects of SOD given 
prior to X/XO, thereby removing the effects of O2
- and causing generation of 
H2O2. Catalase could be used to specifically assess the loss of H2O2 from the 
system.  In  addition,  other  specific  scavengers  of  secondary  ROS  including 
ONOO
- could be used to clarify the influence of these molecules.  
 
2.4.3  Effect of ROS on the EC-platelet interaction 
I demonstrated that healthy ECs maintain the ability to inhibit WBA derived 
from patients with CHD. ECs are thought to inhibit thrombosis predominantly 
through the actions of NO, prostacyclin (205) and the activity of an endothelial 
ecto-ADPase present on the surface of ECs, identified as CD39 (206;207). It was 
reported that depolarization of ECs led to O2
- production, which inactivated the 
ecto-ADPase,  thereby  decreasing  the  inhibitory  properties  of  ECs  on  ADP-
induced aggregation, (208). Therefore it was expected that ROS would at least 
partly neutralise the inhibitory effect of healthy ECs on WBA by opposing the 
effects of NO and/or endothelial ecto-ADPase. However, I have demonstrated 
that the addition of exogenous ROS using X/XO failed to influence the inhibitory 
properties of healthy ECs. This may have resulted from an overall equilibrium of 
negative and positive effects on blood aggregation. The X/XO reaction may have 
produced  ROS  such  as  O2
-,  which  inactivated  NO  and  endothelial 
ectonucleotidases (actions that would promote aggregation), but also produced 
H2O2 and ONOO
-, leading to inhibitory effects. To explore this further, I have 
shown that the inhibitory effect of healthy ECs is decreased by the pretreatment 
of ECs with L-NAME. This supports the notion that isolated removal of EC-
derived  NO  from  the  blood  decreases  its  anti-aggregatory  capacity,  which   93 
implies  an  increased  risk  of  thrombosis  where  endothelial  dysfunction  and 
reduced NO bioavailability occurs. 
 
2.4.4  Limitations 
 
Well recognised limitations exist concerning the translation of this work to the 
clinical field. It is unclear how the addition of exogenously derived ROS relates 
to the extent and nature of ROS release following PCI. The main source of ROS 
after PCI is generation via NOX, the output of which may differ significantly 
from the X/XO reaction. The effects of ROS on blood aggregation have been 
investigated in isolation and subsequently in the presence of healthy ECs, rather 
than in the presence of damaged endothelium and the presence of a foreign body, 
as is present after coronary stenting. We must accept that the applicability of 
these in vitro studies to the clinical scenario of early stent thrombosis may be 
limited.  Porcine  rather  than  human  ECs  were  used  to  replicate  the  effect  of 
human endothelium due to cost constraints, but it seems unlikely that the effect 
would have been significantly different if human ECs had been used. 
 
2.4.5  Conclusions 
ROS generated by X/XO produce a concentration-dependent inhibition of WBA 
in patients with CHD. This concurs with previous studies in healthy individuals 
using X/XO as a source of ROS and is likely to be a result of highly reactive 
molecules  such  as  H2O2  and  ONOO
-,  which  share  inhibitory  properties  that 
appear to predominate over O2
-, which tends to promote aggregation. Healthy 
ECs  maintain  their  physiological  role  to  inhibit  platelet-derived  thrombus   94 
formation in blood derived from atherosclerotic human populations, even after 
short term exposure to ROS. This suggests that strategies to preserve endothelial 
function and improve re-endothelialisation are likely to be beneficial after PCI. 
However, persistent endothelial dysfunction or patchy endothelial regrowth due 
to persistent drug or polymer effects after PCI is likely to diminish the capacity 
of the endothelium to generate NO, which could put patients at greater risk of 
stent thrombosis. 
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Chapter 3 
 
The effect of oxidative stress 
on endothelial cell migration 
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3.1  Introduction 
 
After PCI, the migration of ECs to reconstitute the denuded endothelium is a 
crucial process that occurs early after vessel trauma. In the rat carotid balloon 
injury model, the endothelium regenerates at approximately 2-3 mm per week 
(209), depending on the degree of injury, with more severe cases taking longer. 
Deeper medial injury encourages more SMCs to migrate to the neointima, which 
inhibit  the  migration  and  proliferation  of  ECs  in  that  area  (210).  Endothelial 
regrowth is specific to the species involved. For instance, stent healing in pigs is 
slower than in rats but still occurs around six times faster than in humans (174). 
Identifying the factors controlling the movement of these vital cells is paramount 
to understanding the mechanisms that contribute to ISR. Besides a central role in 
modulating  vascular  tone  and  haemostasis,  regeneration  of  confluent 
endothelium  provides  an  impermeable  barrier  between  medial  SMCs  and 
circulating growth factors. ECs also produce a number of growth-promoting and 
growth-inhibitory  factors  which  regulate  SMC  proliferation.  Healthy  ECs 
maintain the quiescence of SMCs by releasing NO (211). Hence, regeneration of 
the endothelium significantly influences the extent of neointimal formation.  
 
ECs  themselves  are  stimulated  to  a  lesser  degree,  or  inhibited,  by  many 
substances that stimulate SMC migration, such as angiotensin-II (212), serotonin, 
noradrenaline and IL-1 (213). Factors that promote EC migration include VEGF 
(214),  platelet-derived  EC  growth  factor  (PD-ECGF)  (215),  oestradiol  (216), 
oxytoxin  (217),  ACE  inhibitors  (212),  heparins  (218),  endothelins  (219), 
thrombin (220), tPA (221), high density lipoprotein (222) and shear stress, which   97 
increases EC migration onto metallic stent surfaces (223). NO appears to exert a 
biphasic  effect  on  EC  migration.  Acute  release  of  NO,  generated  by  eNOS, 
reportedly promoted EC migration towards angiogenic factors, such as VEGF 
(224),  endothelin  (130)  and  substance  P  (225).  NO  appeared  to  exert  its 
stimulatory  effect  on  EC  migration  through  activation  of  soluble  guanylyl 
cyclase mechanisms (226). On the other hand, others have observed that chronic 
basal endogenous NO release inhibited EC migration (227), an effect which was 
matched  by  other  NO  donors  (228).  Since  the  recognition  that  endothelial 
recovery may reduce ISR and lower the risk of stent thrombosis, more attention 
has  been  re-focussed  on  revascularisation  devices  which  might  accelerate  EC 
regrowth (229;230). The effect of ROS on EC migration is not well defined and, 
given  that  oxidative  stress  is  a  major  consequence  of  PCI,  requires  further 
evaluation. Therefore, the aim of this study was to investigate the effect of ROS 
generated by X/XO on EC migration, using a scratch wound assay. The effect of 
the antioxidant, probucol, on EC migration would also be evaluated. 
 
3.2  Methods 
 
3.2.1  EC culture 
The method for EC cell culture is described in detail in section 2.2.4. Briefly, 
porcine pulmonary artery ECs were removed from fresh pig hearts and cultured 
in large vessel EC growth medium. ECs were maintained at 37°C in a humidified 
atmosphere of 5% CO2, and used from passages 2 to 4. After obtaining sufficient 
quantities, the ECs were collected from T-75 flasks using TrypLE Express and 
seeded in 6 well plates.    98 
3.2.2  EC migration assay 
EC migration was measured by the scratch wound method as described by Bürk 
(231). Once grown to confluence in 6 well plates, ECs were made quiescent by 
exchanging  the  serum-containing  growth  medium  with  serum-free  medium, 
followed by the addition of 1 mg/ml gelatin. The ECs remained in serum-free 
medium for 24 hours. Following this, a wound was made in the EC monolayer by 
pressing a rigid razor blade down on the well. The blade was gently drawn across 
the base of the well, scraping the ECs to one side (Figure 3.1). Care was taken to 
avoid reusing a damaged blade which had developed gaps in the cutting edge, 
otherwise lines of ECs would remain attached to the well, perpendicular to the 
wound. After a successful razor scrape, the detached cell debris and medium 
were aspirated and disposed of. Serum-free medium with 1 mg/ml gelatin was 
replaced  and  the  test  substance(s)  was  added  using  a  pipette.  The  ECs  were 
incubated for a further 24 hours. For each well, 2 adjacent regions consisting of 
1,300 µm lengths of razor wound in the centre of the microscopic field were 
examined  and  the  number  of  cell  nuclei  that  had  crossed  the  starting  line 
produced by the razor scrape was counted. Well plates were fixed and stained 
using modified Wright-Giemsa stain. Images of migrating ECs were captured 
using  an  inverted  microscope  (Nikon)  and  attached  digital  camera 
(CoolSNAP™-Pro, Media Cybernetics). Representative photomicrographs have 
been enhanced digitally for graphical purposes. 
 
3.2.3  Cell treatments 
EC migration was tested under control conditions, after exposure to oxidative 
stress using different X and XO concentrations with and without the antioxidant,   99 
probucol, and with probucol alone. Control cells were always treated with the 
relevant vehicles alone. X and XO were dissolved in 10 mM NaOH and PBS, 
respectively and probucol was dissolved in PBS.  
 
3.2.4  Statistical analysis 
All data are expressed as the mean number ± SEM of ECs which had migrated 
across the 1.3 mm starting line after 24 hours. All experiments were performed in 
duplicate, on at least 2 different cell isolates. Groups were compared using a t-
test  or  repeated  measures  analysis  of  variance  with  post-hoc  Dunnett’s  test. 
Statistical  significance  was  confirmed  at  p  <  0.05.  Statistical  analysis  was 
performed using the SPSS statistical software package 14.0 for Windows (SPSS 
Inc., Chicago, IL, USA). 
 
 
 
Figure 3.1  Razor scrape EC migration assay. Confluent cultured ECs before (A) 
and after the razor scrape wound at 0 hours (B). 
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3.3  Results 
 
3.3.1  General toxicity of X/XO to ECs 
Severe  generalised  toxicity  was  encountered  when  ECs  were  exposed  to 
conditions of oxidative stress, using X/XO. Multiple populations of cultured ECs 
were exposed to X/XO for 24 hours and, even at relatively low concentrations, 
ECs  detached  from  the  base  of  the  well,  rendering  the  migration  assay 
impossible. ECs remained adherent to the base in the presence of X/XO vehicles. 
Extensive concentration ranging experiments were performed and eventually it 
was found that the highest concentration of X/XO which allowed ECs to remain 
consistently attached to the base of the well was 1 µM X + 0.1 mU/ml XO (Table 
3.1). The tolerability of serum-fed ECs to X/XO was considerably better than 
that of quiescent ECs. 
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Table 3.1  Toxicity of X/XO to cultured ECs after 24 hours. 
Xanthine (µ µ µ µM)  Xanthine oxidase (mU/ml)  Serum medium  Quiescent medium 
100  10  ￿  ￿ 
100  2.5  ￿  ￿ 
100  1  ND  ￿ 
10  10  ￿  ￿ 
10  2.5  ￿  ￿ 
10  1  ￿  ￿ 
5  2.5  ND  ￿ 
2.5  2.5  ￿  ￿ 
1  10  ND  ￿ 
1  2.5  ND  ￿ 
1  1  ￿  ￿/￿ 
1  0.1  ￿  ￿ 
 
Key:  ￿ = ECs remained attached to plate 
￿ = ECs detached from plate 
  ￿/￿ = Variable detachment of ECs 
  ND = Not done 
   
3.3.2  Effect of low concentration X/XO on EC migration 
1 µM X and 0.1 mU/ml XO inhibited EC migration significantly compared with 
vehicle solutions (11.5 ± 0.5 vs. 27.5 ± 1.0 migrating cells/wound, respectively 
[p < 0.01]), as shown in Figure 3.2. The addition of 20 µM probucol did not 
influence the effect of X/XO significantly (13.4 ± 0.4 migrating cells/wound, p = 
NS, probucol vs. X/XO).  
   102 
 
 
 
 
 
Figure 3.2  The  effect  of  X/XO  with  and  without  probucol  on  EC  migration. 
Representative photomicrographs of control (A), 1 µM X and 0.1 mU/ml XO (B) and 1 
µM X + 0.1 mU/ml XO with 20 µM probucol (C) in the scratch wound assay. D, X/XO 
inhibited  EC  migration  compared  with  vehicle,  an  effect  which  was  not  altered 
significantly by 20 µM probucol (n = 2), * p < 0.01 vs. control. 
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3.3.3 Effect of probucol on EC migration 
Given  that  probucol  did  not  appear  to  protect  ECs  against  X/XO,  20  µM 
probucol alone was tested to determine whether it would have an effect on EC 
migration  in  isolation.  There  was  no  significant  difference  between  probucol 
vehicle and 20 µM probucol (13.4 ± 3.7 vs. 10.4 ± 2.2 migrating cells/wound, 
respectively, [p = NS]).  
 
 
 
Figure  3.3  The  effects  of  probucol  alone  on  EC  migration.  Representative 
photomicrographs of vehicle (A) and 20 µM probucol (B) in the scratch wound assay.  
C, There was no significant difference between groups (n = 3), p = NS.   104 
3.4  Discussion 
 
3.4.1  General cytotoxicity of oxidative stress to cultured ECs 
I  found  that  oxidative  stress,  applied  exogenously  using  the  X/XO  reaction, 
caused severe toxicity to cultured ECs, leading to widespread cell detachment 
within 24 hours. Direct observation of well plates containing X/XO revealed that 
detachment  started  within  an  hour  of  exposure  to  X/XO  and  was  virtually 
complete within 8 hours. Although I did not directly prove that cell detachment 
was a consequence of cell death, this was highly probable because floating cells 
displayed severe morphological changes and general cellular debris was evident 
on the surface of the culture medium. The cytotoxicity of X/XO was very severe 
in quiescent ECs, whereas serum-fed ECs had greater tolerance. Toxicity seemed 
more  dependent  on  XO  concentration  than  xanthine  concentration,  because 
serum-fed ECs retained adherence by reducing the XO concentration from 10 
mU/ml to 2.5 mU/ml, whereas they showed persistent detachment when xanthine 
concentration was lowered from 100 µM to 10 µM. I have already demonstrated 
in Chapter 2 that 100 µM X + 10 mU/ml XO produces significant quantities of 
ROS.  Thus,  I  propose  that  a  high  concentration  of  ROS  in  the  cell  culture 
medium, released by the X/XO reaction, was responsible for EC death. 
 
3.4.2  Effect of oxidative stress on EC migration 
Unfortunately,  the  migration  experiments  were  severely  hampered  by  the 
somewhat unexpected severe cytotoxicity of X/XO. Nevertheless, migration of 
ECs appeared to be significantly inhibited in the presence of exogenous oxidative 
stress  generated  by  X/XO,  within  24  hours.  Investigating  the  underlying   105 
mechanism for this effect fell outside the time frame for this work, however, 
future experiments could investigate whether ROS generated by X/XO deactivate 
molecular signalling pathways involved in normal migratory activity. The effects 
of SOD and inhibitors of NOX may help clarify the specific role of O2
- in EC 
migration. Given that EC motility is reliant on NO production, attempts could 
also  be  made  to  eliminate  NO  from  the  cell  culture  using  NOS  inhibitors  to 
examine  its  effect  on  migration.  The  effects  of  antioxidants  to  oppose  these 
negative effects could also be tested.  
 
Previous work by other groups also merits consideration. A large proportion of 
published  work  regarding  the  negative  influence  of  oxidative  stress  on  EC 
migration  has  surrounded  oxLDL,  which  acts  as  a  key  oxidant  in  vivo. 
Overwhelming evidence exists to support the role of oxLDL in atherosclerosis 
(232) and the triggering of acute coronary syndromes (233), therefore it is not 
surprising that EC function is a target for its pathological actions. Given that 
repair of injured blood vessels is dependent on EC migration following arterial 
injury, the effect of oxLDL on this phenomenon is likely to be important after 
PCI. OxLDL increases intracellular ROS production by ECs (234). Murugesan et 
al. (235) found that oxLDL markedly reduced EC migration using a razor wound 
assay and this effect was concentration- and oxidation-dependent. In this work, 
the antimigratory activity of oxLDL was not reliant on mortal cell injury, since 
migration was re-established after removal of oxLDL from the culture. Chavakis 
et al. (236) also reported that oxLDL inhibited VEGF-induced EC migration, 
without  inducing  apoptosis  or  necrosis.  This  observation  was  associated  with 
dephosphorylation of the serine/threonine kinase Akt/protein kinase B, which led   106 
to  deactivation  of  eNOS  and  a  reduction  in  NO  generation,  thus  inhibiting  a 
process which is partly NO dependent (237).  
 
More evidence that ROS are pivotal in inhibiting EC migration by oxLDL has 
been provided by van Aalst et al. (126), and this work also provides an important 
insight into my results. As in other studies, the antimigratory effects of oxLDL 
on  ECs  was  demonstrated  using  the  razor  scrape  assay.  Inhibition  of  EC 
migration  was  also  confirmed  using  other  agents  known  to  stimulate  ROS 
production  (lysophosphatidylcholine  and  naphthoquinones).  In  this  study,  the 
effect  of  oxLDL  was  blocked  by  the  presence  of  SOD  or  NADPH  oxidase 
inhibitors (DPI, quinacrine and hydralazine). It was not affected by mannitol or 
glutathione, which inactivate OH
- anions, or  catalase, which scavenges  H2O2. 
These data suggest that oxLDL inhibits migration of ECs by causing the release 
of O2
-, produced enzymatically by NADPH oxidase. This, in turn, supports the 
proposal that the antimigratory effects of X/XO on ECs observed in my study 
may have been mediated by O2
-.  
 
Interestingly, direct administration of H2O2  (10-50 µM) had no effect on EC 
migration, however higher concentrations (> 100 µM) caused ECs to lift off the 
plate (126). This probably explains the general cytotoxicity of the X/XO reaction 
in my study, which is known to produce large quantities of H2O2 (238). The 
inability of H2O2 to inhibit EC migration suggests that different ROS may lead to 
cell death compared to those that modulate motility. ONOO
-, which is created by 
the  rapid  reaction  between  NO  and  O2
-,  has  been  shown  to  impair  actin 
polymerisation and inhibit movement of neutrophils and fibroblasts (239;240),   107 
therefore  it  could  also  affect  ECs.  However,  the  importance  of  this  potent 
oxidising substance in my study, or that of others, with regard to EC migration 
has not been established. 
 
3.4.3  Effect of probucol on EC migration 
I  found  that  20  µM  probucol  had  no  effect  on  EC  migration  in  this  assay. 
Moreover, I have shown that probucol at the same concentration was unable to 
preserve EC migration in the presence of X/XO. This was interesting, since some 
data  already  exists  to  support  the  use  of  probucol  to  encourage  endothelial 
healing in animal models (data from Chapter 1, Table 1.1). Pre-incubation with 
probucol  also  reportedly  provided  ECs  with  protection  against  fatal  oxidative 
injury (129). However, the inability of probucol to preserve EC migration in the 
presence of oxidative stress is in agreement with another study which utilised 
oxLDL as a source of ROS (127). In an identical fashion to my results, probucol 
led to minimal improvement in EC migration compared with oxidative stress. I 
propose that probucol is insufficient to oppose the inhibitory effects of excessive 
ROS on EC migration, possibly due to its delayed uptake into ECs (163;241) and 
poor solubility in aqueous solution.  
 
3.4.4  Limitations 
Significant  limitations  exist  in  this  work  and  the  presented  data  should  be 
interpreted  in  this  context.  In  a  few  cases,  the  razor  scrape  method  caused 
marked damage to the EC monolayer, resulting in an irregular starting line and 
rendering some wells invalid for the EC migration assay. The severe generalised 
toxicity of X/XO severely limited the number of valid experiments, therefore the   108 
number of different cell populations available for each group was low and only a 
single  concentration  of  probucol  was  tested.  The  concentration  of  probucol 
chosen was however similar to that used in previous studies (127). Nevertheless, 
a concentration-response curve for probucol would have been valuable. It would 
have been interesting to confirm the nature and extent of general cell toxicity of 
X/XO  using  specific  methods  such  as  lactate  dehydrogenase  release  assay  or 
trypan blue staining (242). Confirmation that EC migration was abolished in the 
absence of cell death could have been tested by reseeding the ECs in standard 
growth medium to ensure their motility was re-established. However, even in 
those groups in which migration virtually ceased completely, cells maintained 
their normal appearance and adherence in contrast to the findings in chapter 5 
(Figure 5.2.1). Direct measurement of O2
- production in the EC culture medium 
would have been valuable to quantify and characterise ROS generation by the 
X/XO  reaction  and  the  effect  of  probucol,  although  the  former  could  be 
indirectly  confirmed  by  chemiluminometry  reported  in  Chapter  2.3.2.  The 
observer performing microscopic examination of EC migration was not blinded, 
similar to previous work published in this area (126;127). The standard error 
within each group was relatively low, suggesting that the selection of analytical 
fields did not suffer from major variability. 
 
3.4.5  Conclusions 
Taken together, the results of this study and others indicate that oxidative stress 
is an important modulator of EC migration. The fact that ROS may inhibit EC 
migration has direct clinical relevance. In the setting of PCI, potential sources of 
ROS
  include  oxLDL  already  present  in  atherosclerotic  lesions  and  the   109 
consequence  of  the  procedure  itself,  which  is  known  to  generate  ROS  (243). 
Elevated levels of circulating and local ROS, especially O2
-, could contribute to 
delayed stent healing after PCI. Retarded re-endothelialisation would be expected 
to  encourage  SMC  proliferation  and  exacerbate  neointimal  thickening. 
Successful methods to reduce local levels of ROS, particularly O2
-, may promote 
endothelial recovery and reduce ISR. Whilst this study provides no evidence that 
probucol is beneficial, the evaluation of more potent antioxidants with improved 
pharmacokinetic  profiles  to  achieve  this  goal  may  present  an  important  step 
towards the development of novel effective DES.  
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Chapter 4 
 
An in vitro evaluation of nitrone D 
as a potential novel DES coating 
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4.1  Introduction 
 
Nitrone-based  antioxidants  represent  a  family  of  electron  paramagnetic 
resonance (EPR) spin-trapping agents, developed to trap ROS within biological 
tissues (244). Investigation of several novel nitrone-based compounds in human 
fibroblasts  has  suggested  that  the  analogue,  nitrone  D,  may  possess  the  most 
favourable biological profile to take forward into preclinical assessment (245). 
The chemical structure of nitrone D is shown in Figure 4.1. Nitrone D is a highly 
lipophilic  molecule  which  embeds  deeply  within  biological  membranes.  This 
renders it potentially appealing as a therapeutic agent in atherosclerosis and other 
inflammatory  conditions  characterised  by  lipid  peroxidation  and  heightened 
oxidative  stress.  Nitrone  D  has  been  shown  to  be  a  functionally  effective 
antioxidant  by  providing  protection  to  human  fibroblasts  against  oxidative 
challenge with 150 µM H2O2 (245). Another important effect of nitrone D was 
the  five-fold  increase  in  relative  SIRT  1  expression  (245).  SIRT  1  is  a 
deacetylase protein which is implicated in a broad range of cellular functions 
(246;247). Importantly, SIRT 1 promotes EC proliferation and survival (248). 
Furthermore, upregulation of SIRT 1 appears to prevent oxidative stress-induced 
EC  senescence,  which  may  help  to  maintain  a  functional  endothelium  (249). 
Established  DES  coatings  (sirolimus  and  everolimus)  decrease  SIRT  1 
expression  and  cause  a  senescent  phenotype  in  ECs,  an  effect  which  was 
reversed by SIRT 1 overexpression (250).  
 
Bearing in mind these encouraging data, nitrone D was chosen as a potentially 
suitable DES coating for evaluation. First, I assessed the effect of nitrone D on   112 
WBA to determine if it had favourable antithrombotic properties that would be 
attractive as a DES coating. As no data exists for the effects of nitrone-based 
antioxidants  on  platelet  or  blood  aggregation,  this  would  provide  important 
safety data for a novel compound to be potentially used as a stent coating. If 
antithrombotic properties were identified, that may potentially inhibit early stent 
thrombosis and to some extent neointimal formation, although the antirestenotic 
efficacy  of  anticoagulant  coated  stents  has  been  limited  to  date  (251;252). 
Second,  and  more  importantly,  I  set  out  to  test  the  effect  of  nitrone  D  on 
migration of cultured ECs. If nitrone D were to display favourable characteristics 
in vitro, then it would be investigated as a DES coating in a preclinical in vivo 
model to assess whether it would improve endothelial regrowth, reduce ISR or 
lower the risk of stent thrombosis. 
 
 
Figure 4.1  The chemical structure of nitrone D.   
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4.2  Methods 
 
4.2.1  Chemiluminescence 
Lucigenin chemiluminescence was performed with nitrone D to establish that it 
was  acting  as  an  antioxidant,  according  to  the  method  in  Chapter  2.2.1. 
Antioxidant efficacy was assessed using 50 U/ml SOD as a positive control in 
the presence of 100 µM X and 10 mU/ml XO. 
 
4.2.2  Study population for WBA 
This study was approved by the West Glasgow and University of Strathclyde 
ethics  committees.  All  participants  were  provided  with  a  PIS  and  gave  their 
informed written consent. All patients were recruited from adult patients with 
angiographic  evidence  of  stable  CHD,  who  attended  the  Western  Infirmary 
Glasgow for out-patient cardiac appointments. All patients were over age 18 and 
receiving  chronic  oral  aspirin  therapy.  Patients  were  excluded  if  there  was  a 
history of myocardial infarction within previous 3 months, they were unable to 
give informed consent or if they were taking any other antithrombotic therapy (as 
in Chapter 2). 
 
4.2.3  Whole blood aggregometry 
The method of WBA is described in Chapter 2.2.3. To assess the effect of nitrone 
D, blood was incubated with increasing concentrations of nitrone D (1-100 µM), 
for 1 minute prior to addition of each agonist. Finally, to assess the effect of 
nitrone D in the presence of oxidative stress, 100 µM nitrone D was given prior 
to adding 100 µM X and 10 mU/ml XO, 1 minute before the addition of agonist.   114 
4.2.4  EC culture and migration assay  
The methods of EC culture and EC migration assay are described in Chapter 
3.2.1-3.2.2. EC migration after 24 hours was measured under control conditions 
and after exposure to 100 µM nitrone D. Control cells were treated with the 
relevant vehicle (PBS). 
 
4.2.5 Statistical analysis 
All data are expressed as the mean ± SEM, unless otherwise stated. For WBA, 
individual  aggregation  values  were  calculated  as  a  percentage  of  aggregation 
compared to control conditions. For EC migration, the number of ECs that had 
migrated across the 1,300 µm starting line after 24 hours was counted. All EC 
migration experiments were performed in duplicate, on cultures derived from at 
least  2  different  animals.  Groups  were  compared  using  a  t-test  or  repeated 
measures  analysis  of  variance  with  post-hoc  Dunnett’s  test.  Statistical 
significance was confirmed at p < 0.05. Statistical analysis was performed using 
the SPSS statistical software package 14.0 for Windows (SPSS Inc., Chicago, IL, 
USA). 
 
4.3  Results 
 
4.3.1  Confirmation of antioxidant activity of nitrone D 
The addition of 100 µM nitrone D prior to the reaction between 100 µM X and 
10  mU/ml  XO  abolished  chemiluminescence  in  a  similar  fashion to  50  U/ml 
SOD, indicating that nitrone D was acting as an effective antioxidant (Figure 
4.2).   115 
 
 
Figure 4.2  The effect of nitrone D on X/XO-induced chemiluminescence. CL due 
to 100 µM X and 10 mU/ml XO with the effect of 50 U/ml SOD and 100 µM nitrone D 
(n = 4), * p < 0.001 vs. control. 
 
4.3.2  Baseline characteristics of WBA patients 
The baseline characteristics of 10 patients included for WBA are shown in Table 
4.1. The prevalence of additional cardiovascular risk factors was high and most 
patients were taking standard drug therapy for CHD. As in Chapter 2, all patients 
were taking regular aspirin and no patient was taking clopidogrel or any other 
antithrombotic medication. 
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Table 4.1  Baseline characteristics of WBA patients 
  Prevalence, 
(n = 10) 
Patients’ characteristics   
Age, mean (SD), y  66.9 (10.0) 
Male, n (%)  9 (90.0) 
Current smoker, n (%)  3 (30.0) 
Hypertension, n (%)  4 (40.0) 
Hypercholesterolaemia, n (%)  5 (50.0) 
Diabetes mellitus, n (%)  5 (50.0) 
Family history of premature CHD, n (%)  3 (30.0) 
Previous myocardial infarction, n (%)  5 (50.0) 
Previous stroke, n (%)  0 (0.0) 
Previous PCI or CABG, n (%)  1 (10.0) 
Multivessel disease, n (%)  6 (60.0) 
Preserved LV function, n (%)  8 (80.0) 
Heart failure, n (%)  2 (20.0) 
Drug treatment   
Aspirin, n (%)  10 (100.0) 
Clopidogrel, n (%)  0 (0.0) 
Statin, n (%)  8 (80.0) 
ACE inhibitor or ARB, n (%)  6 (60.0) 
Beta-blocker, n (%)  8 (80.0) 
Calcium channel blocker, n (%)  4 (40.0) 
Diuretic, n (%)  6 (60.0) 
Nitrate, n (%)  6 (60.0) 
Nicorandil, n (%)  5 (50.0)   117 
4.3.3  Effect of nitrone D on WBA  
The effect of nitrone D on WBA in CHD patients is shown in Figures 4.3 and 
4.4. Nitrone D caused a concentration-dependent inhibition of WBA compared to 
control, for both agonists. Although the effect of each individual dose fell short 
of statistical significance, a linear trend was evident for each agonist (both p < 
0.05 for trend). As in Chapter 2, 100 µM X and 10 mU/ml XO inhibited WBA 
non-significantly compared to control. However, in the presence of 100 µM X 
and 10 mU/ml XO, 100 µM nitrone D inhibited WBA significantly in response 
to collagen by 18.4% (95% CI 3.9%-33.0%, p < 0.05) and in response to ADP by 
39.0% (95% CI 0.2%-77.8%, p < 0.05).  
 
 
Figure 4.3  The effect of nitrone D on WBA in response to collagen. Nitrone D (1-
100 µM) caused a concentration-dependent inhibition of WBA in response to 3 µg/ml 
collagen in CHD patients (p < 0.05 for trend). 100 µM nitrone D and X/XO significantly 
inhibited WBA (n = 9), * p < 0.05 vs. control.   118 
 
 
Figure 4.4  The effect of nitrone D on WBA in response to ADP. Nitrone D (1-100 
µM) caused a concentration-dependent inhibition of WBA in response to 5 µM ADP in 
CHD patients (p < 0.05 for trend). 100 µM nitrone D and X/XO significantly inhibited 
WBA (n = 7), * p < 0.05 vs. control. 
 
4.3.4  Effect of nitrone D on EC migration  
Initially, the effect of nitrone D alone on EC migration was studied (Figure 4.5). 
100 µM nitrone D caused a marked reduction in EC migration compared with 
control (1.1 ± 0.5 vs. 6.4 ± 1.8 migrating cells/wound, respectively [p < 0.01]). 
Given that nitrone D alone severely limited EC migration, its influence on the 
migration of X/XO-treated cells was not evaluated. 
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Figure 4.5  The  effect  of  nitrone  D  on  EC  migration.  Representative 
photomicrographs of vehicle (A) and 100 µM nitrone D (B) in the scratch wound assay. 
C, 100 µM nitrone D severely inhibited EC migration compared with control (n = 4), p < 
0.05 vs. control. 
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4.4  Discussion 
 
4.4.1  Nitrone D as an antioxidant 
Nitrone D was found to perform well as an antioxidant in chemiluminescence 
experiments. In the presence of X/XO, nitrone D was able to quench O2
- from the 
surrounding environment in a similar fashion to SOD. 
 
4.4.2  Effect of nitrone D on WBA 
Although no individual concentration of nitrone D was found to inhibit WBA, 
there was a trend across the concentration range of an inhibitory effect, which 
may have reflected increasing antioxidant activity. Although antioxidants may 
suppress the pro-aggregatory effects of platelet-derived O2
- (177), this effect was 
not confirmed by this study. When local oxidative stress was enhanced by X/XO, 
addition of 100 µM nitrone D led to a statistically significant reduction in WBA. 
As discussed in Chapter 2, the overall effect of exogenous ROS generated by 
X/XO in this assay is inhibitory, probably due to the relative over-production of 
anti-aggregatory ROS such as H2O2 and ONOO
-, rather than O2
-. I speculate that 
nitrone  D  may  have  been  less  protective  against  inhibitory  ROS;  thus,  co-
administration of X/XO and nitrone D resulted in additive inhibitory effects on 
WBA, which became statistically significant. I have found no data to suggest that 
elevation  of  SIRT  1  or  reduction  in  p16  and  p21  gene  expression  (245)  are 
alternative potential mechanisms of platelet inhibition, although this was unlikely 
given the time frame of the experiments. To my knowledge, the effect of nitrone 
D on platelet function has not previously been described. Therefore, this work   121 
provided evidence that nitrone D is likely to have, at most, a minor inhibitory 
effect on WBA.  
 
4.4.3  Effect of nitrone D on EC migration 
Surprisingly, nitrone D (100 µM) caused a marked reduction in EC migration. In 
fact, migratory activity of ECs was virtually abolished by nitrone D. This was an 
unexpected finding  and  rendered nitrone D very unattractive  as a novel DES 
coating, which would ideally accelerate endothelial regeneration. Although only 
a single concentration of nitrone D was tested, I speculate that concentrations 
less than 100 µM would not have been effective overall, since nitrone D was not 
toxic to human fibroblasts up to 300 µM and relatively high concentrations are 
desirable to trap ROS and the carbon-centred radicals resulting from them (245). 
Human  fibroblasts  grown  in  nitrone  D  had  elevated  SIRT  1  transcription, 
consistent  with  these  cells  being  more  adapted  to  growth  and  survival  (245). 
Therefore positive effects were anticipated in this study, as SIRT 1 is emerging 
as  a  key  protective  regulator  of  ECs  against  oxidative  stress  (253;254).  The 
reason(s)  for  the  marked  inhibitory  effect  of  nitrone  D  on  EC  migration  is 
unclear,  but  can  be  explored  by  considering  the  processes  required  for  cell 
motility.  
 
Migration of ECs involves cytoskeleton reorganisation, extension of lamellipodia 
and filopodia, with formation and detachment of adhesions at the edges of the 
cell to facilitate movement. Nitrone  D is known to reduce p21 expression in 
human fibroblasts (245) and this effect may be relevant to EC migration because 
previous data supports a role for p21 activated kinases in the coordination of   122 
leading edge adhesion formation and contraction/detachment of the trailing edge 
of  the  cell  (255).  Another  strong  possibility  was  that  the  potent  antioxidant 
properties of nitrone D were responsible for reduced EC migration. It is now 
recognised that ROS have a dual role in affecting cell migration, which can be 
stimulatory  or  inhibitory,  depending  on  the  type,  amount  and  duration  of 
exposure. Compelling studies by Moldovan et al. (256) and Ikeda et el. (257) 
found that ECs at the margins of a wound assay produce small amounts of ROS, 
which  appear  to  be  essential  for  normal  migration.  Normal  cell  motility  in 
animals is based on changes in the actin cytoskeleton, which depends on the 
response  to  numerous  signals  (258).  Actin  polymerisation,  necessary  for 
cytoskeleton reorganisation, is mediated by targeted physiological release of O2
- 
from ECs (256). Therefore, potent antioxidants acting deep within cells, such as 
nitrone D, could disturb this process and lead to impaired cell motility. In support 
of  this,  a  SOD  mimetic  and  inhibitor  of  NADPH  oxidase  both  limited  EC 
migration (256). A finely balanced redox state is likely to support EC movement 
which,  like  platelet  aggregation,  is  reliant  on  physiological  cellular  ROS 
generation,  but  may  also  be  disrupted  by  disproportionately  high  levels  of 
oxidative stress present in pathological states.  
 
4.4.4  Limitations 
It would have been beneficial to test a variety of concentrations and construct a 
concentration-response curve for nitrone D in the EC migration assay. The effect 
of X/XO caused a lower chemiluminescence signal compared to the values in 
Chapter 2. This appeared to be due to considerable daily variability in the assay, 
which  was  unexplained.  As  a  result,  to  maintain  scientific  validity,  all   123 
experiments for a given section were performed in succession on the same day 
and excellent reproducibility was achieved for identical conditions within each 
group. As in previous chapters, the relevance of in vitro assays in whole blood to 
the clinical setting is limited. Recent work has shown that some methods of in 
vitro platelet testing can predict clinical events after PCI and although supportive 
data  is  not  available  for  WBA,  this  method  correlates  well  with  light 
transmission  aggregometry  (259),  which  does  display  some  prognostic  value 
(260). 
 
4.4.5  Conclusions 
Although  I  found  that  nitrone  D  displayed  attractive  properties  by  weakly 
inhibiting  WBA,  it  caused  a  marked  reduction  in  EC  migration.  This  latter 
characteristic  is  highly  undesirable  as  a  potential  DES  coating  because,  if 
occurring in vivo, it could significantly impair endothelial healing. Given that 
promotion  of  re-endothelialisation  was  a  primary  objective  of  this  research 
project,  nitrone  D  was  no  longer  considered  suitable  as  a  potential  novel 
antioxidant DES coating. 
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Chapter 5 
 
The effects of a succinobucol-eluting stent 
in a porcine coronary model 
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5.1  Introduction 
 
The advent of DES has enabled a vast array of compounds to be tested as local 
treatments after stent deployment in a bid to modify arterial healing. The primary 
objective of early DES was to inhibit neointimal hyperplasia and resulting ISR, 
the main drawback of BMS. This goal has largely been achieved by the first 
generation of DES, now in widespread clinical use. However, whilst DES have 
successfully decreased the incidence of  ISR, the polymers  and drugs used as 
coatings  can  cause  delayed  arterial  healing  and  inflammation,  which  both 
increase  the  risk  of  late  stent  thrombosis,  a  potentially  life-threatening 
complication  (261).  Thus,  much  effort  is  now  being  directed  towards  the 
development of novel polymer-free DES using drugs which inhibit ISR, but also 
promote healing and reduce inflammation. 
 
Previous  studies  have  shown  that  probucol  can  reduce  ISR  by  inhibiting 
neointimal  hyperplasia  and  improving  re-endothelialisation  after  stent  injury 
(150;155).  Probucol  is  thought  to  mediate  these  beneficial  effects  via  its 
antioxidant properties (148;262) and up-regulation of heme oxygenase-1, which 
induces vascular SMC apoptosis and promotes EC function (160). Unfortunately, 
in  clinical  trials,  the  effects  of  oral  probucol  have  been  less  consistent 
(153;154;156;157).  The  efficacy  of  probucol  as  a  DES  coating  has  been 
evaluated in a preclinical model (263) and subsequently in the ISAR-TEST-2 
clinical trial, which showed that a non-polymer based dual probucol/rapamycin-
eluting stent was equivalent to a polymer-based rapamycin-eluting stent (264). 
This was remarkable, given that rapamycin is known to have superior effects if   126 
delivered using a polymer (265). It is not clear whether probucol was exerting 
polymer-like properties or if it was directly beneficial to vascular healing. The 
efficacy of a probucol-eluting stent is currently unproven. 
 
Succinobucol  is  a  novel  compound  designed  to  improve  upon  many  of  the 
chemical and pharmacological properties of probucol (Figure 5.1). It has several 
properties  highly  attractive  as  a  novel  DES  coating.  The  introduction  of  a 
monosuccinate moiety onto a phenol group renders succinobucol slightly more 
hydrophilic than probucol. This leads to considerably enhanced cellular uptake 
compared with probucol, which suffers from poor bioavailability and requires 
preloading for several weeks (157;163). Succinobucol potently inhibits basal and 
H2O2-induced levels of ROS released from human ECs and monocytic cells in a 
concentration-dependent  fashion,  whereas  probucol  has  a  much  weaker  effect 
(163;166). Succinobucol also exerts antiproliferative effects on vascular SMCs, 
with  50%  inhibition  at  5  µM  (165;166),  compared  with  probucol  which  was 
shown to exert no significant effect on SMC proliferation up to 100 µM (165). 
Succinobucol also has important anti-inflammatory actions. In previous studies, 
succinobucol potently inhibited pro-inflammatory cytokine release by monocytes 
and the expression of several pro-inflammatory adhesion molecules, including 
vascular cell adhesion molecule-1 and MCP-1 (163-166), which may contribute 
significantly to neointimal development (266;267). The anti-inflammatory effects 
of  probucol  in  these  studies  was  greatly  limited.  These  comparisons  with 
probucol may partly explain the poor results of oral probucol in clinical studies 
(154;157) and the negative preclinical effects of a probucol-eluting stent (158).   127 
Finally, succinobucol also reduces platelet aggregation, which may be beneficial 
in lowering the risk of early stent thrombosis (268).  
 
In  the  ARISE  (Aggressive  Reduction  of  Inflammation  Stops  Events)  clinical 
trial, oral succinobucol reduced the incidence of myocardial infarction, stroke 
and diabetes mellitus (269). However, succinobucol caused more adverse effects 
than  placebo,  worsened  lipid  profiles  and  increased  the  incidence  of  atrial 
fibrillation. CART-1 tested oral succinobucol following coronary stenting, but 
the  reduction  in  ISR  was  significant  only  if  drug  compliant  patients  were 
analysed separately (156).  
 
Succinobucol has never been evaluated as a DES coating and appears to offer 
significant advantages over probucol. It is possible that locally targeted therapy 
using stent-based delivery of succinobucol could improve efficacy and reduce 
systemic adverse effects. On the other hand, if negative cellular actions outweigh 
the beneficial effects of succinobucol, delivery of high concentrations into the 
artery wall may result in localised toxicity. The combination of succinobucol 
with a recognised inhibitor of ISR such as rapamycin may potentiate beneficial 
effects  on  neointimal  formation  and  negate  the  proinflammatory  effects  of 
rapamycin  on  injured  arterial  tissue  (170).  There  is  also  some  evidence 
suggesting that oxidative stress may  be linked  to rapamycin  resistance (270), 
therefore  local  application  of  an  antioxidant  may  improve  the  efficacy  of 
rapamycin. Finally, succinobucol may improve the elution profile of rapamycin 
in the absence of a polymer, by retarding drug release in a similar fashion to 
probucol (91) leading to improved efficacy. The aim of this study was to test   128 
whether  succinobucol  alone,  or  in  combination  with  rapamycin,  coated  on  a 
polymer-free DES would have a favourable effect on ISR and vascular healing 
after stent implantation. 
 
 
 
 
 
Figure 5.1  The chemical structure of probucol (A) and succinobucol (B). 
 
5.2  Methods 
 
5.2.1  Drugs 
Succinobucol  ([butanedioic  acid,  mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-
hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-
dimethylethyl)phenyl]ester], previously known as AGI-1067), the monosuccinic 
acid ester of probucol,  was synthesized by esterification of probucol  (Sigma-
Aldrich, Poole, Dorset). The identity of succinobucol was confirmed by NMR 
spectroscopy and purity was in excess of 99%. Succinobucol is metabolically 
stable and no significant active metabolites are formed in vivo (271). Rapamycin   129 
(sirolimus) is a macrocyclic triene antibiotic with potent antiproliferative, anti-
inflammatory and immunosuppressive effects. It forms a complex with FKBP12, 
which  subsequently  binds  to  and  inhibits  the  molecular  target  of  rapamycin 
(mTOR),  causing  arrest  of  cell  proliferation.  Rapamycin  (purity  ≥  95%)  was 
purchased from Cfm Oskar Tropitzsch (Marktredwitz, Germany). 
 
5.2.2  DES coating 
The  Yukon®  DES  (Translumina,  Hechingen,  Germany)  used  in  this  study 
consisted of a pre-mounted, sandblasted 316L stainless steel microporous stent, 
which is designed for individualised and dose-adjustable on-site stent coating. 
The microporous stent surface enables increased drug deposition and improves 
the drug reservoir capacity, allowing for retarded drug release without recourse 
to a polymer (272). All stents were 3.5 mm diameter and 16 mm length. The 
BMS were uncoated versions of the Yukon® stent. All stent coating solutions 
consisted  of  drug(s)  dissolved  in  99.5%  ethanol.  Sterile  stent  cartridges  were 
placed in the coating device (Figure 5.2) and connected to a 1 ml syringe which 
contained a predetermined volume of coating solution (0.33 ml for a 16 mm 
stent). Stent coating was achieved by a mobile ring containing 3 jet units, which 
allowed uniform spraying of drug solution onto the stent surface. The total time 
to spray coat the stent was approximately 6 minutes. The coating device dried the 
stent surface automatically by evaporating the ethanol with pressurised air (4-6 
atmospheres).  When  spray  coating  was  complete,  the  stent  cartridge  was 
removed from the machine and set aside for use within 4 hours. In the absence of 
prior data, three succinobucol coating solutions: 0.5% (5 mg/ml), 1% (10 mg/ml) 
and 2% (20 mg/ml) were tested. The succinobucol concentration that produced   130 
optimal  strut  coverage,  using  scanning  electron  microscopy  (Hitachi  S-4800), 
was selected for preclinical evaluation. The concentration of rapamycin coating 
solution (2%) was derived from favourable data using an identical Yukon® stent 
platform    (272;273).  Three  DES  were  evaluated:  a  succinobucol-eluting  stent 
(SES); a rapamycin-eluting stent (RES); a dual succinobucol/rapamycin-eluting 
stent (SRES) and these were compared to an uncoated Yukon® stent (BMS).  
 
 
Figure 5.2  The DES coating device. Individualised, dose adjustable DES coating 
was achievable using a predetermined volume of coating solution which was sprayed via 
three mobile jet units onto the microporous stent surface under sterile conditions. 
 
5.2.3  Preoperative care and anaesthesia 
Male Large-White/Landrace pigs (approximately 10 weeks old, 20-25 kg) were 
allowed to acclimatise for at least a week before commencement of the study. 
Each pig was preloaded with oral aspirin 300 mg and oral clopidogrel 300 mg 3 
days prior to the procedure, followed by normal diet with supplementation of 
oral aspirin 75 mg and oral clopidogrel 75 mg daily for the remainder of the 
study.  On  the  morning  of  the  procedure,  2-3  stents  were  prepared  for 
implantation.  The  pig  was  sedated  by  an  intragluteal  injection  of   131 
tiletamine/zolazepam (Zoletil®) 100 mg i.m. and a mixture of inhaled isoflurane 
(1–2%) in oxygen/nitrous oxide. Intravenous access was obtained via cannulation 
of the marginal ear vein and propofol (Rapinovet®) 30 mg i.v. was administered 
slowly over 1-2 minutes. Immediately, tracheal intubation was performed using a 
5.5  French  veterinary  tracheal  tube.  The  tracheal  tube  was  connected  to  the 
ventilator and general anaesthesia maintained throughout the procedure using a 
mixture  of  isoflurane  (1–2%)  in  oxygen/nitrous  oxide.  Pigs  were  given 
buprenorphine  (Vetergesic®)  0.15  mg  i.m.  for  perioperative  analgesia  and 
ampicillin  (Amfipen®)  350  mg  i.m.  as  antibiotic  cover.  Electrocardiography 
leads were connected to three limbs for cardiac monitoring. 
 
5.2.4  In vivo stenting 
Heparinised saline (5,000 units heparin in 500 ml 0.9% saline) was used to flush 
all catheterisation equipment. The left groin area of the pig was sterilised using 
povidone-iodine (Betadine®) solution and the surgical field was prepared with 
sterile  drapes.  A  5  cm  incision  was  made  with  a  sterile  scalpel  and  the 
subcutaneous  tissue  was  divided.  The  underlying  muscles  were  separated  by 
blunt dissection to expose the left femoral neurovascular bundle. The left femoral 
artery was dissected carefully to separate it from the femoral vein and femoral 
nerve,  which  allowed  a  blunt  suture  holder  to  pass  two  absorbable  sutures 
(Dexon™ II) around the femoral artery (Figure 5.3A). The femoral artery was 
accessed between the two sutures using a human transradial artery  access kit 
(Arrow® International UK Ltd, Middlesex). Arterial puncture was confirmed by 
pulsatile arterial flow. The 0.025 inch soft tipped guidewire was passed through 
the needle into the arterial lumen, the needle was removed and a 6 French sheath   132 
and dilator were placed over the wire. The wire and dilator were removed and the 
sheath was flushed with heparinised saline (Figure 5.3B).  
 
 
Figure 5.3  Intra-arterial access via the left femoral artery in the pig. A, Two sutures 
were placed around the femoral artery, which lies between the femoral vein and femoral 
nerve. B, The sheath was inserted after arterial puncture and wire access. 
   
Heparin 2000 units (100 units/kg) i.a. was administered via the sheath. Real time 
fluoroscopy (Siremobil 4N, Siemens) was used to image the catheterisation. A 
0.035 inch J-tipped guidewire  was inserted into a 6  French  coronary  guiding 
catheter and both were advanced to the aortic arch. The guidewire was removed 
and the catheter was attached to a 3 port manifold, connected to an electronic 
pressure  transducer,  heparinised  saline  flush  and  radiographic  contrast 
(Omnipaque 140, GE Healthcare), with a luer lock 10 ml syringe (BD 300-912) 
attached to the distal end for intra-arterial injection. The catheter tip was placed 
at the ostium of the left or right coronary artery, confirmed by contrast injection. 
Suitable guiding catheters were Judkins Right 3.5 or 3 for both coronary arteries 
or Judkins Left 3.5 or Amplatz Right 1 for difficult intubations. A 0.014 inch 
coronary guidewire was introduced and advanced to a distal portion of a major 
coronary artery. A Yukon® stent (type of stent was blinded to the operator) was   133 
prepared  by  passively  filling  the  stent  balloon  with  1:1  contrast:saline  and 
advanced  over  the  guidewire  into  a  stable  position  in  the  proximal  or  mid 
coronary  artery,  avoiding  major  coronary  branches.  Balloon  inflation  was 
performed for 20 seconds, aiming for a stent:artery ratio of 1.1-1.2:1 (typically 9-
12  atmospheres),  i.e.  slight  over-sizing.  Appropriate  injury  was  confirmed  by 
angiography before the balloon and guidewire were removed (Figure 5.4).  
 
 
Figure 5.4  Angiograms of coronary stent implantation in the pig. A, Catheter in left 
main coronary artery and guidewire in distal left circumflex coronary artery. B, Inflation 
of balloon and stent deployment. C, Final angiographic result with slight oversizing of 
stent:artery ratio. All angiograms shown are right anterior oblique 30º projection. In this 
view, the left circumflex is medial to the left anterior descending coronary artery. 
 
This procedure was repeated in a total of 2-3 coronary arteries in order to implant 
2-3 stents per pig. Succinobucol was undetectable in blood samples 1 hour and 1 
day after stenting therefore implantation of multiple stent types in each animal 
was  permitted  in  accordance  with  published  guidelines  (175).  During  the 
procedure, the pig received an intravenous saline infusion (approximately 250 
ml)  to  support  blood  pressure.  The  catheter  and  sheath  were  removed  and 
haemostasis was achieved by manual pressure (10-20 minutes) or ligation of the 
femoral artery, if ongoing bleeding. The subcutaneous tissues were closed with   134 
absorbable sutures (Dexon™ II) and the skin was closed with non-absorbable 
sutures  (Ethilon®).  Anaesthesia  was  terminated  and  the  pig  was  extubated. 
Adequate recovery was ensured and the pig returned to the pen. All premature 
and  unexpected  deaths  were  examined  by  post-mortem,  gross  evaluation  and 
stent  examination.  Approval  was  granted  by  Strathclyde  University  Ethics 
Review  Committee  and  all  procedures  were  performed  under  Home  Office 
Project Licence number 60/3410. 
 
5.2.5  Pharmacokinetic studies 
Drug loading of succinobucol was quantified by in vitro elution of the SES in 
pure  ethanol,  followed  by  HPLC  analysis.  To  determine  in  vivo  release 
characteristics of the SES, stents were harvested 1 hour, 1, 3, 7, 14 and 28 days 
after implantation. At the end of each predefined period, the pig was sedated and 
euthanized by a lethal dose of sodium pentobarbital (Euthatal®) 3000 mg i.v. 
The  heart  was  removed  via  midline  thoracotomy  and  placed  in  saline.  The 
coronary  arteries  containing  stents  were  carefully  dissected  from  connective 
tissue.  Stents  were  excised  and  surrounding  arterial  tissue  was  homogenised. 
Succinobucol  in  surrounding  arterial  wall  and  remaining  on  the  stent  was 
extracted  into  acetonitrile.  Samples  were  chromatographed  on  a  Sphereclone 
ODS  (2)  column  (5  µm  particle  size,  150  ×  4.6  mm  [Phenomenex,  UK]). 
Samples were injected using an autosampler and pump system (Gynotek 480) in 
20  µl  aliquots,  at  a  mobile  phase  flow  rate  of  1  ml/min  acetonitrile:water 
(92.5:7.5). The detector (Detector 432,  Kontron  Instruments, UK) output was 
measured at a wavelength of 242 nm.  
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5.2.6  Tissue fixation and processing 
To determine efficacy, stents were harvested 28 days after stent implantation. At 
the end of the study period, each pig was sedated and euthanized as previously 
described. The heart was examined for gross evidence of myocardial infarction. 
The coronary arteries were dissected free from connective tissue and the stented 
segments were excised, including 3-4 mm of non-stented artery at each end. The 
segments were rinsed with saline to remove non-adherent clot. The specimens 
were  fixed  overnight  in  10%  formal  saline,  in  an  Eppendorf  tube  at  4  ºC, 
followed  by  dehydration  in  100%  acetone,  overnight  at  4  ºC.  The  specimens 
were then placed in glycol methacrylate (Technovit® 8100, Kulzer) infiltrating 
solution in an Eppendorf tube and left overnight at 4 ºC. The following day the 
specimens were removed and placed in a small plastic cylindrical tube, using 
circumferential foam padding to ensure correct orientation (distal end of the stent 
at the base of the tube). The tube was filled with Technovit® 8100 embedding 
solution and air bubbles were removed using forceps, before placing in the fridge 
to  allow  the  plastic  resin  to  harden.  The  Technovit®  8100  infiltrating  and 
embedding solutions were made up according to the manufacturer’s instructions. 
This produced a small cylindrical block of plastic resin containing the stented 
coronary segment. All blocks were randomly labelled by an external observer 
with a numbered code, which was placed in a sealed envelope until the end of all 
data collection and analysis. 
 
5.2.7  Slide preparation 
Each resin block containing the stented artery segment was removed from the 
plastic tube using a scalpel. The distal end of the resin block was stuck to a glass   136 
microscope  slide  using  toughened  acrylic  adhesive  (159-3991,  RS).  This 
produced superior bonding compared to Super Glue (Loctite®). Using a diamond 
edged rotary saw (Buehler Isomet® 1000), the slide was mounted on a chuck and 
a thin section cut 300-400 µm from the slide end. The new distal end of the resin 
block was then stuck to another slide with adhesive. This process was repeated to 
produce 6 good quality sections from the distal to proximal portion of the stent. 
Once cut, the sections were ground and polished by hand using a grinder/polisher 
(Buehler Metaserv® 2000) to reduce the thickness of the section to 10 µm and 
give a uniform surface for staining and microscopic evaluation. Sections were 
stained  using  haematoxylin-eosin  and  modified  Carstairs’  stain.  Images  were 
acquired using a Leica DM LB2 microscope and Leica DFC320 digital camera. 
Blinded histological analysis was performed using computerized morphometry 
software (Image-Pro Plus, Cybernetics).  
 
5.2.8  Histomorphometric analysis 
Histomorphometric analysis was according to Schwartz et al. (274) (Figure 5.5). 
Neointimal thickness was calculated as the mean distance from each stent strut to 
lumen; neointimal area was calculated as stent area minus lumen area; diameter 
stenosis was calculated as 100 × (1 − lumen area / IEL area). Binary ISR was 
defined as ≥ 50% diameter stenosis. Stent endothelialisation score was defined as 
the extent of the circumference of the arterial lumen covered by ECs and graded 
from 1 to 3 (1 = 25%; 2 = 25% − 75%; 3 ≥ 75%). Inflammation was graded as 0, 
none; 1, scattered inflammatory cells; 2, inflammatory cells encompassing 50% 
of  a  strut  in  at  least  25%  to  50%  of  the  circumference  of  the  artery;  3,  
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Figure 5.5  Histomorphometry and injury score. Injury score was defined as 0, IEL 
intact, media compressed; 1, IEL lacerated, media compressed; 2, Media lacerated, EEL 
intact; 3, EEL lacerated. Stent struts are represented by rounded squares. 
 
inflammatory  cells  surrounding  a  strut  in  at  least  25%  to  50%  of  the 
circumference  of  the  artery.  The  intimal  fibrin  content  was  graded  as  0,  no 
residual fibrin; 1, focal regions of residual fibrin involving any portion of the 
artery or moderate fibrin deposition adjacent to the strut involving < 25% of the 
circumference  of  the  artery;  2,  moderate  fibrin  involving  >  25%  of  the 
circumference  of  the  artery  or  heavy  deposition  involving  <  25%  of  the 
circumference of the artery; 3, heavy fibrin deposition involving > 25% of the 
circumference  of  the  artery.  All  sections  were  examined  for  presence  of 
uncovered  stent  struts  and  evidence  of  in-stent  thrombus  was  determined 
throughout the entire stent length. 
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5.2.9  WBA studies 
As succinobucol was to be used for the first time as a novel DES coating, its 
effect on WBA was investigated, primarily for safety purposes. This part of the 
study was performed following the premature death of two pigs, to ensure that 
succinobucol  was  not  exerting  a  prothrombotic  effect.  WBA  was  performed 
according to the method described in section 2.2.3. The effect of succinobucol 
(1-100 µg/ml) on WBA was determined using fresh porcine blood, withdrawn 
from the main pulmonary artery immediately after euthanasia for 4 pigs. 1 µl of 
1, 10 and 100 mg/ml succinobucol (in 99.5% ethanol) was added to 1 ml of 
whole blood:0.9% saline (1:1), 1 minute prior to addition of agonist. 3 µg/ml 
collagen and 20 µM ADP were used as platelet agonists. A higher concentration 
of ADP was used in this study because pigs were taking clopidogrel, an ADP 
receptor antagonist. Vehicle (0.1% ethanol) had no effect on WBA. 
 
5.2.10  Cell culture studies 
Bovine pulmonary artery ECs, obtained from a local abbatoir, were seeded on to 
6 well plates (up to passage 4) and grown to 70% confluence. Succinobucol or 
probucol  was  added  to  each  well  at  concentrations  (1-20  µmol/L)  that  have 
previously been shown to inhibit SMC proliferation (149;165;166). An additional 
well received the maximum amount of vehicle (0.3% dimethyl sulphoxide). After 
24 hours, the well plates were inspected and photographed, taking account of any 
evidence  of  cytotoxicity.  The  medium  was  removed,  and  adherent  cells  were 
dislodged  using  trypLE  Express  (Invitrogen,  UK).  Trypan  blue  (0.07%)  was 
added  to  the  cell  suspension  and  cells  counted  using  a  hemocytometer.  The 
percentage  of  the  counted  cells  not  stained  by  trypan  blue  is  reported  as  the   139 
percent viable cells. Identical experiments were performed using abbatoir derived 
bovine  pulmonary  artery  SMCs,  grown  to  90%  confluence.  In  additional 
experiments, 3-morpholinosydnonimine (SIN-1, a peroxynitrite donor) 0.2 µM 
was used to generate oxidative stress and administered to bovine aortic SMCs 
alone and in combination with succinobucol or probucol. Originally, the effect of 
succinobucol  on  cell  proliferation  was  to  be  studied,  however  the 
proinflammatory actions of the SES found in vivo and the damaging effects noted 
in  cell  cultures  led  to  a  change  in  the  protocol  to  address  cytotoxicity  and 
viability. 
 
5.2.11  Toxicology studies 
Given  that  succinobucol  is  a  close  analogue  of  probucol,  which  is  known  to 
prolong  the  QT  interval,  the  effects  of  succinobucol  on  the  surface 
electrocardiogram was assessed. 500 µg succinobucol (an approximation of the 
mass of drug carried on a SES) was infused into a coronary artery of a pig, not 
included in any other study. Electrocardiographic and haemodynamic monitoring 
was  performed  throughout,  looking  specifically  for  evidence  of  ischaemia, 
dysrhythmias  or  QT  interval  prolongation.  Succinobucol  concentration  in  the 
blood (withdrawn from the pulmonary artery) was measured 1 hour and 1 day 
after implantation of 2 SES, using HPLC. 
 
5.2.12  Statistical analysis 
Histomorphometric  data  for  each  stent  was  the  mean  of  six  sections  from 
proximal  to  distal  end.  The  endothelial  score,  inflammatory  score  and  fibrin 
score were the mean of two sections per stent. Group means were calculated and   140 
then compared by one-way analysis of variance and post-hoc Dunnett’s test. For 
WBA experiments, aggregation in response to ADP was severely reduced by 
clopidogrel, therefore values are absolute impedance. For the efficacy study, a 
sample size of 9 per group was calculated to provide 80% power to detect a 
treatment difference of  30% between  groups at a two-sided 0.05 significance 
level, based on the assumption that the SD of the response variable (neointimal 
area) was 20% as shown by similar studies in the porcine model (58;272). All 
data are expressed as mean ± SEM unless otherwise stated. Significance was 
established by a value of p < 0.05. Statistical analysis was performed using the 
SPSS statistical software package 14.0 for Windows (SPSS Inc., Chicago, IL, 
USA). 
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5.3  Results 
 
5.3.1  Optimisation of SES coating 
0.5% (5 mg/ml), 1% (10 mg/ml) and 2% (20 mg/ml) succinobucol solutions in 
99.5% ethanol were sprayed onto a Yukon® stent and examined using scanning 
electron  microscopy.  1%  succinobucol  coating  solution  produced  a  smooth 
uniform complete drug layer, optimal for the Yukon® DES delivery system and 
was  therefore  considered  most  appropriate  for  preclinical  assessment  (Figure 
5.6). 0.5% succinobucol produced incomplete strut coverage, with some areas of 
stent sparsely covered with drug. 2% succinobucol produced excessive coverage, 
with surplus drug deposition between struts and crystallisation of drug (10-25 µm 
diameter) present on the surface of the stent, which may become hazardous after 
balloon  dilatation  if  distal  embolisation  were  to  occur.  The  coating  device 
provided drug deposition on the exterior (abluminal) surface of the stent struts, 
whilst the interior (adluminal) surface remained essentially uncoated with drug 
(Figure 5.7). 
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Figure 5.6  A comparison of stent coverage for succinobucol coating solutions. A, 
0.5% succinobucol provided suboptimal coverage with drug (incomplete coverage areas 
are white). B, 1% succinobucol produced optimal strut coverage. C, 2% succinobucol 
caused surplus drug deposition and crystallisation (SEM, × 100 magnification). 
 
 
 
Figure 5.7  A comparison of uncoated and 1% succinobucol coated stents. A, BMS 
with  microporous  surface  designed  to  act  as  a  reservoir  for  drug  deposition  (insert: 
expanded BMS). B, 1% SES with smooth uniform drug layer (insert: SES with drug 
deposition on abluminal surface). Main figures (SEM, × 1000 magnification); inserts 
(SEM, × 100 magnification).  
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5.3.2  Drug loading of SES 
The total drug loaded on the SES using 1% succinobucol was measured in 4 
stents. The coating process produced a mass of 465 ± 61 µg succinobucol per 
SES. The drug loading of the RES using 2% rapamycin has been reported as 
producing 479 ± 26 µg rapamycin/cm
2 (265), which is equivalent to 842.7 ± 46 
µg for a 3.5 mm × 16 mm stent.  
 
5.3.3  In vivo study plan 
6 pigs underwent coronary stenting to investigate in vivo pharmacokinetics of the 
SES  and  19  pigs  underwent  coronary  stenting  as  part  of  the  in  vivo  efficacy 
study. The study plan is shown in Table 5.1. No pigs died prematurely during the 
pharmacokinetic study. There were 2 unexpected premature deaths during the 
efficacy study. One pig died the first night after successful implantation of a RES 
and SRES. Post-mortem examination identified no gross evidence of myocardial 
infarction, however careful dissection of the coronary arteries revealed occlusive 
stent thrombosis (Figure 5.8) in both stents. A second pig died on the operating 
table during recovery from general anaesthesia. Electrocardiographic monitoring 
displayed ventricular fibrillation during cardiac arrest (Figure 5.9). Post-mortem 
examination showed no gross cardiac abnormality, but there was evidence of 
occlusive stent thrombosis in both stents (SES and SRES). The diagnosis for 
both  premature  deaths  was  acute  stent  thrombosis  (within  24  hours). 17  pigs 
completed the 28 day efficacy study and 41 stents were available for histological 
evaluation.  
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Table 5.1  In vivo study plan. Premature deaths are highlighted in grey (pig 2 and 5 
in efficacy study). Each pig received 2-3 stents. 
Pig  LAD  LCx  RCA 
       
Pharmacokinetic study       
               1 (1 hour)  SES  SES  SES 
               2 (1 day)    SES  SES 
               3 (3 days)  SES    SES 
               4 (7 days)  SES  SES   
               5 (14 days)  SES    SES 
               6 (28 days)  SES  SES   
       
Efficacy study       
1  SES  BMS   
2  SRES  RES   
3  BMS    RES 
4  RES    BMS 
5  SES    SRES 
6    RES  BMS 
7  BMS  RES   
8  BMS    RES 
9  BMS  RES   
10  RES  SES   
11  RES  SES   
12  SES  SRES   
13  SES  BMS  RES 
14  BMS  SES  RES 
15  SRES  SRES  BMS 
16  SRES  SES  SRES 
17  SES  SRES  SRES 
18  SRES  SRES  SES 
19  SRES  BMS  SES 
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Figure 5.8  Fatal stent thrombosis in the pig. A, Gross cardiac specimen showing no 
evidence  of  myocardial  infarction.  B  and  C,  Dissection  of  coronary  artery  revealed 
occlusive stent thrombosis. 
 
 
 
Figure 5.9  Ventricular  fibrillation  during  cardiac  arrest  after  stent  implantation. 
The electrocardiograph shows 4 normal sinus beats followed by an R on T phenomenon 
inducing fatal ventricular fibrillation. 
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5.3.4  In vivo release profile of SES 
To determine in vivo release characteristics of succinobucol from the novel SES, 
13 SES were deployed in 6 pigs, using the techniques as previously described. 
Each pig received 2-3 stents in different coronary arteries (n = 2-3 for each time 
point) and specimens were harvested 1 hour, 1, 3, 7, 14 and 28 days after stent 
implantation. The SES provided sustained in vivo drug release for up to 4 weeks 
(Figure 5.10). 59.4% of the total succinobucol loaded on the SES was eluted 
during the first week and 81.0% was eluted after 28 days. This was very similar 
to the release profile of the RES, which retards drug release for greater than 3 
weeks,  with  around  two-thirds  released  during  the  first  week  (272;273). 
Succinobucol concentration in coronary artery tissue immediately surrounding 
the stent was quantified at 1 hour, 1, 3, 7, 14 and 28 days after stent implantation 
(Figure 5.11). At 1 hour, succinobucol concentration in surrounding artery tissue 
was 22.4 ng/mg. At 1 day, succinobucol tissue concentration peaked at 825.9 
ng/mg. Succinobucol concentration in surrounding artery tissue was > 200 ng/mg 
for the remainder of the study. At 28 days, succinobucol tissue concentration was 
242.2 ng/mg.  
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Figure 5.10  In vivo release profile of SES. Succinobucol elution was controlled over 
4 weeks, with the majority of drug released in the first week. Data points represent % 
succinobucol released as a percentage of total drug loaded on the SES. 
 
 
Figure 5.11  Succinobucol tissue concentration after SES implantation. Succinobucol 
concentration  in  surrounding  artery  tissue  peaked  1  day  after  implantation  and  was 
maintained for the duration of the study period (n = 2).    148 
5.3.5  Efficacy results 
In  total,  41  stents  were  implanted  in  the  coronary  arteries  of  17  pigs  for 
evaluation of efficacy at 28 days (BMS, n = 11; SES, n =10; RES, n = 10; SRES, 
n = 10). Representative photomicrographs from each group are shown in Figure 
5.12. 
 
Injury score 
There was no significant difference in injury score between groups (Figure 5.13).  
 
Vessel size 
EEL area was increased in the RES group, compared with all other groups (7.84 
± 0.30 mm
2, 7.52 ± 0.28 mm
2, 9.03 ± 0.30 mm
2 and 7.61 ± 0.22 mm
2 for BMS, 
SES, RES and SRES, respectively, p < 0.05). IEL area (6.74 ± 0.27 mm
2, 6.35 ± 
0.30 mm
2, 7.94 ± 0.29 mm
2 and 6.56 ± 0.24 mm
2) and stent area (6.35 ± 0.24 
mm
2,  6.01  ±  0.27  mm
2,  7.54  ±  0.29  mm
2  and  6.29  ±  0.24  mm
2)  were  also 
increased in the RES group (BMS, SES, RES and SRES, respectively, both p < 
0.05). Other group comparisons were not statistically significant. 
 
Medial area 
There was no difference in medial area at 28 days between groups (1.10 ± 0.06 
mm
2, 1.17 ± 0.07 mm
2, 1.10 ± 0.06 mm
2 and 1.05 ± 0.06 mm
2 for BMS, SES, 
RES and RSES, respectively, p = NS). 
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Figure 5.12  Representative  photomicrographs  of  stent  sections.  BMS  (A,B)  had 
moderate neointimal formation; SES (C,D) had the most extensive neointima; RES (E,F) 
had minimal neointimal growth; SRES (G,H) had moderate neointima similar to BMS. 
A, C, E, G (× 2 magnification); B, D, F, G (× 10 magnification). 
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Figure 5.13  A  comparison  of  injury  score  between  groups.  No  significant 
differences were present (n = 10-11), p = NS. 
 
Neointimal area and thickness 
Neointimal area was increased significantly in the SES group, whereas there was 
a trend to decreased neointimal area in the RES group (Figure 5.14). Similar 
results  were  evident  for  neointimal  thickness  (Figure  5.15).  There  were  no 
significant differences in neointimal area/medial area. Neointimal area/IEL area 
and  neointimal  area/EEL  area  were  both  increased  significantly  in  the  SES, 
compared with BMS (both p < 0.01). In all groups, the neointima was composed 
almost  entirely  of  SMCs  with  inflammatory  cells  around  the  struts  and  little 
extracellular matrix (Figure 5.16). 
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Figure 5.14  A comparison of neointimal area between groups. Neointimal area was 
increased significantly in SES, compared with BMS (n = 10-11), * p < 0.01 vs. BMS. 
 
 
Figure 5.15  A  comparison  of  neointimal  thickness  between  groups.  Neointimal 
thickness was increased significantly in SES, compared with BMS (n = 10-11), * p < 
0.01 vs. BMS. 
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Figure 5.16  Representative  photomicrographs  of  stent  sections  (high  power).  
A,  Neointima  (n)  over  stent  struts  (s)  was  made  up  predominantly  of  SMCs.  
B, Inflammatory cells (i) around a strut in SES. C, Thin endothelial monolayer (e) over 
the adluminal surface of a stent strut in RES. D, Uncovered strut with interruption of 
endothelium.  E,  Luminal  thrombus  (t)  over  an  area  of  poor  re-endothelialization.  
F, Fibrin (f) deposition around a strut in SES. All sections (× 20 magnification). 
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Diameter stenosis 
SES caused a significant increase in diameter stenosis, whereas the decreased 
diameter stenosis in the RES group was not significant (p = 0.17) (Figure 5.17). 
The  rate  of  binary  ISR  (>  50%  diameter  stenosis)  measured  by  histological 
analysis was 9.1%, 60%, 0% and 20% for BMS, SES, RES and SRES groups, 
respectively (p < 0.01). 
 
 
Figure 5.17  A comparison of diameter stenosis between groups. Diameter stenosis 
was increased significantly in SES, compared with BMS (n = 10-11), * p < 0.05 vs. 
BMS. 
 
 
 
 
 
   154 
Lumen area 
The lumen area was increased significantly in the RES group and the decrease in 
lumen area in the SES group was of borderline significance (Figure 5.18). 
 
 
Figure 5.18  A comparison of lumen area between groups. Lumen area was increased 
significantly in RES and decreased of borderline significance in SES, compared with 
BMS (n = 10-11), * p < 0.05, ** p = 0.05 vs. BMS. 
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Endothelial regeneration 
28 days after implantation, all BMS and SES had an endothelial score of 3. Two 
RES and two SRES had an endothelial score of 2.5 (derived from mean of two 
sections  per  stent).  This  resulted  in  a  small  but  non-significant  reduction  in 
endothelial score in both rapamycin groups (p = 0.30) (Table 5.2). The mean 
semiquantitative percentage of circumference covered by endothelium was 98.3 
± 1.0%, 98.3 ± 1.1%, 96.4 ± 1.8% and 96.0 ± 2.3% in BMS, SES, RES and 
SRES, respectively, p = NS. The rate of stents with any uncovered stent struts 
was 9.1%, 0%, 30% and 0% for BMS, SES, RES and SRES groups, respectively 
(p = 0.08).  
 
In-stent thrombus and fibrin deposition 
The rate of stents with in-stent thrombus was 27.3%, 10%, 20% and 20% for 
BMS, SES, RES and SRES groups, respectively (p = 0.81). Fibrin scores were 
markedly higher in both succinobucol groups (Table 5.2).  
 
Inflammation 
Inflammatory infiltrates present in the sections after 28 days were significantly 
increased in SES and significantly reduced in RES (Table 5.2). Inflammatory 
cells were most prevalent close to the stent struts (Figure 5.16). 
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Table 5.2.  Healing and inflammation. 
Group  Endothelial 
Score 
Fibrin 
Score 
Inflammatory 
Score 
BMS (n=11)   3.00 ± 0.00    0.09 ± 0.20     1.96 ± 0.42 
SES (n=10)   3.00 ± 0.00    0.95 ± 0.69*     2.35 ± 0.41** 
RES (n=10)   2.90 ± 0.21    0.15 ± 0.24     1.55 ± 0.28** 
SRES (n=10)   2.90 ± 0.21    1.25 ± 0.83*     2.00 ± 0.00 
* p < 0.005 vs. BMS; ** p < 0.05 vs. BMS. 
 
5.3.6  In vivo toxicology of succinobucol 
500 µg succinobucol infused directly into the left anterior descending coronary 
artery  over  10  minutes  (50  µg/ml  at  1  ml/min)  was  well  tolerated  with  no 
evidence  of  ischaemia,  thrombosis  or  QT  prolongation.  The  infusion  was 
repeated after BMS implantation (to induce endothelial injury) with no adverse 
effects. Vehicle (0.5% alcohol) was tested without incident. The SES caused no 
significant change in QTc interval (410.3 ± 14.5 ms before vs. 422.3 ± 7.5 ms 
after SES implantation, p = NS). No succinobucol was detected in blood samples 
obtained from the pulmonary artery 1 h or 1 day after deployment of 2 SES. 
 
5.3.7  Effect of succinobucol on WBA 
There  was  no  significant  effect  of  succinobucol  (1-100  µg/ml)  on  WBA 
compared with control, in response to 3 µg/ml collagen (Figure 5.19) or 20 µM 
ADP  in  porcine  blood  (Figure  5.20).  All  pigs  were  treated  with  aspirin  and 
clopidogrel. 
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Figure 5.19  The  effect  of  succinobucol  on  WBA  in  response  to  collagen. 
Succinobucol (1-100 µM) had no effect on WBA in response to 3 µg/ml collagen in 
porcine blood (n = 4), p = NS. 
 
 
Figure 5.20  The effect of succinobucol on WBA in response to ADP. Succinobucol 
(1-100 µM) had no effect on WBA in response to 20 µM ADP in porcine blood (n = 4), 
p = NS.   158 
5.3.8  Effect of succinobucol on cultured ECs and SMCs 
Succinobucol caused marked toxicity to cultured bovine pulmonary artery ECs 
and SMCs.  
 
EC culture 
After 24 hours, 1 µM succinobucol caused a few ECs to detach from the well 
plates in culture, whereas above 5 µM, succinobucol caused almost all ECs to lift 
off  the  plate  (Figures  5.21).  Trypan  blue  staining  showed  that  adherent  ECs 
remained viable up to 5 µM succinobucol. However, with higher concentrations 
of succinobucol, there was a significant decline in EC viability (Figure 5.22).  
 
SMC culture 
After 24 hours, 1 µM succinobucol caused a few cells to detach from the well 
plates in culture, whereas above 10 µM, succinobucol caused almost all SMCs to 
lift off the plate (Figures 5.23). The adherent SMCs had significantly reduced 
viability  in  1,  5  and  20  µM  succinobucol  (Figure  5.24).  Probucol  was 
considerably less toxic to SMCs than succinobucol, with minor detachment of 
SMCs  occurring  only  in  20  µM  probucol  (Figure  5.25).  Probucol  had  no 
significant deleterious effect on SMC viability (Figure 5.26).  
 
Protection against SIN-1 
0.2 µM SIN-1 reduced viability of ECs and SMCs. 1 µM Succinobucol did not 
protect against SIN-1-induced toxicity, whereas 1 µM probucol provided some 
protection (Figure 5.27).  
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Figure 5.21  The effect of succinobucol on cultured ECs. After 24 hours, there was 
evidence of concentration-dependent cytotoxicity, resulting in total cell detachment in 
10 µM and higher concentrations of succinobucol (magnification ×100). 
 
 
Figure 5.22  The  effect  of  succinobucol  on  the  viability  of  adherent  ECs.  Cell 
viability was reduced at concentrations of 10 µM and higher (n = 4-6), * p < 0.05 vs. 
control.   160 
 
Figure 5.23  The effect of succinobucol on cultured SMCs. After 24 hours, there was 
evidence of concentration-dependent cytotoxicity, resulting in total cell detachment in 
20 µM succinobucol (magnification ×100). 
 
 
Figure 5.24  The  effect  of  succinobucol  on  the  viability  of  adherent  SMCs.  Cell 
viability was reduced in 1 µM, 5 µM and 20 µM (n = 4-6), * p < 0.05 vs. control. 
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Figure 5.25  The effect of probucol on cultured SMCs. After 24 hours, there was 
maintained  cell  adherence  with  only  minor  cell  detachment  at  the  20  µM  probucol 
(magnification ×100). 
 
 
Figure 5.26  The effect of probucol on the viability of adherent SMCs. Probucol had 
no significant effect on the viability of remaining adherent SMCs (n = 4-5), p = NS. 
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Figure 5.27  The  effect  of  succinobucol  and  probucol  on  SIN-1-induced  toxicity. 
Succinobucol  was  unable  to  protect  ECs  and  SMCs  from  SIN-1-induced  toxicity, 
however probucol provided some protection (n = 4-5), * p < 0.01 vs. control, ** p < 0.05 
SIN-1 vs. SIN-1 + 1 µM probucol, p = NS all other comparisons. 
 
5.4  Discussion 
 
Since  both  oxidative  stress  (117;275;276)  and  inflammation  (18;277)  are 
responsible for increased neointimal formation, I chose to investigate the novel 
antioxidant and anti-inflammatory drug, succinobucol, coated on a stent, without 
a polymer to reduce the potential for adverse effects. Succinobucol reportedly 
had shown many properties which were extremely attractive as a potential DES 
coating.  These  included  potent  antiproliferative  effects  on  SMCs  (165;166), 
inhibitory effects on vascular inflammation (163-166), antiplatelet effects (268) 
and rapid uptake into cells (163), all of which were superior to probucol, the 
parent molecule with promising results for the prevention of ISR and promotion 
of endothelial healing, especially in animal models (149;150).    163 
5.4.1  Effects of succinobucol 
Drug coatings were sprayed onto unexpanded stents on a balloon, therefore drug 
deposition occurred onto the abluminal surface, which is ideal for a modern DES. 
Preferential abluminal DES coating allows more targeted drug release into the 
artery  wall, reduces systemic exposure and limits potentially unforeseen drug 
toxicity to the ECs which repopulate the adluminal strut surface. This technique 
is now specifically employed in several modern DES currently in clinical use 
(278-280).  Stent-based  delivery  of  succinobucol  was  optimally  controlled  in 
vivo,  despite  the  absence  of  a  polymer,  with  around  two-thirds  of  the  drug 
released  during  the  first  week.  This  matches  closely  the  period  after  stent 
deployment when ROS are released in large quantities from the artery wall (243).  
 
However,  surprisingly,  local  delivery  of  succinobucol  increased  inflammation 
and neointimal growth. Rate of ISR was also significantly increased in the SES 
group.  Subsequently,  succinobucol  was  found  to  destabilise  cells  in  culture 
leading to cell detachment and loss of viability. However, cell toxicity in vitro 
was much less marked with probucol. Rapamycin is a potent inhibitor of SMC 
proliferation but has no deleterious effect on cell viability (281). I postulate that 
succinobucol  exacerbated  neointimal  formation  by  causing  direct  cellular 
damage  and  inflammation,  negating  any  putative  local  beneficial  effects. 
Localised cellular deterioration and necrosis would have been likely to recruit 
inflammatory cells, as was observed. Degree of inflammation has been shown to 
correlate positively with neointimal growth (282) and this relationship has been 
reaffirmed  by  my  results  (Figure  5.28).  Analysis  of  human  peripheral  artery  
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Figure 5.28  Scatter plot of inflammatory score and neointimal thickness. Neointimal 
thickness was strongly correlated with inflammatory score (r = 0.67, p < 0.001). 
 
atherectomy specimens demonstrated that macrophages and leucocytes account 
for  almost  a  quarter  of  neointimal  cells  in  cases  of  ISR  (283).  Coronary 
atherectomy  specimens  from  several  patients  who  had  received  the  paclitaxel 
derivative, 7-hexanoyltaxol (QP2)-eluting polymer stents, which also increased 
ISR, displayed widespread inflammatory aggregates and fibrin deposition in a 
SMC-rich neointima (284). These histological findings are analogous to those 
found with succinobucol in this study. Thus, I propose that the accumulation of 
inflammatory  cells  around  SES  struts  caused  increased  production  of 
chemotactic cytokines and growth factors, which led to the proliferation of SMCs 
and increased neointimal formation. 
 
Succinobucol did not cause improved arterial healing, because increased fibrin 
and excessive inflammation around SES struts in vivo after 28 days are both   165 
features  of  poor  healing  (274).  Fibrin  and  platelet-rich  thrombus  adhere  to 
metallic stent struts within hours of implantation. Normally, this progressively 
resolves over the following weeks, principally due to resorption by macrophages, 
which secrete a number of fibrinolytic enzymes (285;286). Near-total fibrin and 
thrombus resorption is a feature of complete arterial healing in both animal and 
human models. Increased fibrin deposition seen in both SES groups after 28 days 
in  this  study  closely  matched  the  late  histological  findings  of  other  potent 
antirestenosis  therapies  that  impede  arterial  healing,  such  as  intracoronary 
radiation (287) and polymeric DES (62). Endothelial regeneration was difficult 
to  assess  in  this  model  because,  at  the  end  of  the  study,  the  BMS  were 
completely  re-endothelialised.  However,  the  toxic  effects  of  succinobucol  on 
cultured  ECs  suggest  that  endothelial  healing  was  not  accelerated  by 
succinobucol.  In  fact,  succinobucol  may  have  worsened  neointimal  formation 
due to toxicity to ECs, which inhibit SMC proliferation (21;22). Although it has 
been shown that phenolic antioxidants can provide protection against oxidative 
stress, they can also lead to generation of secondary radicals that may modify 
important  intracellular  targets  with  the  potential  to  cause  pro-oxidant  effects 
(288;289). This may also explain some of the unfavourable cellular responses 
identified in our study.  
 
In light of the poorly performing SES, one of the most obvious concerns related 
to  possible  “overdosing”  of  the  SES  on  injured  arterial  tissue.  A  1% 
succinobucol  coating  was  selected  for  preclinical  DES  evaluation.  This  was 
based on the physical properties of the coating, rather than attempts to predict the 
coating  concentration  necessary  to  replicate  previously  published  cell  culture   166 
data. The latter approach is not a common or straightforward method of DES 
development,  since  estimating  the  concentration  of  drug  coating  required  to 
achieve  a  pre-specified  local  tissue  concentration  is  fraught  with  difficulties. 
From prior in vitro studies, 10 µM succinobucol exerted potent antioxidant and 
anti-inflammatory  effects,  whereas  5  µM  was  ~50%  inhibitory  to  SMC 
proliferation  (165;166).  Unfortunately,  quantifying  the  concentration  of  drug 
coating required to obtain this narrow therapeutic range in target tissue would 
require  evaluation  of  multiple  coatings,  with  repeated  measurement  of 
succinobucol  levels  in  the  artery  wall.  The  relationship  between  coating 
concentration,  drug  loading  and  target  tissue  concentration  is  dependent  on 
multiple factors including stent surface affinity for drug, in vivo release kinetics 
and  subsequent  partitioning  into  local  and  distant  tissues.  This  level  of 
preparatory work has considerable resource demands, beyond the scope of this 
research, and its value has not been proven by other groups. Another potential 
method  could  utilise  complex  mathematical  modelling,  but  this  prediction  is 
likely to be imprecise as the relationships may not be linear. In my view, in vitro 
techniques to simulate in vivo pharmacokinetics are of limited value, not least 
because most in vitro release kinetics are performed in aqueous solutions and the 
ability  to  replicate  tissue  absorption  is  greatly  impaired.  Ultimately,  1% 
succinobucol coating was chosen because it provided excellent coating of stent 
struts, no overspill onto the balloon and no areas of sparse deposition, which was 
present with lower concentrations. The local tissue concentration was quantified 
at various time points after SES implantation and this was compared to in-house 
cell culture experiments, which were performed after the in vivo study period, to 
provide  supporting  data.  The  succinobucol  concentration  measured  in  arterial   167 
specimens  throughout  the  28  day  study  period  (200-800  ng/mg,  which  is 
equivalent to 300 µM – 1.3 mM succinobucol) was around one hundred-fold 
greater than the concentration reported to cause antioxidant, anti-inflammatory 
and  antiproliferative  effects  in  previous  studies  (10  µM  succinobucol  is 
approximately 6 ng/mg tissue). However, 1-20 µM succinobucol was found in 
this  study  to  cause  severe  toxicity  to  cells  in  culture.  It  was  not  possible  to 
investigate the effects of much higher concentrations, which were measured in 
the arterial tissue, to cells in culture due to insufficient solubility. The mass of 
succinobucol loaded on the SES (~450 µg per stent) was similar to that of other 
drugs loaded on DES which are even more potent inhibitors of cell proliferation, 
but share similar release characteristics and tissue solubility. For instance, the 
tissue concentration of rapamycin measured after successful drug elution in a 
porcine model (272) was around one thousand-fold greater than that required to 
inhibit SMC proliferation (281;290), yet this stent is currently used in clinical 
practice. Similar findings were reported in another preclinical study of polymer-
based  rapamycin  (58),  which  provided  positive  data  prior  to  clinical  trials.  It 
follows  that  adjustment  of  the  coating  concentration  to  target  a  narrow 
therapeutic range (effective in cell culture) is not a fundamental prerequisite for 
early DES development. It is clear, however, that drugs may differ considerably 
in their safety margins. In retrospect, I believe that inclusion of a “low dose” (e.g. 
0.1% or 0.5%) and “high dose” (e.g. 1%) SES would have been preferable and 
this is supported by recently updated consensus guidelines (175). 
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5.4.2  Effects of rapamycin 
The inhibition of neointimal growth by around a third with the RES in this study 
was very similar to previous preclinical data using an identical non-polymer stent 
platform  (272)  subsequently  validated  in  a  clinical  trial  (89),  although  this 
finding was not significant. No evidence of medial necrosis was evident in the 
RES  group,  but  the  extent  of  re-endothelialisation  was  reduced,  albeit  non-
significantly,  consistent  with  previous  reports  (62).  Inflammation  was 
significantly reduced by the RES, which is in agreement with a similar study of 
the same stent with rapamycin at a lower concentration (272) and another study 
evaluating polymer-based rapamycin (58) in a porcine model. 
 
5.4.3  Effects of succinobucol/rapamycin combination 
When used in combination, the succinobucol coating impaired the antirestenotic 
effect  of  rapamycin.  It  is  likely  that  the  undesirable  biological  effects  of 
succinobucol on the artery wall opposed the actions of rapamycin, although I 
cannot  rule  out  the  possibility  that  succinobucol  impaired  the  delivery  of 
rapamycin. In terms of neointimal growth, the dual DES performed similarly to 
the  BMS.  Persistent  fibrin  deposition  was  present,  as  in  the  SES  group, 
indicating  suboptimal  arterial  healing,  but  inflammation  was  no  different  to 
BMS,  suggesting  equipoise  between  the  toxic  proinflammatory  effects  of 
succinobucol against the anti-inflammatory action of rapamycin. 
 
5.4.4  Other predictors of neointimal growth 
The increase in EEL area identified in the RES group after 28 days may have 
been  a  chance  finding.  A  possible  confounding  factor  was  increased  rates  of   169 
(blinded) implantation of the RES into the RCA, which was a significantly larger 
vessel than the branches of the left coronary system (mean EEL was 7.86 ± 0.21 
mm
2,  7.55  ±  0.23  mm
2  and  8.77  ±  0.35  mm
2  for  LAD,  LCx  and  RCA, 
respectively, p < 0.05). This discrepancy in vessel area may have confounded the 
results for the RES group, although injury scores were well matched. Without 
baseline  measurements,  it  was  not  possible  to  determine  the  role  of  positive 
arterial remodelling, an uncommon sequela of DES implantation, however no 
cases  of  incomplete  stent  apposition  occurred  (291).  Regardless  of  whether 
vessel  enlargement  was  acquired  or  not,  neointimal  thickening  was  inversely 
correlated with EEL (r = -0.53, p < 0.001), confirming the relationship between 
smaller  vessels  and  ISR  (292).  As  expected,  there  was  a  positive  correlation 
between  injury  score  and  neointimal  thickening  (r  =  0.56,  p  <  0.001),  but 
importantly, no relationship between vessel size and degree of injury (r = 0.01, p 
= 0.95). Injury scores were also closely matched between groups and < 20% of 
sections  showed  excessive  injury,  which  is  consistent  with  consensus 
recommendations (274). Overall the mean injury score was 1.61 (SD 0.19) which 
was appropriate for the porcine restenosis model.  
 
5.4.5  Premature deaths 
Two  unexpected  premature  deaths  occurred  during  the  efficacy  study.  These 
were  probably  both  caused  by  acute  stent  thrombosis.  It  is  recognised  that 
difficulties exist in diagnosing whether stent thrombosis occurred premortem or 
postmortem. Ventricular fibrillation was witnessed prior to the second death and 
this was probably the mode of death for the first pig that died suddenly, also 
within  24  hours.  The  occurrence  of  ventricular  arrhythmias  suggested   170 
unrecognised acute ischaemia, which was most likely due to stent occlusion. It 
was not possible to determine whether a particular type of stent was responsible 
for stent thrombosis due to the small number of events. Sudden death may be 
more common in drug-eluting stents, principally due to stent thrombosis (293), 
but importantly, the early mortality rate in this study was less than the suggested 
maximum of 15% for the porcine model (274). To show that succinobucol itself 
was not likely to be directly responsible for the premature deaths, rather than the 
stent procedure itself, it was found to be tolerated well when infused down the 
coronary artery and not found to be proaggregatory (or antiaggregatory) in vitro. 
 
5.4.6  Comparison with other studies 
In CART-1, although oral succinobucol improved coronary artery dimensions six 
months after coronary stenting, the drug failed to influence neointimal growth, as 
observed by intravascular ultrasound (156). The ability of oral probucol to reduce 
neointimal growth has been variable, with encouraging results in predominantly 
animal  models  (148-150;155;262),  but  negative  reports  in  other  studies 
(153;154;156;157;161;294).  Other  compounds  released  from  DES  have  been 
shown to cause local cell toxicity and increased inflammation following coronary 
stenting. Polymeric paclitaxel (62;295) and sirolimus-eluting stents (62;272) are 
both associated with impaired healing, greater inflammation and persistent fibrin 
deposition after arterial injury. Despite these deleterious effects, both are widely 
used in clinical practice because of their ability to reduce ISR. Gold-coated stents 
increased ISR compared with BMS, despite encouraging early preclinical results 
(296). Aggravated neointimal growth and incomplete healing was caused by an 
actinomycin-eluting stent (174), as was found in this study. The effects of the   171 
dual SRES contrasted markedly with the effects of a probucol/rapamycin stent on 
an identical platform, which reduced ISR comparably to a polymeric sirolimus-
eluting stent (264). The dual probucol/rapamycin stent also caused no increase in 
inflammation  (263).  Therefore,  stent-based  delivery  of  succinobucol  in 
combination with rapamycin does not produce similar effects to probucol. This 
study suggests that a critical factor determining the efficacy of antioxidants used 
in  DES  is  the  balance  of  their  local  cellular  actions  and  toxicity.  It  is  also 
possible  that  the  inferior  results  of  the  SRES  group  compared  with  the 
probucol/rapamycin stent may relate to more rapid tissue uptake of succinobucol 
compared with probucol, which could cause less retardation of rapamycin release 
from the stent. 
 
5.4.7  Study limitations 
This  investigation  of  succinobucol  coated  stents  after  arterial  injury  used  a 
standard  preclinical  model.  It  is  possible  that  the  effect  of  local  delivery  of 
succinobucol in human atherosclerotic coronary arteries would differ from the 
effect  demonstrated  in  normal  pig  coronary  arteries.  Nevertheless,  the 
morphological  characteristics  of  neointimal  growth  in  the  porcine  model  are 
similar to that found in human coronary arteries (297). Further study is required 
to determine the concentration-response (particularly for low dose) and the long-
term  effects  of  succinobucol  loaded  on  a  stent,  although  I  think  a  beneficial 
action is unlikely. The pharmacokinetic profile of the SES was characterised by 
measurement  of  drug  remaining  on  the  stent  at  various  time  points  and  by 
estimation of drug levels in surrounding arterial tissue, as described by a recent 
consensus  document  for  the  preclinical  assessment  of  DES  (175).  In  vitro   172 
estimation  of  drug  elution  was  avoided  due  to  the  relative  insolubility  of 
succinobucol  in  aqueous  solutions.  An  alternative  method  to  determine  drug 
release  involves  the  use  of  radio-  or  fluorescent-labelling  to  measure  the 
concentration of the succinobucol in blood or arterial segments adjacent to the 
implanted  stent,  but  this  was  not  possible  due  to  resource  demands.  Drug 
concentration  was  not  measured  in  downstream  myocardium  from  the  target 
artery or in other organs such as liver and kidney to assess the possibility of 
systemic effects. A very early time point (such as 7 days in the efficacy study) 
would have been useful to help determine stent thrombosis risk and the presence 
of early re-endothelialisation. This was not performed in this research to preserve 
group sizes, although smaller numbers (minimum 3 stents) are probably required 
for this endpoint. Further characterisation of the inflammatory cells (for instance, 
semiquantitative  division  into  monocytes/macrophages,  lymphocytes  and 
neutrophils) may have helped to unravel the cellular and molecular mechanisms 
responsible for excessive neointimal growth caused by succinobucol. It would 
also have been beneficial to section the stents from both premature deaths in the 
efficacy study, as certain histological features are characteristic of premortem 
stent thrombosis (variegated platelet-fibrin, thrombus layering and adhesion to 
the artery wall, and presence of polymorphonuclear leucocytes (274)). 
 
5.4.8  Conclusions 
These data suggest that 1% succinobucol is not a favourable stent coating for 
clinical  studies.  After  28  days,  the  SES  was  associated  with  widespread 
inflammation,  substantial  late  fibrin  deposition  and  increased  neointimal 
formation. This maladaptive tissue response is most likely related to localised   173 
cell toxicity, increasing inflammation and impairing healing. The succinobucol 
coating also inhibited the effects of rapamycin from a polymer-free DES, thereby 
reducing its antirestenotic properties. More studies are required to determine the 
role of succinobucol and other antioxidant compounds for the prevention of ISR 
and promotion of stent healing.  
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Chapter 6 
 
The relationship between oxidised LDL, endothelial 
progenitor cells, coronary endothelial function and whole 
blood aggregation in patients with CHD 
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6.1  Introduction 
 
Vascular injury caused by PCI elevates oxidative stress (298;299) and leads to 
increased  oxLDL  in  the  blood  (114;115),  which  can  exacerbate  endothelial 
dysfunction  and  impair  arterial  healing  (102;236;300).  The  mechanisms  by 
which  oxLDL  exerts  these  effects  are  not  fully  understood.  The  traditional 
paradigm  of  endothelial  repair  is  based  on  the  migration  and  proliferation  of 
mature  ECs  from  the  wound  edge  to  repopulate  the  site  of  injury.  OxLDL 
inhibits  EC  migration  (126;235;236)  and  therefore  impairs  this  process. 
However, endothelial repair is also now thought to be regulated by mobilisation 
and homing of bone marrow-derived endothelial progenitor cells (EPCs) to sites 
of vascular damage, which have the potential to differentiate into ECs (176). 
Circulating levels of EPCs in blood are increased following several forms of 
endothelial  injury  including  tissue  ischaemia  (301),  myocardial  infarction 
(302;303) and PCI (304). Mobilisation of EPCs is mediated by cytokines such as 
VEGF (305) and granulocyte macrophage-colony stimulating factor (GM-CSF) 
(301),  and  is  thought  to  be  dependent  on  NO  (306).  Circulating  EPCs  are 
augmented  by  measures  which  increase  NO  bioavailability,  such  as  exercise 
(307)  and  drug  therapy  with  statins  (308;309)  or  ACE  inhibitors  (310). 
Conversely, the number of EPCs in the vasculature appears to correlate inversely 
with the presence of cardiovascular risk factors, which reduce NO bioavailability 
(311;312). Patients with stable CHD have fewer circulating EPCs than healthy 
controls  (311;313;314),  and  lower  levels  are  associated  with  worse 
cardiovascular outcome (315;316).  
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EPCs are more resistant than mature ECs to the toxic effects of oxidative stress, 
probably  due  to  greater  expression  of  potent  antioxidant  enzymes,  including 
manganese SOD, catalase and glutathione peroxidase, which reduce intracellular 
levels of ROS (317;318). This defence mechanism may allow EPCs to proliferate 
and differentiate in areas of high oxidative stress, such as inflamed and ischaemic 
tissues.  However,  EPC  function  and  survival  remain  susceptible  to  oxidative 
stress (319), and their antioxidant defences may be impaired in the presence of 
elevated C-reactive protein, a biomarker and active participant in atherosclerosis 
(125). The addition of oxLDL to cultured EPCs has been shown to impair EPC 
survival and function in a dose-dependent manner (124;320), an effect attributed 
to eNOS inhibition (321).  
 
Taken  together,  the  in  vivo  relationship  between  oxLDL,  EPCs  and  coronary 
endothelial function is likely to be a critical factor which can influence vessel 
healing. Oxidative stress, resulting in elevated oxLDL, may increase vascular 
damage  and  inhibit  endothelial  repair  due  to  impaired  EPC  mobilisation  and 
survival.  This  could  exacerbate  coronary  endothelial  dysfunction.  As  the 
endothelium  modulates  thrombosis  and  haemostasis,  a  defect  in  endothelial 
function may cause increased blood aggregability, which could increase the risk 
of  stent  thrombosis  following  PCI.  A  schematic  diagram  depicting  these 
relationships is shown in Figure 6.1. 
 
Through  these  suggested  interactions,  systemic  levels  of  oxidative  stress  are 
likely to contribute to the ability of injured arterial tissue to repair after PCI. 
Oxidised  lipoproteins  represent  one  of  the  major  oxidative  influences  on  the   177 
vascular  system,  being  potentially  responsible  for  ongoing  endothelial  injury, 
inflammation and impairing healing. There is limited data supporting a direct 
link between whole blood aggregability and clinical thrombosis (322), however 
similar methods of platelet testing such as light transmission aggregometry have 
demonstrated prognostic value (260). The aim of this study was to investigate the 
in vivo relationships between plasma oxLDL levels, the number of circulating 
EPCs,  coronary  endothelial  function  and  WBA  in  patients  with  symptomatic 
CHD. This information may provide indirect evidence as to whether elevated 
levels of oxidative stress (which is increased by PCI) could impair some of the 
mechanisms involved in arterial repair after stent injury, exacerbating endothelial 
dysfunction and rendering the stented artery more prone to thrombosis. 
 
 
Figure 6.1  The potential relationship between oxidative stress, EPCs, endothelial 
dysfunction  and  blood  aggregation.  Increased  oxLDL  may  lead  to  fewer  circulating 
EPCs, exacerbating endothelial dysfunction and causing increased blood aggregability. 
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6.2  Methods 
 
6.2.1  Study population 
The  study  was  approved  by  the  West  Glasgow  ethics  committees.  All 
participants were provided with a PIS and gave informed written consent. All 
patients were scheduled to undergo elective PCI for standard clinical indications. 
All patients were over age 18 and were receiving oral aspirin and clopidogrel 
therapy. The characteristics of each patient with respect to factors which can 
modify endothelial and platelet function were recorded. Patients were excluded if 
they had a history of myocardial infarction within 3 months, if they were taking 
any other antithrombotic therapy or if they were unable to give informed consent. 
On the same day, prior to angiography, venous blood was taken for immediate 
assay  of  circulating  EPC  levels  and  WBA.  Plasma  was  stored  at  -70  ºC  for 
subsequent oxLDL assay. 
 
6.2.2  OxLDL Assay 
OxLDL was detected by the commercial Mercodia solid two-site enzyme-linked 
immunoassay  (Diagenics,  Bletchley,  UK).  In  this  assay,  two  monoclonal 
antibodies were directed against separate antigenic determinants on the oxidised 
apolipoprotein B molecule. Samples were snap-thawed at 37 ºC for 3 minutes. 
All samples were run in duplicate on a single assay. The average coefficient of 
variation of the duplicates was 0.6%. The lowest sample value was 36 IU, which 
is  above  the  lowest  standard  (10  IU).  All  samples  were  therefore  within  the 
sensitivity of the assay. 
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6.2.3  EPC Assay 
Quantification  of  EPCs  was  performed  by  fluorescent-activated  cell  sorting 
(FACS) analysis using a flow cytometer. 1 ml of EDTA anticoagulated blood 
sample was added to 100 µl of FcR Blocking Reagent (Miltenyi Biotec). After 
20 minutes of incubation, 20 µl of the blocked blood was added to 20 µl of anti-
VEGF receptor-2 (KDR) antibody with isotype control mouse IgG1-APC used as 
a control. The blood was incubated for 30 minutes on ice and sheltered from the 
light. 20 µl of 7-amino-actinomycin D (AAD) viability dye was added for the 
exclusion  of  nonviable  cells.  20  µl  of  CD45-FITC/CD34-PE  antibody 
combination was added and CD45-FITC/CTL-PE was used  as a control. The 
solution was incubated at room temperature for 20 minutes, sheltered from the 
light. Diluted lysis buffer was made up by adding 400 µl 10× buffer to 3.6 ml of 
water. After 20 minutes incubation, 500 µl of buffer was added before a further 
10  minutes  of  incubation  in  the  dark.  100  µl  of  fluorospheres  was  added  to 
prepare the sample for FACS acquisition. Data was analysed using Cellquest™ 
Pro software (BD). Analytical gates were used to enumerate the total number and 
subsets of circulating cells. Samples were run until a total of 250,000 events were 
counted or after a 20 minute cut off. Data were stored for interpretation at the 
same time by one observer to remove bias. EPC concentration was calculated as: 
(No.  CD34
+KDR
+  events  ×  concentration  fluorospheres)/total  fluorospheres 
recovered. 
 
6.2.4  Whole blood aggregometry 
WBA  was  performed  according  to  the  method  described  in  Chapter  2.2.3. 
Collagen (3 µg/ml) and ADP (20 µM) (Labmedics Limited, Manchester, UK)   180 
were used as platelet agonists, within 3 hours of venepuncture. 20 µM ADP is 
commonly used to assess clopidogrel response (323). WBA was measured as 
absolute change in impedance 5 minutes after the addition of agonist, compared 
to baseline.  
 
6.2.5  Coronary endothelial function testing 
All vasodilator medication was withheld for 24 hours prior to testing. Coronary 
endothelial  function  was  measured  in  a  coronary  artery  without  significant 
stenosis (< 40% diameter), not scheduled for PCI. This was done by the standard 
method of assessing the change in luminal diameter, using quantitative coronary 
angiography (QCA), in response to an intracoronary infusion of the endothelium-
dependent  vasodilator,  acetylcholine.  In  healthy  arteries,  acetylcholine  causes 
release of NO from ECs, leading to vasodilation. In endothelial dysfunction, the 
NO response is blunted and the direct muscarinic smooth muscle response to 
acetylcholine  predominates,  causing  paradoxical  vasoconstriction  (324). 
Following baseline coronary angiography, the optimal angiographic projection 
for  the  study  artery  was  selected,  avoiding  overlapping  side-branches.  A  3 
French infusion catheter (Cook Medical, Limerick, Ireland) was placed into the 
proximal portion of the coronary artery to be studied via a standard 6 French 
guiding  catheter.  After  intracoronary  infusion  of  0.9%  saline  as  a  control, 
endothelium-dependent  vasomotion  was  assessed  by  serial  infusions  of 
acetycholine (Miochol-E, Novartis) in the following order: 10
-6 M, 10
-5 M and 
10
-4 M. All infusions were given at a flow rate of 2 ml/minute for 2 minutes. 
Careful attention was paid to the dead space within the infusion equipment to 
ensure  accurate  delivery  of  acetylcholine.  Assuming  a  mean  coronary  artery   181 
blood  flow  of  50  ml/minute  (325),  the  final  blood  concentration  for  each 
acetylcholine infusion was estimated at 4 × 10
-8 M, 4 × 10
-7 M and 4 × 10
-6 M, 
which  was  appropriate  for  assessment  of  a  range  of  vasomotor  responses 
(recommended range 10
-8 to 10
-5 M) (326). At the end of each infusion, coronary 
angiography was recorded using non-ionic contrast medium (Omnipaque™, GE 
Healthcare)  in  the  standard  fashion.  Serial  angiograms  were  performed  using 
identical projections, table height and magnification. The acetylcholine infusion 
was  terminated  if  significant  ischaemia  or  bradycardia  were  observed. 
Endothelium-independent  vasomotion  was  then  assessed  by  an  intracoronary 
bolus  injection  of  400  µg  isosorbide  dinitrate.  If  required,  a  further  dose  of 
isosorbide  dinitrate  was  administered  to  fully  reverse  any  latent  effects  of 
acetylcholine,  ensuring  maximal  coronary  artery  vasodilation,  before  a  final 
angiogram was recorded. 
 
Quantitative Coronary Angiography 
Coronary  angiograms  were  stored  digitally  at  the  Golden  Jubilee  National 
Hospital,  Glasgow  for  subsequent  analysis.  An  automated  edge-detection 
software system (Centricity CA1000, GE Healthcare) was used to measure the 
luminal diameter of the coronary artery distal to the infusion catheter, at end 
diastole. The mean percentage change in luminal diameter compared to control in 
two  distinct  5  mm  segments  was  calculated  for  each  patient  following  each 
infusion and after final nitrate injection (each analysis segment consisted of five 
separate measurements 1 mm apart). Each segment was easily identifiable by 
anatomical  landmarks  (such  as  side  branches).  Endothelial  function  was 
represented  by  the  vasomotor  response  to  the  highest  tolerated  acetylcholine   182 
concentration. One patient did not receive 10
-4 M acetylcholine due to recurrent 
transient  atrioventricular  block.  All  other  patients  received  all  three 
concentrations of acetycholine. Negative changes in vessel diameter represent 
vasoconstriction, compared to control. All QCA analysis was performed by a 
single observer, blinded to all other study results. 
 
6.2.6  Statistical analysis 
A formal power calculation was difficult due to the exploratory nature of the 
study, however a sample size of 23 patients was estimated to provide 80% power 
to detect a relationship between the independent and the dependent variables at a 
two-sided 0.05 significance level, if the true change in the dependent variable is 
0.3 units per unit change in the independent variable. This was based on the 
assumption that the SD of the independent variable (oxLDL) is 0.3 and the SD of 
the  dependent  variable  (endothelial  function)  is  0.15  (327).  A  previous  small 
study reported a significant correlation between oxLDL and endothelial response 
to acetylcholine in 15 patients (328). All data are expressed as mean ± SEM 
unless  otherwise  stated.  Correlations  were  performed  using  the  Pearson 
correlation  coefficient.  Coronary  responses  for  each  infusion  were  compared 
using analysis of variance and post-hoc Dunnett’s test. Statistical analysis was 
performed using the SPSS statistical software package 14.0 for Windows (SPSS 
Inc., Chicago, IL, USA). 
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6.3  Results 
 
6.3.1  Baseline characteristics of patients 
The number of patents included in each part of the study is shown in Figure 6.2. 
23  patients  consented  to  the  study  between  June  2007  and  April  2010.  The 
endothelial function study was abandoned in one patient due to time constraints 
in the catheterisation laboratory. All 22 remaining patients underwent coronary 
endothelial function testing. OxLDL assay was performed in the first 14 patients, 
but was not available for the remaining patients. WBA assays were performed 
for all patients. Circulating numbers of EPCs were only available for 18 patients, 
due  to  technical  problems  with  the  assay.  The  baseline  characteristics  of  the 
patients are shown in Table 6.1. All patients had chronic stable angina and were 
taking  standard  pharmacotherapy.  There  was  a  low  prevalence  of  diabetes 
mellitus but high prevalence of other cardiovascular risk factors. Most patients 
had single vessel coronary artery disease. 
 
 
 
 
 
 
 
 
 
Figure 6.2  Patient flow diagram for study. 
23 patients  
consented to the study 
18 patients had  
EPC assay 
1 patient abandoned due 
to time constraints in 
catheterisation laboratory 
22 patients underwent endothelial 
function testing and provided  
venous blood sample 
22 patients had  
WBA assay 
14 patients had 
oxLDL assay 
4 EPC assay not 
performed 
2 machine breakdown,  
1 analysis error,  
1 late arrival of sample 
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Table 6.1  Baseline characteristics of endothelial study patients 
  Prevalence, 
(n = 22) 
Patients’ characteristics   
Age, mean (SD), y  61.5 (9.5) 
Male, n (%)  18 (81.8) 
Current smoker, n (%)  2 (9.1) 
Hypertension, n (%)  10 (45.5) 
Hypercholesterolaemia, n (%)  14 (63.6) 
Diabetes mellitus, n (%)  2 (9.1) 
Family history of premature CHD, n (%)  9 (40.9) 
Previous myocardial infarction, n (%)  7 (31.8) 
Previous stroke, n (%)  0 (0) 
Previous PCI or CABG, n (%)  0 (0) 
Single vessel disease, n (%)  18 (81.8) 
Preserved LV function, n (%)  21 (95.5) 
Heart failure, n (%)  0 (0) 
Drug treatment   
Aspirin, n (%)  22 (100) 
Clopidogrel, n (%)  18 (81.8) 
Statin, n (%)  21 (95.5) 
ACE inhibitor or ARB, n (%)  15 (68.2) 
Beta-blocker, n (%)  20 (90.9) 
Calcium channel blocker, n (%)  6 (27.3) 
Diuretic, n (%)  4 (18.2) 
Nitrate, n (%)  10 (45.5) 
Nicorandil, n (%)  3 (13.6)   185 
6.3.2  Coronary endothelial function 
The  mean  vessel  responses  for  each  acetylcholine  infusion  and  isosorbide 
dinitrate injection are shown in figure 6.3. The mean response to incremental 
concentrations  of  acetylcholine  was  progressive  vasoconstriction,  which  was 
significant for the highest concentration (-1.64 ± 1.21%, -4.80 ± 1.84% and -
13.20 ± 3.33% for 10
-6 M, 10
-5 M and 10
-4 M acetylcholine, respectively, p < 
0.001 for 10
-4 M acetylcholine vs. control). The mean response to isosorbide 
dinitrate was 11.20 ± 2.50%, p = 0.001 vs. control). Figure 6.4 shows the mean 
endothelial  function  of  two  segments  for  each  patient  in  order  of  the  study 
performance. 
 
 
Figure 6.3  Mean  vasomotor  responses  to  acetylcholine  infusion  (concentration 
[M])  and  isosorbide  dinitrate.  There  was  progressive  vasoconstriction  to  serial 
acetylcholine  infusions  whereas  administration  of  isosorbide  dinitrate  caused 
vasodilation (n = 22) * p < 0.001 vs. control, ** p = 0.001 vs. control. 
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Figure 6.4  Individual  patient  vasomotor  responses  to  the  highest  concentration 
acetylcholine infusion in order of study. The group’s mean response was -13.20 (SD 
15.60) %. 
 
There was good agreement between the two segments analysed for each patient. 
The mean difference in endothelial function between the two segments analysed 
in  each  patient  was  7.87  (SD  8.15)  percentage  points.  3  patients  displayed 
vasoconstriction in one segment and vasodilation in the other segment. 
 
6.3.3 Adverse events 
Transient minor atrioventricular block was common (approximately one quarter 
of  patients)  during  acetylcholine  infusion,  especially  during  the  highest 
concentration, but this was usually short-lived (less than 10 seconds) after the 
infusion  was  stopped.  Minor  electrocardiographic  evidence  of  ischaemia  was 
uncommon and clinical  ischaemia was  rare (two patients complained of mild 
angina).  Figure  6.5  shows  an  example  of  severe  vasoconstriction  in  the  left   187 
anterior  descending  coronary  artery  in  one  patient  who  displayed  marked 
electrocardiographic ischaemic changes during  the highest acetylcholine dose, 
but  this  was  quickly  reversed  with  isosorbide  dinitrate  injection  (serial 
angiography  was  successfully  recorded).  No  serious  complications  were 
encountered. 
 
Figure 6.5  Angiographic  example  of  severe  coronary  endothelial  dysfunction. 
Progressive vasoconstriction of the left anterior descending artery after 0.9% saline (A), 
10
-6  M  acetylcholine  (B);  10
-5  M  acetylcholine  (C)  and  10
-4  M  acetylcholine  (D) 
infusions. Isosorbide dinitrate caused complete reversal of vasoconstriction (not shown). 
All angiograms shown are right anterior oblique 30º cranial projection. 
 
6.3.4  Correlations  
Endothelial function correlated significantly with the number of circulating EPCs 
(CD34
+/KDR
+ cells) (Figure 6.6). Patients with fewer circulating EPCs displayed   188 
 
Figure 6.6  Scatter  plot  of  EPC  number  and  coronary  endothelial  function. 
Endothelial  function  is  represented  by  %  change  in  vessel  diameter  during  highest 
acetylcholine  concentration,  compared  to  control.  Endothelial  function  was  strongly 
correlated with EPC number (CD34
+/KDR
+ cells) (r = 0.57, p = 0.01). 
 
more severe endothelial dysfunction. Stepwise multiple linear regression analysis 
demonstrated that this correlation was independent of age, gender, hypertension, 
hypercholesterolaemia,  diabetes  mellitus,  current  smoking,  family  history  of 
premature CHD and total number of cardiovascular risk factors (p < 0.05). No 
other significant correlations were found between plasma oxLDL concentration, 
number of circulating EPCs (CD34
+/KDR
+ cells), number of circulating CD34
+ 
cells,  endothelial  function  or  WBA,  except  for  a  highly  significant  positive 
correlation between WBA in response to collagen and WBA in response to ADP 
(Table 6.2). Figures 6.7 and 6.8 show the lack of correlation between plasma 
oxLDL and EPC or endothelial function, respectively. Endothelium-independent   189 
vasodilation  induced  by  isosorbide  dinitrate  injection  showed  no  significant 
correlation with any parameter (data not shown). 
 
Table 6.2  Correlations between main study parameters. 
   oxLDL 
(IU) 
CD34 
/µl 
blood 
CD34+/ 
KDR+/ 
µl blood 
Endo. 
function 
WBA 
(collagen) 
WBA 
(ADP) 
oxLDL (IU)  r  1  -0.134  0.197  0.452  -0.441  -0.369 
   p    0.648  0.519  0.105  0.114  0.194 
   n  14  14  13  14  14  14 
CD34+/µl blood  r  -0.134  1  0.329  -0.089  0.107  -0.294 
   p  0.648    0.273  0.763  0.715  0.308 
   n  14  14  13  14  14  14 
CD34
+/KDR
+/µl 
blood 
r  0.197  0.329  1  0.569*  -0.185  -0.040 
   p  0.519  0.273    0.014  0.464  0.874 
   n  13  13  18  18  18  18 
Endo. Function  r  0.452  -0.089  0.569*  1  -0.283  -0.028 
   p  0.105  0.763  0.014    0.202  0.903 
   n  14  14  18  22  22  22 
WBA (collagen)  r  -0.441  0.107  -0.185  -0.283  1  0.692** 
   p  0.114  0.715  0.464  0.202    0.000 
   n  14  14  18  22  22  22 
WBA (ADP)  r  -0.369  -0.294  -0.040  -0.028  0.692**  1 
   p  0.194  0.308  0.874  0.903  0.000   
   n  14  14  18  22  22  22 
r represents the Pearson correlation coefficient; * p < 0.05; ** p <  0.001.  
   190 
 
 
Figure 6.7  Scatter  plot  of  oxLDL  and  EPC  number.  There  was  no  significant 
correlation between oxLDL and EPC number (CD34
+/KDR
+ cells) (r = 0.20, p = 0.52). 
 
 
Figure 6.8  Scatter plot of oxLDL and coronary endothelial function. There was no 
significant correlation between oxLDL and endothelial function (r = 0.45, p = 0.11). 
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Age was inversely correlated with number of circulating EPCs (Figure 6.9) and 
positively  correlated  with  WBA  in  response  to  20  µM  ADP  (Figure  6.10). 
Stepwise  multiple  linear  regression  analysis  confirmed  that  the  correlation 
between  age  and  EPC  number  was  independent  of  other  cardiovascular  risk 
factors (p = 0.05), however the correlation between age and WBA in response to 
ADP  was  no  longer  significant  after  correction  for  other  cardiovascular  risk 
factors (p = 0.08). The total number of cardiovascular risk factors (male gender, 
hypertension, hypercholesterolaemia, diabetes mellitus, current smoking, family 
history  of  premature  CHD)  did  not  correlate  significantly  with  oxLDL,  EPC 
number, endothelial function or either WBA result (data not shown). 
 
 
 
Figure 6.9  Scatter plot of age and EPC number. EPC number (CD34
+/KDR
+ cells) 
was inversely correlated with age (r = -0.47, p = 0.05). 
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Figure 6.10  Scatter plot of age and WBA in response to ADP. WBA in response to 
20 µM ADP was positively correlated with age (r = 0.46, p = 0.03). 
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6.4  Discussion  
 
This  observational  study  in  patients  with  stable  CHD  has  demonstrated  that 
coronary endothelial dysfunction was common and correlated with low levels of 
circulating  EPCs.  Plasma  oxLDL  concentration  did  not  correlate  significantly 
with EPCs, coronary endothelial function or WBA. 
 
6.4.1  Endothelial function in stable CHD 
The high prevalence of endothelial dysfunction in this population was consistent 
with other studies in patients with stable angina (324;327;329). Only 1 out of 22 
patients displayed significant coronary vasodilation (> 5 % increase in diameter) 
in  response  to  acetylcholine,  suggesting  good  endothelial  function  (in  that 
artery). 7 patients exhibited a minimal response to acetylcholine (< 5 % change 
in diameter). In 14 patients, a definite constrictive response (> 5 % decrease in 
diameter)  to  acetylcholine  occurred,  due  to  direct  muscarinic  effects  of 
acetylcholine predominating over acetylcholine-induced NO release from ECs, 
indicating significant endothelial dysfunction (324;326). These findings reflect 
the  patients’  persistent  exposure  to  cardiovascular  risk  factors  and  high 
probability  of  subclinical  atherosclerosis  in  the  study  vessel,  which  cause 
endothelial dysfunction and reduced NO bioavailability.  
 
The incidence of clinical symptoms during the endothelial function studies was 
low and consistent with previous work using identical acetylcholine regimens 
(330).  Aiming  for  a  lower  estimated  final  blood  acetylcholine  concentration   194 
(between  10
-8  and  10
-6  M)  may  reduce  the  incidence  of  clinical  symptoms 
further, as in other studies (331).  
 
6.4.2  EPCs and endothelial function 
The  observation  that  circulating  levels  of  EPCs  in  the  peripheral  blood  are 
correlated  with  coronary  endothelial  function  is  a  relatively  novel  finding. 
During the initial stages of this research, no studies had reported the relationship 
between circulating EPC levels and coronary endothelial function.  
 
Hill  et  al.  (312)  previously  showed  in  45  individuals  without  cardiovascular 
disease  that  peripheral  vascular  function  (assessed  by  flow-mediated  brachial 
artery  reactivity)  was  significantly  correlated  with  the  number  of  EC  colony 
forming units in culture, thought  at the time to represent EPCs derived from 
peripheral  blood.  It  has  since  been  established  that  this  widely  cited  study 
assessed an aspect of endothelial biology which did not reflect the number of 
EPCs present in the circulation (332;333). Uncertainty still surrounds the true 
identity of cells previously described as EPCs in the literature and, crucially, the 
most accurate way to identify and measure them. EPCs are widely believed to 
originate from haematopoietic stem cells, which are positive for CD34 (or the 
more immature marker protein CD133) and the EC antigen, KDR. These putative 
EPCs appear to make a valuable contribution to vessel formation (334). Hence, 
the  measurement  of  CD34
+/KDR
+  cells  is  currently  thought  to  be  the  most 
appropriate way to define circulating EPCs (333), as was the case in this study. A 
more detailed discussion on the controversies surrounding the identification and 
measurement of EPCs can be found elsewhere (176;332).   195 
During the course of this research, Werner et al. (335) was the first to report a 
correlation  between  EPCs  and  coronary  endothelial  function.  This  landmark 
study in 90 patients with stable CHD measured the number of circulating EPCs 
in peripheral blood using flow cytometry to quantify CD34
+/KDR
+ and CD133
+ 
cells. The ability of EPCs to produce endothelial colony forming units (described 
as EPC function) was also measured. It was found that levels of circulating EPCs 
(using CD34
+/KDR
+ and CD133
+ methods) and EPC function correlated with 
coronary  endothelial  function,  assessed  invasively  using  serial  acetylcholine 
infusions.  CD34
+/KDR
+  cells  were  more  strongly  correlated  with  coronary 
endothelial  function  than  CD133
+  cells.  After  multivariate  analysis,  only  the 
number  of  circulating  EPCs  correlated  with  coronary  endothelial  function 
independently of traditional cardiovascular risk factors. The failure of endothelial 
colony  forming  units  to  independently  predict  endothelial  function  probably 
relates to their dissociation with the number of circulating CD34
+/KDR
+ cells 
(333) and doubtful function in vascular regeneration (332).  
 
The work in this thesis therefore corroborates the novel findings by Werner et al. 
that EPCs (defined as CD34
+/KDR
+ cells) correlate with coronary endothelial 
function.  Evidence  is  accumulating  that  suggests  EPCs  provide  an  important 
repair  mechanism  after  vessel  damage  due  to  cardiovascular  risk  factors 
including hypertension, hyperlipidaemia, smoking and diabetes. Despite this, in 
many cases, progressive vessel injury progresses to the clinical manifestations of 
CHD, stroke and peripheral artery disease. The role of EPCs to repair the vessel 
injury  caused  by  PCI  is  not  well  defined,  but  emerging  as  an  important 
component of re-endothelialisation and restoration of vessel function (176). By   196 
reducing the capacity of the endothelium to be repaired after vessel injury, an 
obvious link between circulating EPC numbers and coronary endothelial function 
exists. The confirmation herein and by Werner et al. (335) that lower numbers of 
EPCs are associated with impaired coronary endothelial function (and hence at 
risk of subsequent vascular events) provides a basis for the ability of EPCs to 
predict  cardiovascular  outcome  (315;316).  Furthermore,  it  also  provides  a 
valuable link between cardiovascular risk factors and endothelial dysfunction, 
which are both associated with fewer circulating EPCs. 
 
6.4.3  The role of oxLDL 
The  relationship  between  EPCs  and  endothelial  function  was  independent  of 
traditional cardiovascular risk factors, which implied that EPCs may be causally 
involved in the regulation of endothelial function and are themselves regulated 
by other factors. In this study, plasma oxLDL levels were not correlated with the 
number of circulating EPCs or coronary endothelial function. Therefore, I have 
failed to demonstrate a biological explanation or peripheral biomarker for the 
deficiency of EPCs and associated severe coronary endothelial dysfunction in 
these  patients,  despite  substantial  evidence  that  oxLDL  is  toxic  to  EPCs 
(124;320;321;336-338). Besides the diverse methods to confirm EPC identity in 
laboratory  studies,  the  absence  of  correlation  in  my  results  may  relate  to  a 
number of issues.  
 
In previous studies, EPC dysfunction in vitro occurred at 1-10 µg/ml oxLDL 
(124;320) and marginally increased EPC apoptosis (5-10%) was present at 25 
µg/ml oxLDL or higher (321;337). Wang et al. reported a major reduction in   197 
cultured EPCs (~50%) at 100 µg/ml (336). In my study, the mean (SD) plasma 
oxLDL concentration was 60.2 (18.3) IU, which was approximately 18.0 (5.5) 
µg/ml  (personal  communication  from  manufacturer),  OxLDL  levels  were 
therefore lower than would be expected to significantly reduce EPC numbers in 
the  circulation.  Furthermore,  the  studies  that  investigated  statin  pre-treatment 
found  that  oxLDL-induced  EPC  dysfunction  and  senescence  were  both 
profoundly inhibited by 1 µM atorvastatin (124;320), possibly via activation of 
Akt (320;339). Thus, I speculate that the very high prevalence of statin therapy in 
this contemporary CHD population (90.9%) protected circulating EPCs against 
oxLDL-induced  damage  in  the  blood  and  may  have  masked  a  possible 
correlation with EPC levels. Further studies could address this relationship in 
statin-naïve patients; however, blood concentration may represent a blunt way to 
fully define the interaction between oxLDL and EPCs in vivo.  
 
This study was also underpowered to detect minor correlations between oxLDL 
and EPCs, due to the small number of patients with oxLDL results (n = 14). 
Nevertheless, there was no signal from the available data that plasma oxLDL was 
correlated with EPCs. I believe a much larger study would be required to confirm 
or  exclude  with  confidence  a  relationship  between  plasma  oxLDL  and  the 
number of circulating EPCs. A larger population would reduce the impact of 
important confounding factors such as co-existing medical conditions and drug 
treatments, both of which can influence oxLDL and EPC count and probably 
impaired the statistical  validity of this  component of my study.  If  an  inverse 
correlation between oxLDL and EPCs was evident from a larger study, then the 
ability of oxLDL to predict cardiac events in patients with CHD (340) would   198 
gain further mechanistic insights. Moreover, future directions for novel therapies 
may be possible, if they could provide EPCs with protection from oxLDL in vivo 
in a similar fashion to statin therapy. 
 
In  this  study,  plasma  oxLDL  levels  also  failed  to  correlate  with  coronary 
endothelial  function.  I  believe  this  relationship  was  similarly  affected  by  (or 
possibly  even  more  susceptible  to)  factors  which  accounted  for  the  lack  of 
correlation  with  EPCs;  that  is,  the  protective  influence  of  statin  therapy,  the 
confounding effects of other risk factors and the relatively small sample size. 
Hein  et  al.  (300)  has  shown  that  oxLDL  specifically  impaired  NO-mediated 
endothelium-dependent  vasodilation  to  shear  stress  and  adenosine,  but  not 
bradykinin (a cytochrome P-450 monooxygenase activator) in isolated porcine 
coronary arterioles. A study of 15 CHD patients was first to report an inverse 
correlation between coronary endothelial function, represented by the vasomotor 
response  to  acetylcholine,  and  plasma  oxLDL  (328).  Importantly,  this  small 
study  excluded  patients  taking  lipid-lowering  therapy,  which  reinforces  the 
potential role that statins may have played in my results. A larger study in 36 
cardiac  transplant  patients  (17%  were  prescribed  statins)  demonstrated  that 
coronary endothelial function was inversely related to oxLDL antibody levels, 
but not circulating oxLDL detected by monoclonal antibody EO6 (341). More 
recently, Matsumoto et al. (342) showed that impaired endothelium-dependent 
vasodilation in response to bradykinin was weakly correlated with oxLDL levels, 
measured by an immunosorbent assay. 
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6.4.4  Other predictors of EPCs and endothelial function 
In this study, age was inversely correlated with the number of circulating EPCs. 
This  relationship  was  independent  of  traditional  cardiovascular  risk  factors, 
suggesting that other age-related factors are responsible for the decline in EPCs 
in older patients. Older patients are likely to be more sedentary than younger 
patients  and  this  may  contribute  to  the  reduction  in  EPCs,  because  physical 
activity  increases  EPC  levels  (307),  even  after  a  single  episode  of  strenuous 
exercise (343). Another factor may be the lower use of medications that increase 
EPC levels, such as statins and ACE inhibitors. In this study, patients prescribed 
statin therapy were younger than those not prescribed statins (60.2 ± 2.0 years vs. 
74.0 ± 2.8 years, respectively, p < 0.05). Statin prescription was associated with 
more  circulating  EPCs  (0.32  ±  0.08  CD34
+/KDR
+  cells/µl  vs.  0.03  ±  0.03 
CD34
+/KDR
+ cells/µl, respectively, p = 0.25) and improved endothelial function 
(mean vessel response to acetylcholine -12.4 ± 3.6 % vs. -20.9 ± 5.9 %, p = 
0.33), but neither result was statistically significant due to the very small number 
of patients (two) not prescribed a statin. There were no discernable differences in 
any of these parameters for the prescription of ACE inhibitors. Aging per se may 
be associated with progressive exhaustion of bone marrow derived progenitor 
cells after several decades of exposure to cardiovascular risk factors and vascular 
damage (344). Even if not actually reduced in number, a decline in EPC function 
(345) is likely to make older patients more at risk of endothelial dysfunction and 
cardiovascular events. 
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6.4.5  Discussion of WBA results 
This study demonstrated that age was correlated with WBA in response to ADP, 
but  not  with  collagen,  in  patients  taking  aspirin  and  clopidogrel.  Since 
clopidogrel selectively and irreversibly inhibits the ADP receptor on platelets, 
this  suggests  a  relative  lack  of  clopidogrel  response  in  older  patients  (346). 
Indeed,  ADP-induced  platelet  aggregation  is  probably  the  gold  standard 
technique  to  assess  clopidogrel  response.  Variability  in  clopidogrel 
responsiveness  is  well  recognised  and  known  to  be  mediated  by  numerous 
clinical, cellular and genetic factors (346). To my knowledge, few studies have 
specifically reported the influence of age on clopidogrel responsiveness and have 
provided contrasting results (347;348). Since the correlation between age and 
ADP-induced  WBA  was  not  independent  of  cardiovascular  risk  factors,  it  is 
likely that other factors such as female gender (an independent predictor after 
multivariate  adjustment  in  this  study),  diabetes  and  smoking  are  involved 
(346;348;349). 
 
6.4.6  Limitations 
As already discussed, a limitation of this study was the low statistical power to 
confidently  determine  the  true  relationship  between  plasma  oxLDL  and  other 
study  parameters.  However,  accurate  assessment  of  these  relationships  may 
require a much larger population to avoid the influence of confounding factors. It 
is not known whether the specific oxLDL assay used in this study may have 
affected the results, as accurate quantification of oxLDL can be challenging. The 
method  to  identify  EPCs  in  this  study  using  specific  haematopoietic  and 
endothelial  markers,  CD34  and  KDR  respectively,  is  consistent  with   201 
contemporary  recommended  guidance  (332),  but  the  most  accurate  way  to 
quantify EPCs currently remains speculative (176;333). It would also have been 
useful to assess EPC function, as this may have revealed an association with 
plasma oxLDL levels and provided further insights into the high prevalence of 
severe endothelial dysfunction in CHD patients. It was noted that QCA using 
automated  edge  detection  software  appeared  to  underestimate  the  change  in 
lumen diameter for the most severe cases of endothelial dysfunction, compared 
to qualitative visual assessment, but this was unlikely to have greatly affected the 
correlations  between  variables.  Despite  a  statistically  significant  correlation 
between EPCs and endothelial function, there was a wide variation in endothelial 
responses to acetylcholine. This variation is likely to be due to the influence of 
other mediators which contribute to vascular function, such as the presence of 
cardiovascular risk factors and other unknown factors. As a result, measurement 
of EPCs alone is likely to be a fairly blunt predictor of endothelial function in a 
tested individual. 
 
6.4.7  Conclusions  
This observational study has confirmed a high prevalence of coronary endothelial 
dysfunction in patients with chronic stable angina. Coronary endothelial function 
in this population was strongly correlated with the number of circulating EPCs, 
independent of traditional cardiovascular risk factors, which is a relatively novel 
finding and has only been reported by one other group (335). Plasma oxLDL did 
not correlate with EPC count or endothelial function, possibly due to the high 
prevalence  of  statin  use,  other  confounding  variables  and  insufficient  sample 
size. Future studies should aim to define the specific reasons for a decline in   202 
number  and  other  functional  aspects  of  EPCs  in  cases  of  severe  endothelial 
dysfunction. This may aid the development of novel therapies which can protect 
or  accelerate  the  vital  endogenous  processes  required  for  rapid  endothelial 
healing after vessel injury, including PCI. 
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Chapter 7 
 
Concluding discussion 
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7. 1  Basic concept of the thesis 
 
Oxidative  stress  plays  an  important  role  in  vascular  repair  by  influencing 
multiple targets after arterial injury. Oxidative stress is mediated by numerous 
ROS including the superoxide anion (O2
-), which inactivates NO and leads to an 
accumulation  of  peroxynitrite  (ONOO
-),  hydrogen  peroxide  (H2O2)  and  other 
potent  oxidising  secondary  molecules.  These  ROS  and  others  affect  critical 
signalling  pathways  in  platelets  and  vascular  cells  after  PCI.  The  principal 
aspects of this include: 
 
•  Stent thrombosis – modulation of platelet aggregation 
•  Healing – endothelial regrowth and function, EPCs, inflammation 
•  ISR – re-endothelialisation, neointimal growth, extracellular matrix  
 
The  vascular  processes  modulated  by  oxidative  stress  are  also  closely  inter-
related themselves. Stent thrombosis is mediated to a large extent by platelets, 
but it is also influenced by the presence of healthy ECs. The regrowth of ECs not 
only protects against stent thrombosis, it also restricts neointimal formation, the 
main cause of ISR. Inflammation is an important element of vascular healing, but 
it is also strongly related to ISR and can predispose to stent thrombosis. The 
research  presented  in  this  thesis  aimed  to  investigate  the  effects  of  oxidative 
stress on several of these key processes and explore whether a strategy to target 
ROS would favourably modify vascular remodelling after PCI.  
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7.2  Oxidative stress: effects on stent thrombosis 
 
7.2.1  Specific effects on thrombosis  
Many studies have reported diverse effects of ROS on platelet function and this 
is discussed in detail in Chapter 2 and by others (177). The overall conclusion 
from the literature is that ROS are heterogenous regulators of platelet function. 
Whilst some ROS appear to stimulate platelets, the actions of others may be 
inhibitory.  Stent  thrombosis  is  predominantly  made  up  of  platelets,  but  other 
factors in the circulation and in the vascular wall are also closely involved, so 
particular attention in this thesis was given to the effects of ROS on thrombus 
formation in whole blood and in the vicinity of ECs. The X/XO reaction was 
used  to  generate  ROS  in  this  thesis  and  although  the  formation  of  specific 
molecules was not characterised, this reaction is known to produce large amounts 
of O2
- and H2O2 (238). The effect of oxidative stress in this setting was to inhibit 
thrombus  formation  in  a  concentration-dependent  manner.  This  was  an 
interesting finding, because ROS released by this reaction were expected to cause 
a stimulatory effect. This early conjecture was fortified by the assumption that 
ROS were uniformly prothrombotic molecules. By corroborating my results with 
the extensive literature, it is now clear that this supposition was inaccurate. I 
speculate  that  my  experiments  generated  abundant  ROS  and  secondary 
molecules,  which  were  toxic  to  platelets  and  other  aggregating  factors  in  the 
blood. The ultimate effect of this “super-release” of ROS was a decrease in the 
rate  of  thrombosis.  The  addition  of  ECs  to  blood  also  impaired  thrombus 
formation, which was consistent with the primary function of the endothelium. 
This effect was not significantly altered by the exogenous application of ROS,   206 
suggesting that ROS would not greatly oppose the antithrombotic properties of 
nearby endothelium after PCI. Consistent with previous work, NO was partly 
responsible  for  the  inhibitory  effect  of  ECs.  Although  O2
-  may  diminish  this 
influence, the formation of inhibitory ROS appear to counterbalance the effect 
overall.  Of  course,  whether  this  experimental  situation  approximates  with  the 
ROS  generated  by  PCI  is  uncertain.  Nevertheless,  it  would  seem  that  non-
specific targeting of the acute effects of ROS on platelets and other aggregating 
factors  in  blood  after  PCI  to  lower  the  intrinsic  risk  of  thrombosis  may  be 
ineffective.  In  fact,  substantial  release  of  ROS  after  PCI  might  even  provide 
some  protection  against  stent  thrombosis.  The  widespread  use  of  intensive 
antiplatelet  medications  has  dramatically  reduced  the  incidence  of  stent 
thrombosis  during  the  first  month  after  PCI  to  less  than  1%,  therefore  novel 
approaches  to  reduce  acute  thrombotic  events  further  would  need  to  have 
substantial inhibitory effects on thrombosis. Unravelling the effects of oxidative 
stress on other vascular processes associated with late stent thrombosis and ISR 
(such as endothelial regeneration) may offer a more plausable strategy. 
 
7.2.2  Re-endothelialisation 
The  movement  of  ECs  to  regenerate  the  endothelial  monolayer  is  a  critical 
component of vascular healing. The work presented by this thesis implies that 
EC  migration  may  be  inhibited  by  ROS,  but  it  may  also  be  antagonised  by 
antioxidants. The explanation for this seemingly paradoxical observation may lie 
in  the  fact  that  pathological  release  of  ROS  can  clearly  disrupt  important 
biological functions but, on the other hand, targeted physiological release of ROS 
often constitutes an essential component of normal cell activity. In this case, the   207 
impact of ROS is not solely damaging to ECs, but necessary to support motility. 
The  important  role  of  ROS  during  normal  EC  migration  has  been  reviewed 
comprehensively (258). This should guide future strategies away from near-total 
elimination  ROS  after  PCI,  as  that  may  negatively  influence  some  arterial 
healing processes. The ideal antioxidant to promote endothelial healing would 
oppose pathological ROS production, but permit lower level physiological ROS 
release. If this were achieved, antioxidant therapy could potentially accelerate 
endothelial regeneration. Some data in animal models suggest probucol may be 
successful for this purpose (149;150), although it would be gratifying if other 
groups could validate this work. It is not clear whether the reported effectiveness 
of probucol to promote re-endothelialisation is primarily due to its antioxidant 
effects  or  its  effects  on  HO-1  (160;350;351).  EPCs  may  represent  another 
potential target to modify arterial healing after PCI. A major current limitation of 
this approach is the lack of clear understanding of the identity and precise role of 
these endothelial precursors. The work in this thesis has confirmed a crucial link 
between  putative  circulating  EPCs  (identified  by  haematopoietic  and  EC 
markers) and coronary endothelial function. This provides further impetus for 
future studies to fully characterise the role of these cells in vascular repair after 
PCI and the impact oxidative stress may exert.  
 
7.3  Antioxidants: prevention of ISR  
 
7.3.1  Nitrone D: the good, the bad and the ugly? 
The initial compound to be investigated in this thesis was the spin trapping agent, 
nitrone  D,  a  potent  antioxidant,  but  with  relatively  few  supporting  studies.  I   208 
found  that  nitrone  D  caused  slight  inhibition  of  whole  blood  aggregation. 
However,  subsequent  evaluation  was  abruptly  terminated  after  nitrone  D  was 
found to cause a disturbing inhibitory effect on EC migration. Since acceleration 
of arterial healing was a primary aim of this thesis, there was no option other 
than to eliminate nitrone D from further investigation. This was disappointing, 
since nitrone D would have been an intriguing substance to take forward into 
preclinical assessment. Other than its antioxidant properties, nitrone D has other 
effects which may have influenced neointimal formation. Nitrone D decreases 
p21  expression  (245),  which  may  be  problematic  after  stent  injury  because 
animal studies have indicated that p21 can attenuate neointimal thickening (352). 
Nitrone D also promotes SIRT 1 transcription, which is a negative regulator of 
p53 gene expression (245). Although this may be protective towards ECs (249) 
and  EPCs  (353),  it  may  accelerate  neointimal  thickening  (354;355).  These 
studies  emphasise  the  need  to  recognise  potentially  diverse  effects  of  novel 
compounds  as  well  as  their  primary  intended  action.  Until  nitrone-based 
compounds are tested in a preclinical stent model, it is not clear which effects 
would predominate and which tissue responses that would produce. 
 
7.3.2  Succinobucol: the end of the road? 
In  contrast  to  nitrone  D,  succinobucol  had  tantalising  supportive  data  which 
made it an exciting compound to test in a preclinical model. In many respects, 
the  properties  of  succinobucol  matched  those  of  an  ideal  DES  coating. 
Succinobucol shares many of its appealing properties with probucol, except it is 
more  potent  and  is  taken  up  more  readily  by  cells  (271;356).  It  also  has 
additional anti-inflammatory effects on vascular adhesion molecules, which are   209 
ideally  suited  to  neointimal  suppression.  Despite  these  promising  qualities,  I 
found  that  succinobucol  was  damaging  to  arterial  tissue  after  stenting,  by 
increasing inflammation and neointimal growth. These two effects were probably 
inter-related.  Speculation  remains  as  to  whether  a  lower  dose  would  have 
improved the results. I am not convinced that simply coating a stent with a lower 
concentration of succinobucol solution would have provided beneficial effects. 
Based  on  my  pharmacokinetic  results,  targeting  a  succinobucol  tissue 
concentration in the range of favourable in vitro data (published by Atherogenics, 
who manufactured succinobucol) would be extremely difficult. Moreover, the 
cell  culture  data  presented  in  this  thesis  suggests  that  succinobucol  at  low 
concentrations is toxic to ECs and SMCs. Of course, toxicity towards SMCs is 
not necessarily a negative characteristic of a DES, as this may limit neointimal 
proliferation, but the risk of inflammation and impaired healing would present a 
similar situation to that already offered by current DES, which are also uniformly 
toxic to vascular cells. Incidentally, the development of succinobucol as an oral 
medication to treat cardiovascular disease was suspended during the writing of 
this thesis after disappointing results in clinical trials. 
 
7.4  The antioxidant-eluting stent: still a worthwhile concept? 
 
This  thesis  investigated  two  novel  antioxidant  compounds,  with  ultimately 
negative effects. In fact, neither came close to providing promising data. In many 
respects, this contradicts the scientific literature that has broadly endorsed the 
potential  role  of  antioxidants  in  vascular  remodelling  after  PCI.  The  relevant 
studies  have  been  reviewed  in  Chapter  1.  Animal  studies  of  probucol  have   210 
yielded the most positive results, yet this drug has not been effective in humans. 
Clinical  studies  of  oral  probucol  which  included  IVUS  measurements  have 
consistently  found  that  this  drug  has  no  effect  on  NIH  (156;157;161).  Oral 
succinobucol was identical in this regard (156). It was a central hypothesis of this 
thesis  that  local  delivery  of  antioxidants  would  circumvent  the  obvious 
limitations of oral dosing in humans compared to animals, but no studies have 
reported  a  positive  result  for  this  strategy.  Incorporation  into  dual  DES 
technology  may  offer  the  only  viable  alternative.  It  is  worth  noting  that 
successful  reports  of  a  probucol/rapamycin-eluting  stent  have  conspicuously 
omitted  probucol  as  a  sole  coating  (264).  The  efficacy  of  a  probucol-  or 
succinobucol-eluting  stent  therefore  seems  improbable,  so  attention  should 
probably be re-focussed on other antioxidant techniques.  
 
The obvious question relates to which antioxidant therapy holds most promise 
for human applications. Given that NADPH oxidase is the principal contributor 
to ROS production after PCI, it is conceivable  that inhibitors of this enzyme 
might  offer  the  greatest  chance  of  success  (143;144).  Antioxidants  that 
decompose O2
- and H2O2 (both promote SMC proliferation) may be a worthwhile 
strategy and several animal studies using SOD with and without catalase have 
reported positive results (145;146;357-360). Unfortunately, the targeted delivery 
of these agents in humans provides significant challenges. Their ultra-short half-
life in the circulation presents their foremost limitation: the requirement for viral 
gene transfer. Viral transfer of eNOS (361) and VEGF (29) has been effective in 
animal models but suffers from the same disadvantage, which is significant. The 
concept of a gene-eluting stent has not been successfully translated to humans.   211 
Accumulation  of  viral  vectors  in  non-target  tissues  is  a  concern,  given  their 
relatively narrow therapeutic index and potentially harmful immune responses. 
Nevertheless, whilst gene-based therapy in general for cardiovascular diseases 
has so far provided limited successes, it offers the potential to make a major 
impact if translated to humans successfully. Ex vivo antioxidant gene transfer of 
progenitor cells may provide an alluring prospect in the future (362).  
 
Ultimately, will an antioxidant-based strategy ever be successful in improving 
clinical outcome after PCI? Innumerable animal models have provided satisfying 
results,  whereas  human  studies  have  been  universally  disappointing.  This 
situation unfortunately mirrors the use of antioxidants in cardiovascular disease 
in general. It is difficult to envisage that antioxidants will ever induce favourable 
vascular  responses  after  PCI  to  rival  the  success  of  established  devices.  The 
arrival of new generation DES on the market will elevate the competition further. 
An  antioxidant-based  approach  would  need  to  be  potent  enough  to  inhibit 
profound tissue stimuli without causing toxicity. At the same time, it must permit 
ROS  signalling  which  is  necessary  for  normal  vascular  cell  function.  These 
challenges may prove insurmountable for an antioxidant, but future attempts are 
awaited with great interest.  
 
7.5  Final conclusions 
 
In conclusion, this thesis has examined the role of oxidative stress in platelet and 
EC  function,  known  be  important  after  PCI,  and  found  this  to  be  damaging. 
Despite this, the effects of a novel antioxidant-eluting stent were detrimental to   212 
vascular repair. Coronary endothelial dysfunction was correlated with reduced 
circulating EPCs, but plasma oxLDL was not related to either parameter. These 
findings highlight the difficulties and complexities of targeting oxidative stress to 
improve  outcome  after  PCI.  I  hope  the  work  contained  in  this  thesis  will 
stimulate clinicians and scientists alike to continue with research in this exciting 
and rapidly progressing area of cardiovascular disease. 
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